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ACAT acyl-coenzyme A: cholesterol-acyltransferase 
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chol cholesterol 
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d density 
DHEA dehydroepiandrosterone 
EDTA (sodium salt of) ethylene diamino tetra acetic acid 
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Chapter 1 
INTRODUCTION 
и 
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Elevated levels of serum cholesterol or, more specifically, low density lipoprotein 
(LDL) cholesterol are related to the development of atherosclerotic coronary heart 
disease (1-4). There is evidence at least in male subjects with hypercholesterolemia 
that lowering total and LDL cholesterol levels by diet or drugs reduces the incidence 
of coronary heart disease, and retards or possibly reverses the atherosclerotic process 
(2,3,5-8). These findings have resulted in an increased interest in serum cholesterol as 
a risk factor, an increased attention paid to the importance of dietary habits in the 
development of hypercholesterolemia and a more aggressive approach of the indivi­
dual patient with hypercholesterolemia (9,10). 
1. CHOLESTEROL METABOLISM 
Cholesterol is the major sterol in human and animal tissues (11). Both free choleste­
rol and esterified cholesterol are constituents of the cell membranes. Cholesterol is the 
precursor of steroid hormones in the adrenal cortex and in the testis or ovary, and of 
bile acids in the liver (12). In normal man on a Western diet, 350 mg cholesterol is taken 
up daily with the food, whereas 800 mg is newly synthesized every day (13). 
Free cholesterol has a polar head and a non-polar tail, whereas cholesterol which is 
esterified with a fatty acid is non-polar. In the blood cholesterol is transported 
together with triglycerides, phospholipids and characteristic proteins, the apolipo­
proteins, as lipoproteins. The non-polar triglycerides and esterified cholesterol mole­
cules are hidden in a coat of hydrophilic apolipoproteins, and the polar heads of free 
cholesterol and phospholipids (11,12). 
Circulating lipoproteins are divided into groups based on their physical properties, 
which reflect their role in the lipoprotein metabolism, in which the liver plays the most 
important role (Figure 1) (14). 
Chylomicrons are very large, triglyceride-rich lipoproteins with the lowest density 
(d<1.006 g/ml) which are secreted by the small intestine. They contain as structural 
protein apolipoprotein B48 and, in addition, apolipoproteins A, C, and E. Apolipo-
protein B48 lacks the carboxy-terminal half of the hepatic form of apolipoprotein В 
(apolipoprotein B100), necessary for clearance by the low density lipoprotein (LDL) 
receptor (15, 16). Chylomicrons transport exogenous triglycerides and cholesterol 
from the intestine to the liver and the fat stores. In the plasma, they interact with 
lipoprotein lipase, an endothelial enzyme which hydrolyzes the triglycerides. The 
fatty acids are taken up by the tissues and the remaining particle, the chylomicron-
remnant, is subsequently taken up by the liver cells by a supposed receptor-mediated 
mechanism, the apolipoprotein E or chylomicron-remnant receptor. The latest candida­
te for this elusive receptor seems to be a reiterated form of the LDL receptor called 
LDL receptor related protein (LKP) (17,18). 
Very low density lipoproteins (VLDL) are large, triglyceride rich lipoproteins 
which also have a density of less than 1.006 g/ml. They contain endogenous triglyceri­
des synthesized in the liver and transport these to the fat stores and to the muscles as 
source of energy. The structural apolipoprotein is apolipoprotein B100. Every VLDL 
particle has one single apolipoprotein B100 molecule which is contained throughout 
the metabolic cascade. In addition, it contains apolipoprotein С and E. In the circula­
is 
Figure 1. Separate pathways for receptor-mediated metabolism of lipoproteins caivying endo-
gevous and exogenous cholesterol. (From ref. І0, with permission.) 
tion, the triglycerides of the VLDL particle are hydrolyzed by the enzymatic activity 
of lipoprotein lipase and taken up by the cells. The particle also looses apolipoproteins 
С and to some extent E, and surface components. The remaining VLDL particles, 
which have become more dense by the delipidation process, are called VLDL-rem-
nants or intermediate density lipoproteins (ÍDL). In metabolic respect VLDL com-
prise a heterogenous group of particles. The larger VLDL particles are taken up 
directly from the plasma after delipidation, without conversion to IDL and LDL, 
whereas the smaller VLDL particles are converted to IDL and LDL by mechanisms 
largely unknown (19-21). 
IDL particles have a density between 1.006 and 1.019 g/ml. They contain one single 
molecule of apolipoprotein B100, next to a variable number of molecules of apolipo-
protein С and E. IDL are delipidated further, and gradually lose their apolipoproteins 
С and in part apolipoproteins E. Afterwards, they are either taken up by the liver and 
other tissues by a receptor-mediated mechanism, the LDL receptor, or they are 
converted to LDL by largely unknown mechanisms, in which both the hepatic LDL 
receptor and hepatic lipase may be involved (22-24). 
These cholesterol-rich LDL particles with a density between 1.019 and 1.063 g/ml 
contain only apolipoprotein B100 and are the end-products of the lipoprotein cascade in 
the plasma. These particles are also taken up by the cells by way of the LDL receptor, 
although at a slower rate than IDL. Beside the production of LDL from VLDL via 
IDL, there are also indications from metabolic and in vitro studies that LDL is directly 
secreted by the liver (25). Normally, approximately 60-70% of the cholesterol in the 
blood is transported in LDL. The LDL particles are especially atherogenic and a high 
cholesterol level usually reflects high levels of LDL. 
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High density lipoproteins (HDL) are the densest lipoproteins with a density be-
tween 1.063 and 1.21 g/ml. They are produced by the liver and intestine, and formed in 
the blood as a result of the catabolism of triglyceride-rich lipoproteins. HDL contain 
apolipoprotein A as major protein and are rich in cholesterol. HDL particles may play 
an important role in the so called reverse cholesterol transport from peripheral tissues 
back to the liver. They also regulate the lipid transfer between lipoproteins, and the 
transfer of apolipoproteins. The level of HDL is inversely correlated to the risk of 
coronary artery disease (26-28). 
2. THE LDL RECEPTOR AND HYPERCHOLESTEROLEMIA 
IDL and LDL particles are removed from the plasma by a high-affinity mechanism, 
the LDL receptor. This receptor is a cell-surface protein within the cell membrane of 
mammalian cells which interacts with the receptor-binding domain of the apolipo-
protein B100 molecule of the lipoproteins. The binding of the IDL particle to the 
receptor may be facilitated by apolipoprotein E. The lipoprotein particle is subse-
quently taken up by the cell and catabolized further (22,29). In addition, a portion of 
the lipoproteins is taken up by slower mechanisms which are not receptor-mediated 
and are concentration dependent. In normal man, approximately 45% of the LDL 
particles in the plasma is taken up every day; two third by the LDL receptor, and the 
remaining one third by non-receptor-mediated pathways (30). 
From studies with human fibroblasts it was learned that a cell regulates its free 
cholesterol content by 3 different mechanisms (29) (Figure 2): 
LDL Binding • l n t e r n a | - _ ^ Lysosomal ^ Regulatory 
ization Hydrolysis Actions 
Figured. Sequential sLeps in the LDL recepterpathway in mammalian cells. (From Goldstein 
JL, Brown MS. The LDL receptor defect in familial Injpercholesterolernia. Implications for 
pathogenesis and therapy. The Medical Clinics of North America 1982;e6:,UD-.ì62,fig. ¿, with 
peiynissioii.) 
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1. The biosynthesis of cholesterol within the cell 
The activity of a specific enzyme, 3-hydroxy-3- methylglutaryl Coenzyme A reductase 
(HMG CoA reductase), which catalyzes the rate limiting step of the biosynthesis of 
cholesterol, is regulated according to the cellular needs. When the free cholesterol 
levels in the cell increase, the activity of this enzyme (as well as of HMG CoA 
synthetase) is suppressed. 
2. The estenfication of free cholesterol 
When the intracellular free cholesterol concentration increases, the activity of the 
enzyme acyl-coenzyme A:cholesterol-acyltransferase (ACAT) is increased, resulting 
in esterification of free cholesterol to cholesteryl esters. 
3. The number of LDL receptors 
When the free cholesterol concentration in the cell increases, the messengerRNA 
level for the LDL receptor decreases and less LDL receptors are synthesized; the 
number of receptors will decrease. This results in a decreased uptake of LDL particles 
from the blood. 
By these three mechanisms the free cholesterol concentration in the cell is kept 
within narrow limits. 
The pivotal role of the LDL receptor in the cholesterol metabolism and its influence 
on the level of the serum cholesterol is clearly shown in patients with a genetic defect 
in the synthesis or function of the LDL receptor. This disease, familial hypercholeste-
rolemia, which was first described in 1939 (31), is an autosomal-dominant genetic 
disease with a gene dosage effect (32). Various gene defects have been described, 
which all lead to a decreased or absent activity of the receptor (33). In the heterozy-
gous state, which occurs in one of every 500 persons in Western societies, there is one 
normal and one abnormal gene and the number of functioning LDL receptors on the 
cell surface is decreased to 50% of normal. In the rare homozygous state, which is 
mostly a compound of two different gene defects, and which occurs in 1 out of 1 million 
persons, the LDL receptor activity may be virtually absent. As a result of the LDL 
receptor defect, the uptake of LDL and IDL particles from the blood is decreased, 
leading to increased levels of LDL cholesterol, whereas the conversion of IDL to LDL 
is increased. Indeed, LDL turnover studies showed that in patients with heterozygous 
and homozygous familial hypercholesterolemia, the fractional catabolic rate of LDL 
was decreased whereas total LDL production was increased (34,35). In heterozygotes, 
60% of LDL cholesterol clearance is achieved by non-receptor-mediated pathways, 
and in homozygous patients, all LDL cholesterol may be taken up by non-receptor-
mediated pathways (30). In heterozygous patients, LDL cholesterol levels are in-
creased two to threefold resulting in xanthomatosis and premature coronary artery 
disease: 50% of men and 20% of women with heterozygous familial hypercholesterole-
mia suffer from a myocardial infarction before the age of 60 (32). In the homozygous 
patient, cholesterol levels are increased up to 6 times normal; these patients often 
suffer from coronary artery disease as early as in their first or second decade of life 
(32). 
Striking evidence of the important role of the LDL receptor in regulating serum 
cholesterol has been obtained by two observations: 
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- a 6-year-old girl with homozygous familial hypercholesterolemia was treated suc­
cessfully by transplantation of a normal liver; the donor liver provided sufficient LDL 
receptors to lower her LDL cholesterol to a near-normal value (36, 37). 
- transgenic mice have been produced recently, in which the number of hepatic LDL 
receptors could be increased. As a result, apolipoprotein В and E virtually disappear 
from the blood (38). 
In addition to a genetic defect which results in decreased LDL receptor activity and 
subsequently increased levels of serum cholesterol, the liver may also change its 
number of LDL receptors according to the amount of cholesterol taken up with the 
food: if large amounts of cholesterol are taken up with the food, the intracellular 
cholesterol content increases, resulting in a decreased number of LDL receptors on 
the liver cells and to increased LDL levels in the blood (39). Actually, most patients 
with elevated levels of serum cholesterol do not have familial hypercholesterolemia, 
but have hypercholesterolemia due to subtle abnormalities in many genes in combina­
tion with environmental factors such as a high intake of dietary fat, calories and 
cholesterol (40). 
3. INTRACELLULAR CHOLESTEROL HOMEOSTASIS AND CHOLESTEROL 
LOWERING DRUGS 
The concept of the LDL receptor as a control mechanism for cholesterol homeosta­
sis in the cell and the cholesterol level in the blood is shown by the mechanism of 2 
groups of cholesterol lowering drags: the bile acid binding resins and the inhibitors of 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) which 
inhibit the biosynthesis of cholesterol. 
3.1 Bile acid binding resins 
Bile acid binding resins, cholestyramine and colestipol, exert their effect in the 
intestinal lumen where they bind bile acids and inhibit their enterohepatic circulation. 
This results in an increased synthesis of bile acids in the liver cell (41). The cholesterol 
needed for this process is partly obtained by increasing the number of LDL receptors 
on the cell surface, thus increasing the uptake of LDL and lowering LDL levels in the 
blood. Indeed it was shown in animal studies and in patients with heterozygous 
familial hypercholesterolemia that treatment with bile acid binding resins increases 
the receptor-mediated uptake of LDL particles (42-44). This finding indicates that 
even in heterozygous familial hypercholesterolemia it is possible to increase the 
number of functioning LDL receptors, by which the consequences of the genetic 
defect are partially overcome. Unfortunately, the effect of bile acid binding resins is 
blunted by the fact that the liver also enhances intracellular cholesterol synthesis by 
increasing the amount of HMG CoA reductase (45). This mechanism prevents the 
intracellular cholesterol content to decrease further and prevents a fuither increase of 
the LDL receptors. The production of VLDL, the precursor of LDL is also increased 
(46). In addition, the drug has adverse effects including gastrointestinal disturbances. 
Altogether, lowering of LDL cholesterol concentration is limited to 20-30% on the 
average. 
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3.2 Inhibitors of 3-hydroxy-3-methyl-glutaryl Coenzyme A 
In man, the majority of the cholesterol metabolized each day is derived from 
endogenous biosynthesis (13). Therefore, inhibition of the cholesterol biosynthesis will 
result in lower intracellular cholesterol levels and to an increase of the number of LDL 
receptors. This concept has been confirmed by the application of a new class of drugs, 
the inhibitors of HMG CoA reductase. 
In 1976, Endo in Japan discovered compactin (ML-236B, later called mevastatin), a 
fungal product of Penicillum citrinum, which appeared to be a highly potent inhibitor 
of HMG CoA reductase, the rate limiting enzyme of the cholesterol biosynthesis which 
involves a series of more than 25 separate enzymatic reactions (Figure 3) (47). In 
primary hypercholesterolemia the drug has a marked cholesterol lowering effect of 
20-30% (48,49). Compactin has not been developed for clinical application. Subse-
quently, a new inhibitor of HMG CoA reductase, lovastatin (MK-703, formerly mevi-
nolin) was discovered. This substance is also a fungal product, from Aspergillus 
terreus. Compared to compactin it has an additional methyl group in the naphthalene 
ring (Figure 4). It also has strong cholesterol-low ering effects of more than S07r in 
dogs, humans with normal cholesterol levels and humans with hypercholesterolemia 
(50-52), whereas it increases the number of LDL receptors on the cell surface in 
animals (43, 53). LDL turnover studies revealed that lovastatin induced receptor-
mediated clearance without a decrease in the LDL production in familial hyper-
cholesterolemia (54). In non-familial hypercholesterolemia, however, the LDL de-
crease was due to a decreased production rather than to an increase of the LDL uptake 
(55). Other HMG CoA reductase inhibitors have been developed recently, including 
HMG CoA 
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Figure J. The pathway of cholesterol biom/nthesiH. (From ref ¿7, with permission.) 
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simvastatin (MK-733, formerly synvinolin), derived by chemical alteration from lova-
statin, and pravastatin (CS-514, SQ 31,000, formerly eptastatin), derived from compac-
tin (Figure 4). These 4 drugs all have strong inhibitory effects on HMG CoA reductase 
(Table 1) (56). An entirely synthetic HMG CoA reductase inhibitor, fluvastatin, is 
currently tested in clinical trials, and others are being developed as well. 
Lovastatin and simvastatin are used as prodrugs in their lacton form; after rapid 
resorption they are converted by esterases in the liver to the open hydroxyacid form, 
the active drug (Figure 5). By this mechanism the active drug is targeted towards the 
liver, which is the main organ of cholesterol synthesis (57). There is a large first pass 
effect by the liver and only 5% of the active drug enters the circulation, which 
presumably limits the potential concentration-dependent adverse effects (57). Pra-
vastatin is taken in the active open hydroxyacid form, shows hardly any first pass 
effect by the liver, and consequently relatively more active drug is found in the 
systemic circulation. Serum protein binding of lovastatin and simvastatin is more than 
90%. There is a rapid elimination with a plasma half life of 2 hours. Both drugs are 
/ Mevastatin [ Pravastatin 
FigureÍ. Inhibitors of3-hydroxy-3-methylglutcmjl coenzyme A. The mvows indicate differen-
ces between the i compounds Mevastatxn = Compactin 
Table 1. Dissociation constants (K,) for the inhtbitor-enzyme complex of the HMG CoA 
reductase inhibitors. (From ref 06) 
К (Tì-nol/l) 
compactin1 1.4*10° 
lovastatin1 3.0 ^lO10 
bimvastatin1 2.3 ^ 1010 
pravastatin 2.3* 10'' 
': concerns the open hydroxyacid form. 
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Figure 3. Piodrug und active form of lorastatin. (From réf. ¿7, mth permission.) 
excreted mainly by the liver, whereas only small amounts are excreted with the urine. 
Clinical studies so far have shown that with these drugs cholesterol can be lowered 
by 30 to 4Q9c on the average, with maximal decreases of 60%, without serious 
subjective or objective adverse experiences (58-64). This effect concerns mainly the 
concentration of LDL cholesterol, whereas those of triglycerides and VLDL choleste-
rol are lowered also; HDL cholesterol concentration is increased by about 10%. 
As outlined, the therapeutic effect of bile acid binding resins on LDL cholesterol 
levels is limited by a concomitantly occurring increase in the cholesterol biosynthesis; 
the latter could be inhibited by an HMG CoA reductase inhibitor. On the other hand, 
one may anticipate an additional effect of bile acid binding resins on the cholesterol 
lowering effects of an HMG CoA reductase inhibitor. Indeed, the combination of an 
HMG CoA reductase inhibitor with a bile acid binding resin yields an important 
additive effect to the cholesterol decrease of either drag alone, whereas the LDL 
receptor activity is further increased (60, 64). 
4. THE WATANABE HERITABLE HYPERLIPIDEMIC (WHHL) RABBIT, AN 
ANIMAL WITH A GENETIC LDL RECEPTOR DEFECT 
In 1973, Watanabe discovered a mutant rabbit with a high cholesterol level. A rabbit 
strain was developed of spontaneous hypercholesterolemic rabbits, which \\ ere cha-
racterized by hypercholesterolemia, atherosclerosis and xanthomatosis (65, 66). The 
genetic defect appeared to be a monogenetic inherited disorder, as was found in 
familial hypercholesterolemia in humans (65,66). In binding studies with hepatocytes, 
cells of the adrenal gland, and fibroblasts from homozygous animals, the LDL receptor 
activity in vitro was found to be less than 5% of normal (67-69). LDL cholesterol was 
cleared from the plasma at a decreased rate and the conversion of VLDL to LDL was 
increased (70, 71). 
Further studies showed that the LDL receptor was synthesized normally, but 
glycosylated at a decreased rate, probably due to an impaired intracellular transport 
of newly synthesized receptors, and that it bound LDL poorly (72). The molecular 
defect was found to be an in-frame deletion of 12 nucleotides in the LDL receptor gene, 
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resulting in an abnormal folding of the receptor protein in the apolipoprotein B100 and 
E binding region (73). 
The grossly elevated serum cholesterol levels found in the WHHL rabbit in the 
homozygous state result in premature atherosclerosis, xanthomatosis and a decreased 
coronary vascular reserve (40,74,75). This animal serves therefore as a unique model 
for both the metabolic and atherosclerotic aspects of homozygous familial hyper-
cholesterolemia in man (40). 
4.1 Cholesterol lowering therapies in the WHHL rabbit 
In patients with homozygous familial hypercholesterolemia, treatment by diet and 
cholesterol lowering drugs has limited or no effect on serum cholesterol levels due to 
their inability to induce functioning LDL receptors (32). In the WHHL rabbit, one 
might expect a similar lack of response to lipid-lowering therapies. However, it 
appeared to be possible to lower cholesterol levels by i) interruption of the enterohe-
patic circulation of bile acids by means of the bile acid séquestrant cholestyramine or 
by partial ileal bypass surgery (76-79), ii) cholesterol synthesis inhibition with lovasta-
tin and pravastatin (53,80,81), and iii) the use of probucol (82). In addition, this 
cholesterol lowering was accompanied by a retardation of the development of athero-
sclerosis (77, 79, 81). 
4.2 Possible mechanisms of cholesterol lowering therapies in the WHHL rabbit 
A decreased number of LDL particles after treatment can be due to an increased 
uptake of LDL, a decreased production of LDL or a combination of both mechanisms. 
Since the WHHL rabbit lacks the LDL receptor, one might postulate that LDL 
lowering can not be achieved by a increased LDL uptake by the receptor. Indeed, in 
WHHL rabbits with and without partial ileal bypass surgery, native and methylated 
LDL (which does not bind to the receptor) decayed at a similar rate. It was therefore 
concluded that the observed LDL cholesterol decrease was caused by a decreased 
LDL production (78). This decreased LDL production theoretically can be due to any 
of the following 3 mechanisms: i) a decreased synthesis of VLDL, the precursor of 
LDL; ii) a decreased conversion of VLDL to LDL; and iii) a decreased synthesis of 
LDL from other sources than from VLDL (78). 
A decreased VLDL synthesis is unlikely to be the cause, since interruption of the 
enterohepatic circulation of bile acids is accompanied by an increase rather than a 
decrease of the VLDL synthesis (79). 
The fraction of VLDL which is ultimately converted to LDL may be influenced by 
the interruption of the enterohepatic circulation of bile acids. As outlined, VLDL 
contain a heterogenous group of particles which can be taken up directly, converted to 
denser VLDL particles and to IDL and LDL. Little is known about the mechanisms 
by which VLDL is converted to LDL. In humans, the larger VLDL particles are taken 
up very rapidly and contribute only little to the formation of LDL; the latter stem 
mainly from the smaller, more dense VLDL particles, which are directly secreted by 
the liver (19-21,23). Studies with large VLDL particles showed that in both normal and 
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WHHL rabbits a subpopulation of large particles is metabolized very rapidly without 
conversion to LDL (83). The fractional conversion of VLDL to IDL and LDL, 
however, is increased in WHHL rabbits compared to normal rabbits (71, 84). 
Cholesterol-lowering therapies might also lower LDL cholesterol levels in the 
WHHL rabbit by an effect on the putative direct LDL production. Such a direct LDL 
production has been suggested for many species, including humans with homozygous 
familial hypercholesterolemia (23, 85), but has not been demonstrated so far in the 
WHHL rabbit; in perfusates of livers of WHHL rabbits no lipoproteins in the density 
range of LDL were found (86, 87). 
Studies on the mechanism by which serum cholesterol levels are lowered in the 
situation that the LDL receptor-mediated processes are absent may enhance the 
insight in the process of formation of LDL. This could have implications for the 
therapeutic approach towards patients with hypercholesterolemia. 
OUTLINE OF THE STUDY 
An elevated level of serum cholesterol is associated with an increased risk of 
coronary artery disease. Cholesterol lowering therapies by diet and drugs decrease 
this risk. If diet alone is insufficient, cholesterol lowering drugs may be warranted. So 
far, the bile acid binding resins have been the drugs of first choice. However, these 
drugs have only limited therapeutic effects and patient's compliance is often hampe-
red by the adverse effects. A promising new development is the development of a new 
class of drugs, the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, 
the rate-limiting enzyme of cholesterol biosynthesis. 
We evaluated the efficacy and safety of simvastatin, one of these new cholesterol 
lowering drugs, as monotherapy and in combination with bile acid binding resins in 
patients with heterozygous familial hypercholesterolemia (chapter 2-4). 
Since cholesterol is necessary for steroid synthesis in the adrenal cortex and gonads, 
inhibition of cholesterol biosynthesis by simvastatin and related compounds may 
interfere with this steroid synthesis. To evaluate this interference, the effects of 
simvastatin on the hypophyseal-adrenal axis were studied in patients with primary 
hypercholesterolemia (chapter 5). 
Homozygous familial hypercholesterolemia is a very rare disorder and, due to the 
lack of LDL receptors, treatment with diet and drugs has only limited effect. Two 
patients with this rare disorder were studied. Diagnostic and metabolic studies and 
the results of treatment with drags and with a new therapeutic approach of selective 
LDL apheresis are described (chapter 6). 
The Watanabe heritable hyperlipidemic (WHHL) rabbit is an animal model for 
homozygous familial hypercholesterolemia. In contrast to its human counterpart with 
homozygous familial hypercholesterolemia, it is possible to lower LDL cholesterol 
levels by various means, including interruption of the enterohepatic circulation of bile 
acids and cholesterol synthesis inhibition in this animal, despite its lack of LDL 
receptors. This cholesterol decrease appeared not to be caused by an increased uptake 
of LDL, but rather by a decreased production. This finding prompted us to further 
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investigate the mechanism by which this decreased LDL production was effected. 
To determine whether the decreased LDL cholesterol level was due to changes in 
LDL metabolism caused by alterations in the LDL particles after bile acid seque-
stration, we evaluated the composition of LDL obtained from normal WHHL rabbits 
and WHHL rabbits after interruption of the enterohepatic circulation of bile acids by 
partial ileal bypass surgery. Moreover, we studied the metabolism of LDL from 
normal and treated WHHL rabbits in both normal and treated rabbits (chapter 7). To 
evaluate whether the decreased production was due to a decreased synthesis of 
VLDL -the precursor of LDL-, to a decreased conversion of VLDL to LDL or to a 
decreased synthesis of LDL from other sources than from VLDL, we investigated the 
metabolism of VLDL, its conversion to IDL and LDL and the metabolism of LDL in 
normal WHHL rabbits and WHHL rabbits after partial ileal bypass sui'gery in a 
combined VLDL and LDL turnover study (chapter 8). 
Finally, we explored the influence of inhibition of cholesterol synthesis on serum 
lipids, lipoprotein composition, the metabolism of LDL and the conversion of VLDL to 
LDL in a series of VLDL and LDL turnover studies in control WHHL rabbits and 
WHHL rabbits treated with simvastatin (chapter 9). 
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SUMMARY 
The effects of simvastatin (MK-733), a competitive inhibitor of 3-hydroxy-3-me-
thylglutaryl coenzyme A reductase, were investigated in 43 patients with heterozy-
gous familial hypercholesterolaemia in a double-blind, placebo-controlled, dose-fin-
ding study. Simvastatin was given in doses ranging from 2.5 to 80 mg per day for four 
weeks. 8 patients received placebo. Low-density-lipoprotein cholesterol fell on aver-
age by 18% on 2.5 mg/day and 42% on 80 mg/day. The drug was as effective whether it 
was given once or twice daily. Serum high-density-lipoprotein cholesterol tended to 
increase and serum triglycerides to decrease on the higher doses. The drug was 
tolerated well. Except for a slight rise in alanine aminotransferase in three patients no 
objective side-effects were observed. 
INTRODUCTION 
A high serum cholesterol level is a major risk factor in coronary heart disease (1). 
Intervention studies with diet and drugs have shown that lowering the concentrations 
of total and low-density-lipoprotein (LDL) cholesterol in the blood can reduce the risk 
of coronary heart disease (2) and arrest the progression of atherosclerotic lesions (3). 
Patients with familial hypercholesterolaemia are at especially high risk of premature 
atherosclerosis (4). Heterozygous subjects with this disorder have only half the 
normal amount of high-affinity receptors for LDL on cell membranes, and LDL levels 
are two to three times higher than normal; cholesterol-lowering diets have only a 
limited effect, which makes drug therapy necessary in these patients (5). This therapy 
is primarily aimed at enhancing the removal of LDL from the plasma by increasing the 
number of LDL receptors. With bile acid séquestrants a reduction in LDL-cholesterol 
of 20-30% can be achieved. In combination with nicotinic acid a reduction of up to 55% 
is possible (6). Owing to side-effects of these drugs, however, compliance is often poor 
and optimum LDL cholesterol levels are usually not attained. A promising new 
approach has been the recent development of inhibitors of the key enzyme in the 
biosynthesis of cholesterol, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase. The two prototype inhibitors, the fungal products compactin (mevastatin) 
and lovastatin (mevinolin), reduced LDL cholesterol in familial hypercholesterolae-
mia patients by 30-35% with excellent tolerance (7-10). Addition of a small amount of 
cholestyramine or colestipol can even lower LDL levels to normal (11-13). 
Simvastatin (synvinolin, MK-733) is another HMG-CoA reductase inhibitor, which 
differs from compactin by two additional methyl groups and from lovastatin by one. 
Because of the additional methyl group in lovastatin it has a greater inhibitory effect 
on HMG-CoA reductase than compactin (14). 
Simvastatin (1,2,6, 7,8a-hexahydro-ß-o-dihydroxy-2,6-dimethyl-8-(2,2-dimethyl-l-
oxobutyoxy)-l-naphtalene-heptanoic acid-lactone) is obtained by chemical synthesis 
from lovastatin. After oral ingestion it is rapidly absorbed from the intestine, reaching 
its peak plasma concentration after 2 h in healthy volunteers. Approximately 4 h after 
ingestion the plasma concentrations have fallen by 50%. From animal studies it has 
appeared that the main route of excretion is through the biliary tract (Merck, Sharp 
29 
and Dohme, data on file). We report here the effects of simvastatin in patients with 
heterozygous familial hypercholesterolaemia. 
PATIENTS AND METHODS 
In a multicentre, double-blind, placebo-controlled study, four centres in The Ne­
therlands contributed a total οΓ43 patients (Amsterdam 11, Leiden 10, Nijmegen 11 and 
Utrecht 11 patients). All had persistent primary hypercholesterolaemia (LDL-choles-
terol concentrations above 6.7 mmol/l) with typical tendon xanthomas and/or family 
members with hypercholesterolaemia, consistent with an autosomal dominant in­
heritance pattern of the disorder. There were 28 men and 15 women. The mean age 
was 44 years (range, 22-69 years) and mean relative body weight 106% (range, 
86-138%). Manifest coronary heart disease (myocardial infarction or angina pectoris) 
was present in 11 of the 43 patients, but they were stable at the time of the study. Each 
patient gave informed consent, and the protocol was approved by the Ethical Commit­
tees of the four institutions. All patients were on a low-cholesterol diet (<300 mg), 
containing 30 energy % as fat and a 1/1 ratio of saturated and polyunsaturated fatty 
acids, which remained unchanged throughout the study; the body weight was constant 
in this period. The patients discontinued any lipid-lowering drugs at least six weeks 
before to the start of the study. A few patients used ß-blocking agents; this treatment 
was not changed during the study. No other drugs known to affect lipid metabolism 
were taken. After the washout period, the patients received placebo matching sim-
vastatin for two weeks and were then randomly assigned to treatment with sim-
vastatin at different doses (35 patients) or placebo (8 patients) for the next four weeks. 
Simvastatin was given either twice daily (1.25 mg, 2.5 mg, 5 mg, 10 mg, 20mg, 40 mg) or 
in one daily dosage immediately before the evening meal (2.5 mg, 10 mg, 40 mg), 
supplemented with placebo before the morning meal. Each treatment group consisted 
of 4 patients, except for the group taking 20 mg twice daily (n=3). These groups were 
comparable with regard to age, sex, body weight and plasma lipid levels. During the 
6-week study, visits to the clinic were scheduled for weeks -2 and 0 (baseline period) 
and weeks 1,2 and 4 (treatment period). Plasma lipids were measured and laboratory 
tests and a brief physical examination carried out at every visit. Laboratory tests 
included: haematological parameters; renal and liver functions; creatine Phosphokina-
se; uric acid; glucose; total protein; thyroxine; sodium, potassium, calcium, and phos-
phate ions; and urinanalysis. A full ophthalmological examination was performed at 
the beginning and the end of the 6-week study, because of some observations of 
cataract formation in dogs after very high doses of mevinolin (Merck, Sharp and 
Dohme, data on file). 
Patients were questioned about adverse experiences and adherence to therapy was 
assessed by capsule counting. Compliance appeared to be over 95% in this highly 
motivated group of patients. Blood samples were obtained after a 12 h overnight fast. 
Serum cholesterol and triglycerides were determined by enzymic methods (15-17). 
High-density-lipoprotein (HDL) cholesterol was determined after precipitation of 
very-low-density lipoproteins (VLDL) and LDL (18,19). LDL cholesterol was calcula-
ted from total serum cholesterol, triglycerides and HDL cholesterol by the Friede-
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wald formula (20). Comparison with ultracentifugical methods to determine LDL-
cholesterol in one centre (Nijmegen) (21) confirmed the accuracy of this formula. The 
mean difference (± SD) between the two methods was 0.10 ±0.15 mmol/1 (1.1 ±1.7%; 
n=55). Statistical analyses were done with the Wilcoxon test for paired and unpaired 
data. Results are expressed as mean ±1SD. 
RESULTS 
There were no significant differences between the two values in the baseline period 
for total serum cholesterol, LDL cholesterol, HDL cholesterol, or triglycerides. The 
changes in lipid levels during the treatment period were compared to the mean of the 
two values at week -2 and 0. The mean baseline values for the whole group of patients 
were: total serum cholesterol 11.44 ± 2.00 mmol/1 (range 8.50 -16.30); LDL cholesterol 
9.66 ± 1.92 mmol/1 (range 6.72 -13.95); HDL cholesterol 1.03 ± 0.19 mmol/1 (range 0.65 -
1.47); and triglycerides 1.67 ± 0.75 mmol/1 (range 0.65 - 3.95). 
The effects of simvastatin in doses of 2.5,10 and 40 mg daily are summarised in table 
I. All these doses produced significantly (P<0.05) greater reductions in total and LDL 
cholesterol than placebo, except for treatment with 2.5 mg once a day. One dose 
appeared to have the same effect as the twice-daily regimen (table I). There were 
similar reductions in LDL cholesterol; the percentage changes on the twice daily 
regimen were 19.5,27.9 and 37.0% after the 2.5 mg, 10 mg and 40 mg daily, respectively, 
compared with 16.0,27.5 and 37.0% after the same daily amounts of simvastatin in one 
dose. The data for patients receiving the same daily dose on the two regimens were 
therefore combined, giving seven treatment groups. 
Table II and Figure 1 show the effects of various doses of simvastatin on the 
concentration of total serum and LDL cholesterol. The 80 mg dosage was no more 
effective than 40 or 20 mg in these small groups. However, plotting the logarithm of 
the simvastatin dose against the percentage change in LDL cholesterol after four 
weeks gave a straight line with a highly significant correlation (r=-0.74, n=35, p<0.001). 
From this curve we calculated that in the range 2.5 to 80 mg simvastatin every 
two-fold increase in dose causes an additional reduction in LDL cholesterol of 4.6%. 
Table I Effect of Simvastatin on ьетт cholesterol after U weeks of treatment 
Treatment 
2.5 mg 
Two doses 
One dose 
10 mg 
Two doses 
One dose 
40 mg 
Two doses 
One dose 
η 
4 
4 
4 
4 
3 
4 
Baseline 
12.95 ± 2.42 
11.00 ± 1.63 
10.77 ± 2.09 
13.69 ± 2.22 
10.23 ± 1.63 
10.64 ± 1.68 
Serum cholesterol (mmol/1) 
After treatment 
10.72 ± 2.79 
9.39 ± 1.51 
8.15 ± 1.94 
10.24 ± 1.40 
7.01 ± 1.12 
7.16 ± 1.40 
Change (Ψο)* 
18.0 ± 6.1 
14.5 ± 7.4 
24.6 ± 7.7 
24.9 ± 2.9 
31.5 ± 3.6 
32.9 ± 6.8 
* None of the differences between one dose and two doses was significant. 
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Table II. Effect of Simvastatin after U weeks of treatment on serum concentration of total and LDL Cholesterol 
Treatment 
Placebo 
2.5 mg/day 
5 mg/day 
10 mg/day 
20 mg/day 
40 mg/day 
80 mg/day 
η 
8 
8 
4 
8 
4 
7 
4 
Baseline 
11.95 ± 1.22 
11.97 ±2.18 
10.27 ± 2.05 
12.23 ± 2.53 
11.89 ±2.63 
10.47 ± 1.53 
10.17 ± 0.95 
Total cholebterol (mmol/l) 
After treatment 
11.32 ± 1.12 
10.06 ± 2.20 
7.93 ± 1.36 
9.19 ± 1.92 
9.02 ± 2.67 
7.09 ± 1.19 
6.54 ± 0.48 
Change (7c) 
- 4.7 ± 6.6 
-16.2 ±6.6* 
-22.5 ± 3.0* 
-24.8 ± 5.4* " 
-25.0 ± 8.4* 
-32.3 ± 5.3** 
-35.5 ± 5.9* 
LDL cholesterol (mmol/l) 
Baseline 
10.13 ± 1.04 
9.89 ± 2.13 
8.80 ± 2.00 
10.47 ± 2.42 
9.97 ± 2.90 
8.78 ± 1.60 
8.72 ± 1.01 
After treatment 
9.55 ± 1.12 
8.17 ± 2.15 
6.46 ± 1.42 
7.58 ± 1.89 
7.11 ±2.99 
5.51 ± 1.04 
5.02 ± 0.69 
Change(%) 
- 5.5 ± 7.4 
-17.7 ± 8.0* 
-26.5 ± 1.(5* 
-27.7 ± Co·1 * 
-30.4 ± 13.6* 
-37.0 ± 6.5* 
-42.2 ± 6.9" 
*p ( ь placebo) <0.01; A*p (vs placebo) <0.001 
Δ LDL-cholesterol (%) 
0-
- 2 0 -
-40-
-60-* ι -
Ο 
I 
20 
— ι — 
40 
— ι 1 1 — 
60 80 
dose ( mg ) 
Figure 1. Effect of simvastatin at various doses on LDL cholesterol. Results in percentage 
change from baseline given as mean ± SEM. 
Δ LDL-cholesterol (β/ο) 
0 -
- 2 0 -
-40-
•60 
О 
• Synvinolin 10 mg/day (n-BÌ 
о Synvinolin 40 mg/day Ι η -71 
—\ 1 -
3 4 
t i m e (weeks ) 
Figure 2. Effect of simvastatin (synvinolin) on LDL cholesterol. Results in percentage change 
from baseline given as mean +SEM. 
*p<0.05 vs. values at week 0,1 and 2; + p<0.05 vs. values at week 0 and 1. 
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Table HI. Effect of Simvastatin after 4 weeks of treatment on serum concentration of HDL Cholesterol aiid LDL Triglycerides 
HDL cholesterol (mmol/1) Triglycerides (mmol/1) 
Treatment 
Placebo 
2.5 mg/day 
δ mg/day 
10 mg/day 
20 mg/day 
40 mg/day 
80 mg/day 
η 
8 
8 
4 
8 
4 
7 
4 
Baseline 
1.14 ±0.18 
1.10 ± 0.12 
0.93 ± 0.16 
0.93 ± 0.19 
1.21 ± 0.13 
0.89 ± 0.17 
1.01 ± 0.08 
After treatment 
1.13 ±0.19 
1.12 ± 0.18 
0.89 ± 0.13 
1.02 ± 0.18 
1.34 ± 0.17 
LOG ± 0.25 
1.10 ±0.19 
Change(%) 
- 0.5 ± 7.3 
+ 1.7 ± 7.8 
- 2.1 ± 18.7 
+ 9.6 ± 7.0* 
+ 11.0+ 8.2** 
+ 21.5 ±31.7** 
+ 8.6 ± 17.6 
Baseline 
1.51 ± 0.56 
2.19 ±1.14 
1.21 ± 0.28 
1.84 ± 0.68 
1.59 ± 0.77 
1.78 ± 0.54 
0.99 ± 0.21 
After treatment 
1.49 ± 0.50 
1.71 ± 0.89 
1.27 ± 0.44 
1.33 ± 0.44 
1.26 ± 0.54 
1.16 ±0.45 
0.92 ± 0.48 
Change Ш 
+ 1.5 ±29.7 
-17.4±18.3 : 
+ 5.0 ±21.2 
-25.9 ± 14.5 
-14.0 ±24.4 
-33.6 ± 23.4: 
-10.7 ±29.3 
*p (vs placebo) <0.05; **0.05 <p (vs placebo) <0.10 
The percentage changes in LDL cholesterol with time during treatment with 
simvastatin in doses of 10 mg and 40 mg daily are shown in figure 2. There was a rapid 
fall during the first 2 weeks. With 10 mg/day the LDL cholesterol level was significant-
ly lower at 4 weeks than at 2 weeks. This was not the case, however, for the group 
taking 40 mg/day. 
HDL cholesterol tended to increase on simvastatin, but the only significant change 
was in the group taking 10 mg/day (table III). Serum triglyceride concentrations fell 
significantly on 10 mg/day and 40 mg/day (table III). 
The drug was tolerated very well. Subjective side-effects were not mentioned. In 3 
patients serum alanine aminotransferase (ALAT) levels rose but did not exceed 200% 
otthe upper limit of normal (1 patient each on 10 mg, 40 mg, and 80 mg simvastatin per 
day). All other test results were normal. Ophthalmological examinations af the end of 
the study showed no formation of lenticular opacities. 
DISCUSSION 
Our results prove the efficacy of simvastatin in lowering LDL cholesterol levels in 
patients with heterozygous familial hypercholesterolaemia. It is possible that the 
patients had not reached steady-state levels in the 4-week trial and that reductions in 
LDL cholesterol on extended therapy may be even greater than in our study. Al-
though the value of comparing different studies is limited, our data suggest that 
simvastatin is even more effective than lovastatin on a mass basis (9, 10, 12). Sim-
vastatin had the same effects on cholesterol levels when taken in one daily dose or 
divided in two doses. Lovastatin, in contrast, is less effective in healthy volunteers 
when given in a single dose (21). Since patient compliance is extremely important in 
the life-long treatment of hyperlipidaemia, the lower dose frequency needed with 
simvastatin is an advantage over lovastatin. The somewhat stronger effect of sim-
vastatin is possibly caused by a higher affinity for HMG-CoA reductase owing to the 
additional methyl group in this compound, as has been shown for lovastatin compared 
with compactin (14). HDL cholesterol during simvastatin treatment showed a tenden-
cy to rise at doses of 10 mg/day and more. In studies with mevastatin or lovastatin as 
single therapy in heterozygous familial hypercholesterolaemia patients, HDL choles-
terol did not change (9,12) or rose slightly (10). The effects of these drugs on HDL 
cholesterol are therefore not yet conclusive. 
The HMG-CoA reductase inhibitors exert their effect on cholesterol levels by a 
competitive inhibition of the rate-limiting enzyme in cholesterol biosynthesis (23). It is 
postulated that the subsequent reduction in intracellular cholesterol leads to compen-
satory induction of LDL receptors and to a rise of the fractional catabolic rate of LDL 
(24,25). 
Studies in animals and patients have also shown that a fall in the production rate of 
LDL may contribute to the observed decrease in LDL after therapy (24-26). The 
lower production might be the result of enhanced removal of the precursors of LDL, 
which are also bound by the LDL receptors (27), or of reduced production of VLDL by 
the liver. The fall in serum triglycerides observed at higher doses of lovastatin (9) 
supports these possibilities. In our study w7e also found a fall in serum triglycerides in 
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all groups receiving simvastatin except the group receiving 5 mg/day. 
Simvastatin was well tolerated in this study; ALAT rose slightly in 3 of the 35 
patients. In studies with lovastatin, slight rises in ALAT have also been seen (10,22). 
No consistent side-effects have been noted in patients treated for up to 24 months with 
lovastatin (12). Doses of simvastatin of 10 mg/day or more did not seem to yield much 
further reduction in cholesterol. However, every doubling of dose resulted in an 
additional 4.6% decrease in LDL cholesterol. Based on these figures a dose of 40 
mg/day would result in a reduction of LDL cholesterol of 35% after 4 weeks. 
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SUMMARY 
Simvastatin (MK-733), a new inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase, was administered to 38 patients with heterozygous familial hypercholeste-
rolaemia for 24 weeks. A dose of 40 mg per day produced a mean reduction in low 
density lipoprotein cholesterol of 43-45% and in triglycerides of 21-31%. Mean high 
density lipoprotein cholesterol increased significantly by 10-13%. There wTere no major 
differences in response whether the drug was taken in one or two doses. MK-733 was 
tolerated well. Adverse effects were infrequent and limited to slight increases of 
alanine aminotransferase, creatine Phosphokinase and bilirubin. This drug appears to 
be a potent inhibitor of cholesterol synthesis and has produced the largest therapeutic 
response as monotherapy in patients with familial hypercholesterolaemia. 
INTRODUCTION 
Patients with heterozygous familial hypercholesterolaemia are at increased risk of 
premature atherosclerosis (1). Due to a genetic defect, they exhibit only half the 
number of low density lipoprotein (LDL) receptors on the cell membrane, and LDL 
levels are 2-3-fold higher than normal (2). Drug therapy is necessary in these patients 
to enhance the removal of LDL from the plasma by increasing the number of LDL 
receptors (2). However, due to side effects of conventional cholesterol lowering drugs, 
such as bile acid-binding resins and nicotinic acid, patient compliance is often in-
sufficient and normal values are seldom reached. On the other hand, recent clinical 
trials with inhibitors of the key enzyme in cholesterol synthesis, S-hydroxy-S-me-
thylglutarylcoenzyme A (HMG-CoA) reductase, have proved the efficacy and toleran-
ce of these drugs. LDL-cholesterol decreased on average by 30-35% (3-6). Addition of 
a small amount of bile acid binding resins can even lower LDL levels to normal (7-9). 
Simvastatin (MK-733) is obtained by chemical alteration of lovastatin. The methyl-
butanoyl group of lovastatin is replaced by a 2,2-dimethylbutanoyl group. Recently, 
we reported the effects of simvastatin in a double-blind, placebo controlled dose-
finding study during a short period of 4 weeks in patients with heterozygous familial 
hypercholesterolaemia. LDL-cholesterol fell on average by 18% on 2,5 mg/day to 42% 
on 80 mg/day after 4 weeks; high density lipoprotein (HDL)-cholesterol tended to 
increase and triglycerides tended to decrease at higher doses (10). Similar results were 
published by Olsson et al. (11) using the same protocol. We now report the effects of 
simvastatin during 24 weeks of treatment in an open extension trial of the first study. 
PATIENTS AND METHODS 
In a multicentre dose-finding study (10) 4 centres in the Netherlands contributed a 
total of 43 patients. They received placebo or simvastatin at a dose between 2.5 and 80 
mg for 4 weeks; after informed consent, all patients entered the current study except 
one for personal reasons. During the study, one patient, a 26-year-old man, suffered 
from a myocardial infarction and underwent coronary bypass surgery; one patient had 
a period of abdominal discomfort during which no medication was taken; one patient 
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forgot to take medication for 7 days, and one patient did nog complete the study 
because of serious injury in an accident. The results of these 4 patients were not 
included. Thus, 38 patients (15 women and 23 men) completed the study. They all had 
highly elevated serum total cholesterol and LDL-cholesterol levels. Based on typical 
xanthomas and/or family studies, all had heterozygous familial hypercholesterolae-
mia. Mean age was 45 ± 12 years (range 22-G9), and mean weight was 72.9 ± 10.0 kg 
(relative weight 106.0 ± 12.9%; range 87.4-138.1). All subjects were on a standard lipid 
lowering diet, low in cholesterol ( < 300 mg/day), containing 30% of energy as fat and a 
1:1 ratio of saturated and unsaturated fatty acids, which remained unchanged through-
out the study. Except for ß-blocking agents no drugs known to influence lipid metabo-
lism were used. The dosage of this medication was stable throughout the study. 
Patients underwent a full physical and ophthalmological examination including colour 
vision tests, visual acuity testing and slit-lamp examination at the beginning and at the 
end of the study. 
Between the end of the dose-finding study and the start of the cun-ent study 2^1 
weeks elapsed during which the patients did not receive lipid lowering therapy. 
Simvastatin was given for 24 weeks. In the first 8 weeks all patients received 10 mg 
twice daily, thereafter the dose was increased to 20 mg twice daily. Ten patients were 
kept on this regimen during the remainder of the study, whereas 20 patients were 
changed to a single dose of 40 mg before the evening meal from 16 to 24 weeks, and 8 
patients to this single dose from 20 to 24 weeks. Patients visited the clinic at 4-week 
intervals. They were questioned about possible adverse experiences and underwent a 
brief physical examination. Blood was taken for determination of serum lipids and 
safety paramaters after a 12-h overnight fast. Serum cholesterol and triglycerides 
were determined by enzymatic methods (12-14). HDL-cholesterol was determined 
after precipitation of very low density lipoprotein (VLDL) and LDL (15,16). LDL-
cholesterol was calculated from total cholesterol, total triglycerides and HDL-choles-
terol by the Friedewald formula (17). Safety parameters included haematological 
parameters, liver and renal function tests, creatine Phosphokinase, uric acid, glucose, 
total protein, thyroxine, sodium, potassium, calcium and phosphate ions, prothrombin 
time and urinalysis. 
Apolipoproteins (apo) A-I, A-II, В and E were determined in serum by radial 
immunodiffusion in 9 patients from one centre. This method agrees well with a rocket 
Immunoelectrophoresis method (18). If duplicates differed more than 10%, results 
were rejected and the determination was repeated. All results were compared with 
the mean of the 2 values obtained from the initial dose-finding study before active 
treatment. Statistical analyses were done with the Wilcoxon test for paired data. A 
two-sided P-value of less than 0.05 was considered to be significant. Correlations were 
estimated according to Spearman. Values are expressed as mean ± SD unless otherwi­
se indicated. 
RESULTS 
Since there were no significant differences between the 3 groups in total cholesterol, 
LDL-cholesterol, triglycerides and HDL-cholesterol both before and at all times 
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Figure 1. Total señan cholesterol levels during administration of simvastatin (MK-733) to 38 
patients with heterozygous familial hypercholesterolaemia. 
Table 1 Fffecl of simvastatin (MK-733) on serum concentration of LDL-cholesterol in 38 
patients. 
Results are mean ± SD. 
Time (weeks) 
0 
4 
8 
12 
16 
20 
24 
Dose (mg/day) 
0 
20 
20 
40 
40 
40 
40 
LDL-cholesterol (mmol/l)* 
9.70 ± 1.93 
6.25 + 1.47"*.***« 
S.96±1.36 , ,** i 
5.37 ± 1.19 
5.40 ± 1.37 
5.27 ± 1.26+ 
5.54 ± 1.38 
Change 
— 
-35.5 ± 8.9 
-38.3 ± 8.7 
-44.4 ± 8.5 
-44.2 ± 9.0 
-45.3 ± 9.5 
^ 2 . 5 ± 10.5 
range 
(-10.2 to-54.9) 
(-17.5 to-56.9) 
(-19.0 to -62.8) 
(-27.2 to-62.2) 
(-30.9 to -70.9) 
(-24.2 to-66.0) 
* All values during treatment differed significantly from baseline value (P < 0.001). 
** Ρ (vs. 8 weeks) < 0.01; *** Ρ (vs. 12,16,20 weeks) < 0.001; * Ρ (vs. 24 weeks) < 0.01; 
++
 Ρ (vs. 24 weeks) < 0.001. 
during treatment, the results of all patients were combined. Administration of sim­
vastatin resulted in a rapid and highly significant decrease of mean total and LDL 
cholesterol, at maximum of 39.2 and 45.3%, respectively, after 20 weeks (Fig. 1, Table 
1). At 8 weeks, these values were significantly lower than at 4 weeks. The values for 
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mean total LDL-cholesterol during a dose of 40 mg/day were lower than those on 20 
mg/day at all times. No major changes were observed after 12 weeks of treatment. At 
24 weeks, the LDL-cholesterol levels were slightly but significantly higher than at 20 
weeks. Analysis of the results of the groups receiving the drug divided in 2 doses 
during the entire study (n = 10), in one single dose after 16 weeks (n = 20), and in one 
single dose after 20 weeks (n = 8), showcnl that this increase was largely due to changes 
in the last group (Table 2). 
The average percentage reduction in total cholesterol and LDL-cholesterol in women 
was not significantly higher than in men at all time points during treatment. On 40 
mg/day, the average percentage reduction in total cholesterol ranged from -39.9 ± 9.7 
to -41.8 ± 10.8% for women and from -34.2 ± 8.0 to -37.6 ± 6.0% for men, and for 
LDL-cholesterol, from -46.3 ± 12.7 to -48.6 ± 11.7% for women and from -40.0 ± 8.1 to 
-43.1 ± 7.3% for men. 
HDL-cholesterol increased during treatment by 10.3-14.3%; this effect was appa­
rently not related to the dose (Table 3). Triglycerides decreased by 30.8% after 24 
weeks (Table 3). Apolipoprotein levels, studied in 9 patients only, showed a decrease of 
apo В of 43-45% on 40 mg/day, but no major change in apo A-I was seen. There was an 
increase of apo A-II up to 23% on a dose of 40 mg/day; apo E decreased with a 
maximum of-43% after 20 weeks (Table 4). 
The drug was tolerated well. One patient complained about dizziness lasting for 2 
days and another patient had diarrhoea for 1 week. Laboratory side-effects were 
limited to an increase in alanine aminotransferase, occurring in 4 patients, which was 
Table 2. Serum total cholesterol and LDL-cholebterol levels at baseline period and at 12,16,20 
and 2U weeks. 
All patients received Simvastatin (МК-73.І) 40 mg/day orally divided iiito2 doses from week 8-16, 
group 1 (n = 10) remained on this regimen, group 2 (n = 20) received the dmg in one single dose 
before the evening meal from week 16 to 24, gmup .1 (n = 8) in one single dose from week 20 to 24. 
Results are mean ± SD. 
Cholebterol (mmol/1) 
Group 1 
(dose) 
Group 2 
(dose) 
Group 3 
(dose) 
Baseline 
11.74 ± 1.90 
11.17 ± 1.98 
11.88 ±2.39 
LDL-cholebterol (mmol/1) 
Group 1 
(dose) 
Group 2 
(dose) 
Group 8 
(dose) 
10.03 ± 1.99 
9.39 ± 1.93 
10.05 ± 1.97 
Week 12 
7.21 ± 1.39 
(2x20 mg) 
7.03 ±1.11 
(2x20 mg) 
6.92 ± 1.70 
(2x20 mg) 
5.57 ± 1.40 
(2x20 mg) 
5.32 ± 1.05 
(2x20 mg) 
5.24 ± 1.39 
(2x20 mg) 
Week 16 
7.41 ± 1.67 
(2x20 mg) 
7.06 ± 1.09 
(2x20 mg) 
6.89 ± 1.80 
(2x20 mg) 
5.70 ± 1.69 
(2x20 mg) 
5.31 ± 1.17 
(2x20 mg) 
S.24 ± 1.51 
(2x20 mg) 
Week 20 
7.18 ± 1.42 
(2x20 mg) 
6.89 ± 1.16 
(1x40 mg) 
6.70 ± 1.68 
(2x20 mg) 
5.58 ± 1.46 
(2x20 mg) 
5.19 ± 1.13 
(1x40 mg) 
5.10 ± 1.42 
(2x20 mg) 
Week 24 
7.28 ± 1.49 
(2x20 mg) 
7.09 ± 1.20 
(1x40 mg) 
7.37 ± 2.12* 
(1x40 mg) 
5.61 ± 1.52 
(2x20 mg) 
5.46 ± 1.19* 
(1x40 mg) 
5.67 ± 1.79* 
(1x40 mg) 
Ρ (vs. 20 \еекь)<0.05. 
44 
Table J. Effect of Simvastatin (МК-7.ІЗ) on serum concentration of HDL-Cholesterol and Triglycerides in SS patients. 
Results are mean ± SD. 
Time 
(weeks) 
0 
4 
8 
12 
16 
20 
24 
Dose 
(mg/day) 
0 
20 
20 
40 
40 
40 
40 
HDL-chol. 
(mmol/l)* 
1.03 ± 0.19 
1.17 ± 0.25 
1.16 ± 0.25 
1.13 ± 0.25 
1.15 ± 0.27 
1.12 ± 0.20 
1.16 ± 0.24 
Change 
% 
-
14.3 ± 15.4 
13.4 ± 15.4 
10.6 ± 15.7 
11.7 ± 17.4 
10.3 ± 14.5 
13.2 ± 17.2 
range 
(-18.7 to +46.3) 
(-13.0 to+47.1) 
(-24.1 to +47.5) 
(-13.0 to +52.5) 
(-19.6 to +40.6) 
(-11.8 to +49.3) 
Triglycerides 
" (ттоІЛ)* 
1.65 ± 0.74 
1.21 ± 0.67 
1.24 ± 0.58*** 
1.24 ± 0.67** 
1.26 ± 0.56*** 
1.18 ± 0.54 
1.10 ± 0.54 
Change 
% 
-
-25.0 ± 21.8 
-20.7 ± 22.5 
-24.2 ± 18.5 
-21.1 ± 17.6 
-25.9 ± 24.5 
-30.8 ± 17.0 
range 
(-67.4 to +36.4) 
(-56.9 to +27.0) 
(-63.6 to +18.2) 
(-55.0 to +22.7) 
(-56.2 to +60.0) 
(-68.1 to + 2.2) 
All values during treatment differed significantly from baseline value (P < 0.001); ** Ρ (vs. 24 weeks) < 0.05; *** Ρ (vs. 24 weeks) < 0.01. 
Table 4. Apo В, A-I, A-II, and E lecels before and after treatment with Simvastatin (MK-7,i,i) 
in 9 patienta. 
8 patients received the drug in 2 daily doses from week 0 to 20 and in one dose from week 20 to 24; 
1 patient used the drug in 2 doses during the entire study. Only results of statistical analyses 
versus baseline values are indicated. Results are mean ± SD. 
Time 
(weeks) 
0 
4 
8 
12 
16 
20 
24 
Dose 
(mg/day) 
0 
20 
20 
40 
40 
40 
40 
mg/dl 
ApoB* 
324 ± 59 
194 ± 39 
193 ± 31 
177 ± 39 
178 ± 48 
181 ± 37 
184 ± 49 
Apo A-I 
172 ± 22 
159 ± 8 
179 ± 16 
169 ± 16 
180 ± 2 1 " 
181 ± 23 
179 ± 19 
Apo A-II 
51 ± 8 
56 ± 7** 
53 ± 9™* 
63 ± 1 1 * * * 
61 ± 10*** 
55 ± 10** 
59 ± 1 1 * * * 
ApoE* 
10 ± 3 
7 ± 2 
7 ± 2 
6 ± 2 
6 ± 1 
5 ± 1 
6 ± 2 
* All values differed significantly from baseline values (P < 0.01); ** Ρ (vs. 0 weeks) < 0.05; *** Ρ 
(vs. 0 weeks) < 0.01. 
higher than the 200% upper normal level in one patient on one occasion only. The mean 
value of alanine aminotransferase in the entire group showed a tendency to rise from 
week 16, and at week 24 the mean value was 30% higher than the basal value (P < 0.01). 
Mean values of aspartate aminotransferase also rose during treatment up to 30%; from 
week 8, these rises were significant. Other laboratory side effects were short lasting 
increases in creatine Phosphokinase in 6 patients. These did not occur on more than 2 
subsequent occasions and values returned to normal while the drug was continued. 
The average value of creatine Phosphokinase showed no significant rise. Bilirubin 
levels were elevated in 2 patients on one occasion to 30 and 41% above the upper 
normal level, respectively. The drug was continued and on the next visit the values 
had returned to normal. Prothrombin time was prolonged in one patient on one 
occasion. The ophthalmological examination at the end of the study did not reveal any 
changed from the pre-trial examination. In particular, no new lens opacities were 
noted. 
DISCUSSION 
This study shows the efficacy of simvastatin as a single therapy in patients with 
heterozygous familial hypercholesterolaemia. A mean decrease of LDL-cholesterol of 
45.3% was found with an oral dose of 40 mg/day after 20 weeks. In this respect, 
simvastatin appears to be even more potent than lovastatin or mevastatin. Mean 
reductions in LDL-cholesterol in heterozygous familial hypercholesterolaemia pa­
tients by lovastatin have been reported to be 30-38% (4,5,8) and by mevastatin 25-30% 
(3). Although these drugs were not tested in the same patients and some difference in 
response might be due to patient selection, simvastatin appears to be even more 
potent than lovastatin or mevastatin in LDL-cholesterol lowering capacity. The 
apparently higher potency of simvastatin might be the result of a higher affinity for 
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HMG-CoA reductase, owing to the additional methyl group compared to lovastatin, 
and the 2 methyl groups compared to mevastatin, as suggested earlier (10). 
Simvastatin appeared not to have reached a steady therapeutic effect before 8 
weeks of administration. Doubling the dose thereafter yielded an additional, small 
decrease and after 12 weeks a plateau was reached. Since the drug was not given on a 
dose per kg body weight basis, a higher cholesterol lowering effect might be expected 
at lower body weights. However, there was no significant correlation between the 
percentage decrease of total cholesterol or LDL-cholesterol and the reciprocal value 
of body weight at any time during treatment. 
Mean HDL levels clearly increased by 10-14%; in studies with mevastatin or 
lovastatin as a single therapy in heterozygous familial hypercholesterolaemia pa­
tients, HDL-cholcsterol levels did not change (4, 8), or increased by 16% (5). In our 
previous study, we found an increase of HDL-cholesterol of 10-22% at doses of 10-40 
mg simvastatin per day (10). This increase, which is epidemiologically correlated with 
a decreased risk of coronary artery disease, is also reflected in the change of the 
LDL-cholesterol/HDL-cholesterol ratio which decreased from a baseline value of 9.7 ± 
2.5 to 4.9 ± 1.5 (-49.7 ± 10.7%) after 20 weeks. However, it is as yet uncertain whether a 
drug-induced increase of HDL-cholesterol has the same beneficial effects on the risk 
of cardiovascular disease as might be expected from the results of epidemiological 
studies. 
The observed changes in apolipoproteins are largely in accordance with the changes 
in cholesterol and triglycerides; apo В decreased parallel to the decrease in LDL, 
whereas apo E decreased parallel to triglycerides. In contrast to apo A-II, apo A-I did 
not change, whereas HDL-cholesterol in the whole group increased. However, apoli-
poprotein levels were only determined in 9 patients; HDL-cholesterol levels in these 
patients showed only small increases. 
The drug appeared to be as effective, whether taken in 1 or 2 doses. The small but 
significant increase after 24 weeks was largely due to the group of 8 patients who 
started using the drug in one daily dose at 20 weeks; after 28 weeks, cholesterol and 
LDL-cholesterol levels in this group had decreased again to levels not significantly 
different from the levels at 12,16 or 20 weeks (total cholesterol after 28 weeks: 7.07 ± 
1.54 mmol/1; LDL-cholesterol 5.31 ± 1.20 mmol/1). Although this may indicate some 
influence of dose frequency on therapeutic response, this effect seems to be rather 
small and clinically unimportant. Since patient compliance may improve with a lower 
dose frequency, this might be advantageous. 
Clinical side effects of the drug were non-specific. Increases in alanine aminotrans­
ferase exceeded the 200% level of normal values in one patient at one occasion only. 
Such increases have also been found in other studies on HMG-CoA reductase in­
hibitors (5, 6, 10, 19). The rise in creatine Phosphokinase, probably due to physical 
excercise, wTas not accompanied by clinical symptoms and never occurred on more than 
2 subsequent occasion. Rises in bilirubin were occasionally observed. Such rises have 
not been mentioned in other studies on HMG-CoA reductase inhibitors. However, 
increases never exceeded the 150% level of the normal value, and levels had returned 
to normal at the next visit in all cases. Since these changes in creatine Phosphokinase 
and bilirubin normalised while the drug was continued, it seems not likely that they 
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were drug-related. The nse in prothrombin time occurred in one patient at one 
occasion only without clinical symptoms. 
The cholesterol lowering effects of the HMG-CoA reductase inhibitors are caused 
by increased production of the LDL receptor and the subsequent increase in the 
fractional catabolic rate of LDL (20-22). Studies in both animals and patients have also 
shown that a decreased production of LDL may contribute to a decreased LDL 
concentration (19,23); this decreased production may be the result of enhanced remo­
val of LDL precursors or reduced production of VLDL by the liver. The decrease in 
triglycerides and also of apo E found m the current stud}' may reflect the result of this 
mechanism. Therefore, simvastatin might also be of use in those hyperlipidaemias 
which are caused by overproduction of VLDL, whether or not in combination with 
impaired remnant removal. Indeed, this type of drug appears to be effective in type 
III hyperlipidaemia (24). 
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SUMMARY 
The effects of simvastatin, an inhibitor of the cholesterol synthesis, on serum 
lipids, lipoprotein composition and apolipoproteins were evaluated in a total of 50 
patients with hypercholesterolaemia. In the first study 24 patients (mean serum 
cholesterol 10.74 ±1.59 mmol/1) were treated with simvastatin 40 mg daily for 24 
weeks. Serum cholesterol and low density lipoprotein (LDL) cholesterol decreased 
to average values 29-36% and 35-42% below the basal value, respectively. Serum 
triglycerides decreased 16-28% and high density lipoprotein (HDL) cholesterol 
increased 6-11%. Apolipoprotein A-I concentration increased 6-8% and that of apoli-
poprotein В decreased 29-33%. The composition of LDL remained unchanged whe­
reas the very low density lipoproteins became enriched in triglycerides. Lipoprotein 
Lp(a) was not affected. In the second study 26 patients (mean serum cholesterol 
12.35 ±2.05 mmol/1) were treated with simvastatin 40 mg daily as monotherapy or 
combined with a bile acid binding resin for 2 years. Serum cholesterol levels de­
creased to values which remained stable throughout the entire study period; after 2 
years this decrease amounted to 43%. Compared to monotherapy, combination 
therapy yielded a further 12% decrease of cholesterol. In the entire group, triglyceri­
des decreased by 16% and HDL cholesterol increased by 9%. Side effects were 
limited to slight increases in alanine aminotransferase and creatine Phosphokinase 
in some patients. Simvastatin appears to be an important asset in the treatment of 
hypercholesterolaemia. 
INTRODUCTION 
It is generally accepted that a high serum cholesterol level plays a crucial role in the 
development of coronary artery disease. In intervention studies in patients with 
hypercholesterolaemia it has been demonstrated that lowering the cholesterol level 
with drugs can lower the risk of coronary atherosclerosis (1-3). The dings of first 
choice up till now are the bile acid binding resins, cholestyramine and colestipol, and 
nicotinic acid. Treatment with these drugs is often disappointing, because patient's 
compliance can be influenced by the subjective adverse effects of these drags causing 
a limited therapeutical response in many patients (4). 
Recently, a new class of drags has been developed, the group of inhibitors of the 
synthesis of cholesterol. These drugs are competitive inhibitors of 3-hydiOxy-3-
methyl-glutaryl coenzyme A (HMG CoA) reductase, the rate limiting enzyme in the 
cholesterol biosynthesis. Clinical studies have shown that with these drugs choleste­
rol can be lowered by 30 to 40% on the average, with maximal decreases of 60%, 
without serious adverse experiences (5-12). Combination with a bile acid binding resin 
yields an important additive effect to the cholesterol decrease produced by the 
cholesterol synthesis inhibitor alone (7,11). 
We here report on the effects on serum lipids, apolipoproteins and lipoprotein 
composition in patients with hypercholesterolaemia treated with simvastatin, the 
most potent cholesterol synthesis inhibitor so far (8, 9). 
53 
PATIENTS AND METHODS 
A total of 50 patients with severe hypercholesterolaemia was investigated in two 
separate studies. On the basis of family studies and/or the presence of tendon xan­
thomas, in all but 3 patients the diagnosis of familial hypercholesterolaemia was 
established. In these 3 remaining patients this diagnosis could not be made with 
certainty; the serum cholesterol levels of these 3 patients ranged from 9.09 to 9.66 
ттоШ. All patients were on a standard lipid lowering diet (cholesterol less than 300 
mg/day; ratio saturated to poly-unsaturated fatty acids of less than 1). They had not 
used any lipid lowering drugs at least С weeks before the start of the study. All women 
were postmenopausal or had been surgically sterilized. 
In the first study 24 patients (13 men and 11 women, mean age 42 ±13 years) were 
treated with placebo for 4 weeks followed by simvastatin 40 mg per day, in a single 
dose before the evening meal for 24 weeks. One patient was lost to follow-up after 16 
weeks because he moved to a different city. 
The second study concerned 26 patients (16 men and 10 women, mean age 41 ±12 
years), who were treated for 2 years with simvastatin in a single daily dose of 40 mg 
per day before the evening meal. In 14 patients simvastatin was combined with a bile 
acid binding resin (daily dose 2 to 6 sachets cholestyramine of 4 grams each or 
colestipol of 5 grams each; average daily dose 3 sachets). The results were evaluated 
after one year (50 ±3 weeks) treatment in all patients and after 2 years (106 ±14 weeks) 
treatment in 24 of the 26 patients (the remaining 2 patients had only been treated for 
one year at the time of evaluation). At evaluation after one year, the medication had 
not been altered for at least 8 weeks. In the second year the dose was unaltered. 
The patients visited the clinic at intervals of 4 to 8 weeks; at all visits blood was 
taken for determination of the lipids and safety parameters, which included liver and 
renal function, creatine Phosphokinase (CK), haemoglobine, leucocyte count and 
thrombocyte count. In addition, in the 24 patients of the first study, serum was taken 
at several time points for determination of apolipoproteins, lipoprotein Lp(a), very low 
density lipoprotein (VLDL) cholesterol and VLDL triglycerides; and for determina­
tion of the composition of the LDL particles (at the start and end of the placebo period 
and after 8 weeks treatment; the latter time point was chosen because after 4 weeks of 
treatment with simvastatin stable lipid values have not yet been reached (8,9)). Every 
six months an ophthalmological examination was performed. 
Cholesterol and triglycerides were measured by enzymatic methods (no 237574, 
Boehringer Mannheim GmbH, FRG and no 6684, Sera PAK, Miles, Italy, respectively) 
(13). Phospholipid and free cholesterol were measured with enzymatic kits (nos 691844 
and 310328, respectively, Boehringer Mannheim GmbH, FRG). Protein was determi­
ned according to the method described by Lowry et al (14). The serum high density 
lipoprotein (HDL) cholesterol was measured after precipitation of the other lipo­
proteins with polyethylene glycol 6000 (15). The LDL cholesterol concentration was 
calculated using the Friedewald formula (LDL cholesterol = serum cholesterol - HDL 
cholesterol - 0.45 · serum triglycerides) (16). Apolipoproteins (apo) B, A-I, A-II and E 
were determined in serum by radial immunodiffusion; this method agrees well with a 
rocket immunoelelectrophoresis method (17). Lipoprotein Lp(a) was determined with 
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a specific radioimmunoassay (Apolipoprotein(a) RIA 100, Pharmacia Diagnostics AB, 
Uppsala, Sweden). VLDL cholesterol was determined after sequential ultracen-
trifugation of the serum at a density < 1.006 g/ml (18). LDL was isolated by density 
gradient ultracentrifugation as described previously (19). LDL separated in this way 
can be identified as a separate band with a density between 1.025 and 1.063 g/ml. The 
average recovery of the lipoproteins isolated by gradient ultracentrifugation based on 
cholesterol concentration averaged 92 ±4% before and 92 ±3% after treatment, with a 
range of 85 to 106%. Compositions of the LDL particles were calculated as percentage 
of dry mass. 
Statistical evaluation of the data was performed using the Student's T-test or 
Wilcoxon's test for paired and unpaired data; a 2-sided P-value of less than 0.05 was 
considered to be significant. Correlations were calculated according to Spearman. The 
results are expressed as means ±SD. 
RESULTS 
Lipids 
In the 24 patients of the first study the average serum cholesterol levels at the end of 
the placebo period amounted to 10.74 ±1.59 mmol/1 (range 8.09 to 13.83 mmol/1). The 
serum cholesterol concentration decreased in 4 to 8 weeks to a steady state level. After 
24 weeks, the serum cholesterol and LDL cholesterol concentration had decreased by 
an average of 36% and 42%, respectively (Table 1). The serum triglyceride levels were 
significantly lower during treatment, on the average 25% after 24 weeks (Table 1). On 
average, the HDL cholesterol concentration was higher during treatment, ranging 
from 6% after 24 weeks to 11% after 16 weeks (Table 1). Comparison of the results of the 
serum cholesterol levels with the levels recommended in the Dutch cholesterol con­
sensus conference (20) (which are largely in agreement with those of the European 
Atherosclerosis Society (21)) showed that before treatment all patients had a strongly 
elevated serum cholesterol (more than 8.0 mmoW). After 24 weeks of therapy 22% had 
a strongly elevated level, 39% a slightly elevated level, (between 6.5 and 8.0 mmol/1), 
30% a normal level (between 5.0 and 6.5 mmol/1), and 9% an ideal level (less than 5.0 
mmol/1). 
The results of changes in the apolipoproteins are summarized in table 2. There was a 
rapid decrease in apo В concentration of 31% after 4 weeks after which the decrease 
remained stable. The apo A-I concentration increased by on the average 4-8%. After 8 
weeks the apo A-II concentration had increased by 9%, while that of apo E had 
decreased by 15%. All these changes were significant. Lipoprotein Lp(a) amounted to 
587 ±637 U/l (median: 395 U/l) before treatment and 628 ±777 U/l (median: 397 U/l) 
after treatment; this difference was not significant. 
Compositions of LDL were determined at the start of the placebo period in 24 
patients and at the end of the placebo period in 16 of 24 patients. Since there were only 
minor and non-significant changes in the lipoprotein concentration and composition 
beween the values obtained at both time points in these 16 patients, values during 
treatment were compared with those at the begin of the placebo period in all 24 
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Table 1. Effects ofiO mg simvastatin per day on serum cholesterol, low density lipoprotein (LDL) cholesterol, semm triglycerides and high density 
lipoprotein (HDL) cholesterol (in means ±SD) and the percentual changes (%) in ¿i patients with hypercholesterolaemia. 
Week 
0 
4 
8 
12 
16 
20 
24 
Cholesterol 
(mmol/1) 
10.74 ± 1.59 
7.59 ± 1.39a 
6.96 ± 1.22'' 
7.45 ± 1.33" 
7.53 ± 1.46" 
7.20 ± 1.44a 
6.89 ± LSS" 
(%) 
-29% 
-35% 
-30% 
-30% 
-33% 
-36% 
LDL cholesterol 
(ттоІЛ) 
8.83 ± 1.77 
5.77 ± 1.44·' 
5.21 ± 1.29" 
5.65 ± 1.38a 
5.77 ± 1.56" 
5.43 ± 1.47" 
5.14 ± 1.40" 
(%) 
-
-35% 
-417c 
-36% 
-35% 
-38% 
-42% 
Triglycerides 
(ттоШ) 
1.79 ± 0.92 
1.39 ± 0.55'' 
1.24 ± 0.48* 
1.36 ± 0.58b 
1.21 ± 0.50" 
1.33 ± 0,47a 
1.32 ± 0.64" 
(%) 
-16% 
-25% 
-18% 
-28% 
-21% 
-25% 
HDL cholesterol 
(mmol/1) 
1.11 ±0.34 
1.20 ± 0.37" 
1.19 ± 0.29" 
1.19 ± 0.33b 
1.22 ± 0.33" 
1.18 ± 0.32' 
1.15 ± 0.32 
m 
+ 8% 
+ 9% 
+ 8% 
+11% 
+ 8% 
+ 6% 
Ρ (vs. week 0) < 0.001. 
Ρ (vs. week 0) < 0.01. 
Ρ (vs. week 0) < 0.05. 
patients. There was a decrease in all components of this fraction without any change in 
compositions (Table 3). 
In the VLDL fraction (d<1.006 g/ml), there was a decrease in cholesterol content 
from 0.68 ±0.44 mmol/1 after placebo to 0.38 ±0.25 т т о І Л after 8 weeks of treatment 
(-35 ±37%; P<0.001) and in triglycerides content from 0.95 ±0.78 mmol/1 after placebo to 
0.63 ±0.39 mmol/1 after 8 weeks of treatment (-21 ±33%; P<0.01). The ratio cholesterol 
to triglycerides in the VLDL fraction decreased by 18 ±22% from 0.77 ±0.31 after 
placebo to 0.59 ±0.17 after 8 weeks of treatment (P<0.01). 
Table 2 Effects of simvasiatm on serum apohpoproteins (apo) B, A-I, A-II and E and 
percentual changes (in weans ±SD) in 24 patients with hypercholesterolaemia Patients 
received placebo from week -h to 0 followed by simvastatin 40 mg daily from week 0 to 24 
Changes are obtained by companson with the values at the end of the placebo penod Values are 
mean ± SD. 
Treatment 
Weeks 
η 
Apo В (mg/dl) 
change(%) 
Apo A-I (mg/dl) 
change(%) 
Apo A-II (mg/dl) 
change (%) 
Apo E (mg/dl) 
change (9r) 
1
 n
i
n n 
, , 
-Л 0 
24 
273 ± 61 
1G6 ± 32 
54 ± 7 
6 ± 1 
24 
292 ± 58 
174 ± 29 
55 ± 7 
6 ± 1 
4 
24 
201 ± 54a 
-31 ±14 
180 ± 29 
+ 4 ± 13 
60 ± 9a 
+10 ± 12 
5 ± 1" 
-13 ± 11 
simvastatin 
8 
24 
200 ± 47" 
-32 ± 9 
186 ± 27b 
+ 8 ± 13 
60 ± 6* 
+ 9 ±13 
5 ± V 
-15 ± 14 
12 
22 
205 ± 60" 
-29 ± 15 
186 ± 26b 
+ 7± 12 
— 
— 
— 
— 
1 
24 
20 
203 ± 55" 
-33 ± 11 
183 ± 23 
+ 6 ±12 
— 
— 
— 
— 
': Ρ (vs. end of placebo period) < 0.001. 
b
: Ρ (vs. end of placebo period) < 0.05. 
Table 3. Effects of simvastatin on the absolute concentrations and concentrations as percenta­
ge of dry mass in the Urn density lipoproteins fraction of cholesterol, free cholesterol, cholesteryl 
esters, tnglycendes, phospholipids and protein (in means ±SD) before and after 8 weeks 
treatment with simvastatin in 24 patients with hypercholesterolaemia 
Cholesterol (mmol/1) 
Free cholesterol (mmol/1) 
(% of dry mass) 
Cholesteryl esters (mmol/1) 
(% of dry mass) 
Triglycerides (mmol/1) 
(% of dry mass) 
Phospolipids (mg/dl) 
(% of dry mass) 
Protein (mg/dl) 
(% of dry mass) 
before 
treatment 
7.41 ± 1 72 
2.01 ± 0.50 
8.9 ±0.8 
5.40 ± 1.24 
40.5 ± 2.4 
0.50 ± 0.21 
5.1 ±1.7 
170 ±36 
19 7 ± 1.3 
222 +42 
25.8 ± 1.7 
after 8 weeks 
simvastatin 
4.47 ± 1.12" 
1.21 ± 0.31a 
8.9 ±0.7 
3.25 ± O.SS·1 
40.0 ± 2.4 
0.28 ± 0.09a 
4.8 ± 1.1 
105 ±25" 
19.9 ± 0.9 
138 ±33·' 
26.4 ± 2.3 
change 
(%) 
-39 ±13 
-38 ± 14 
-39 ±13 
-39 ± 17 
-37 ±14 
-38 ± 10 
": Ρ (vs. placebo) < 0.001. 
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Spearman correlation coefficients between the lipid values at the end of the placebo 
period and the average lipid values from week 8 to 24 after starting treatment, 
determined in the 23 patients who completed the study, revealed no significant 
correlation between basal cholesterol, LDL cholesterol and HDL cholesterol levels 
and the percentual changes, whereas there was a significant negative con-elation 
between basal triglyceride levels and percentual changes (-24 ±8%; con-elation coeffi-
cient= -0.52; P<0.05). 
In the 26 patients in the second study, the average basal cholesterol level amounted 
to 12.35 ±2.05 mmol/1 (range 9.28 to 16.30 mmoM). The basal levels of total serum 
cholesterol and LDL cholesterol in the group treated with a combination of sim-
vastatin and a bile acid binding resin (after 1 year n=14; after 2 years n=12) were on 
average higher than in the group treated with simvastatin alone (n=12) (Table 4). The 
serum cholesterol level decreased in a few weeks to stable values; thereafter the 
therapeutic effect did not diminish. After 2 years, the serum cholesterol concentration 
had decreased on the average by 43% in the entire studied group, by 37% in the 
patients treated with simvastatin alone and by 49% in the patients treated with 
combination therapy (Table 4). For LDL cholesterol, these percentages were 50%, 
44% en 56%, respectively (Table 4). The percentual decrease of serum cholesterol and 
LDL cholesterol in the group with combination therapy was significantly larger than 
in the group treated with monotherapy. In the entire group, the level of serum 
triglycerides decreased significantly by an average of 16% after 2 years, whereas that 
of HDL cholesterol increased significantly by an average of 9% after 2 years (Table 4). 
After 1 and 2 years of treatment, there were no significant differences between the 
lipid levels obtained in the group treated with simvastatin alone and the group treated 
with combination therapy. Comparing the serum cholesterol levels of the entire group 
with those recommended in the Dutch cholesterol consensus conference (20) showed 
that before treatment all patients had a strongly elevated serum cholesterol level, 
whereas after 2 years of treatment 17% had a strongly elevated level, 42% a slightly 
elevated level and 42% a normal level. 
Adverse effects 
In those patients who used simvastatin as a single therapy there were no com-
plaints. In the group treated with simvastatin combined with a bile acid binding resin, 
some patients complained of obstipation and abdominal discomfort, well known adver-
se effects of the bile acid binding resins. One patient suffered from a myocardial 
infarction and one developed an instable angina pectoris while taking simvastatin; 
both underwent coronary artery bypass surgery. In all remaining patients the cardial 
condition remained stable. There was no significant increase in the average level of 
transaminases or CK. In 6 patients (1 from the first and 5 from the second study) there 
was an increase of the alanine aminotransferase (AL AT) level during treatment; in 2 
patients this increase amounted to more than 100% of the upper level of normal at one 
occasion. The increase of the ALAT level occurred at various time points of treatment; 
in 1 patient this was observed in the weeks after the start of therapy with simvastatin 
at a daily dose of 20 mg. In the other patients, the ALAT level increased after a few 
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Table i. Effects of Ζ years treatment inth simmstahn as monotherapy (n = 12), and in 
combination with a bile acid binding resin (after 1 year η = Η, after 2 years η = 12) on serum 
cholesterol, low density lipoprotein (LDL) cholesterol, ьегкт triglycerides and high densittj 
lipoprotein (HDL) cholesterol (mmolll ±SD) and the percentual changes (9r) in patients with 
hypercholesterolaemia. 
basal 
SERUM CHOLESTEROL 
total 12.35 ± 2.05 
simvastatin 10.88 ± 1.35 
combination 13.61 ± 1.69'1 
LDL CHOLESTEROL 
total 10.50 ± 1.87 
simvastatin 9.09 ±1.12 
combination 11.71 ± 1.5Г' 
SERUM TRIGLYCERIDES 
total 1.81 ± 0.75 
simvastatin 1.54 ± 0.65 
combination 2.05 ± 0.78 
HDL CHOLESTEROL 
total 1.03 ± 0.22 
simvastatin 1.10 ± 0.24 
combination 0.97 ± 0.20 
after 1 year 
7 02+1.21" 
6 80 ± 0.95" 
721 ±1.41'' 
5.23 ± 1.11' 
5.00 ± 0.70" 
5.34 ± 0.77* 
1 43 ± 0.70b 
1.28 ± 0.70 
1 55 ± 0.70л 
114 ± 0.25" 
1 23 ± 0.27" 
1.07 ± 0.23ς 
m 
-43% 
-37% 
-47%" 
-50% 
^ 5 % 
-54%c 
-19% 
-16% 
-21% 
+12% 
+12% 
+12% 
after 2 years 
6.85 ± 1.05a 
6.76 ± 1ЛЗЛ 
6.93 ± 0.98" 
5.09 ± 0.79a 
5.00 ± 0.84" 
5.18 ± 0.77" 
1.44 ± 0.77b 
1.33 ± 0.80 
1.55 ± 0.74b 
1.11 ±0.24 
1.16 ± 0.29 
1.05 ± 0.18 
(9f) 
^ 3 % 
-37% 
-497c' 
-50% 
-44% 
-56%r 
-16% 
-12% 
-21% 
+ 9% 
+ 7% 
+12% 
": Ρ (vs. basal) < 0.001. 
b
: Ρ (vs. basal) < 0.01. 
c
: Ρ (vs. basal) < 0.05. 
Λ
: Ρ (vs. simvabtatin monotherapy) < 0.001. 
'': Ρ (vs. simvastatin monotherapy) < 0.01. 
Γ
: Ρ (vs. simvastatin monotherapy) < 0.05. 
months after starting with simvastatin, at a daily dose of 40 mg. In all patients the drug 
was continued and the AL AT level normalised within 4 to 12 weeks. 5 patients showed 
an increase of the CK level on a single occasion; this was not accompanied by any 
symptoms, was usually associated with streneous physical excercise and had dis­
appeared by the next control visit. Slit lamp examination of the lens revealed minute 
increases in lens opacities in 2 patients of the 24-week study and in 4 patients of the 
2-year study, which were not considered to be of clinical importance. 
DISCUSSION 
Simvastatin appeared to be an effective drug in the treatment of patients with 
hypercholesterolaemia, and was well tolerated. In 4 to 8 weeks the serum cholesterol 
levels were decreased to stable levels approximately 35% below the baseline values. 
The cholesterol lowering effect mainly concerned the LDL fraction. The percentual 
change observed during monotherapy was stable during the entire period studied up 
to 2 years. Serum triglyceride levels decreased and the HDL cholesterol levels 
increased. Changes in apolipoproteins were parallel to those of serum lipoproteins. 
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When simvastatin was combined with a bile acid binding resin, an additional decrease 
was observed in serum cholesterol level of 12% of the baseline value or approximately 
19c/r of the value observed after monotherapy with simvastatin. 
The results of the present study confirm the effects of simvastatin on lipoproteins 
and apolipoproteins in patients with severe hypercholesterolaemia (5-11). In addition, 
it was found that there were no alterations in composition of LDL, indicating that only 
the number of circulating particles had decreased as a result of cholesterol synthesis 
inhibition. This was also found in studies with two other cholesterol synthesis in-
hibitors, lovastatin and pravastatin (22, 23). In contrast, the bile acid binding resin 
colestipol reduced also the cholesterol content of LDL particles, probably due to 
up-regulation of LDL receptors in the liver, and to preferential uptake of larger, 
cholesterol rich LDL particles (24, 25). In addition, it was found that LDL particles 
isolated after bile acid sequestration were cleared less rapidly from the plasma than 
LDL particles prior to this treatment (25). 
In the VLOL fraction there was a decrease of cholesterol relative to triglycerides; 
this has also been found by others (26). Kinetic studies with VLDL have shown that 
large triglyceride-rich VLDL particles are taken up rapidly without conversion to 
LDL (27, 28). Thus, a change in VLDL composition due to the use of an HMG CoA 
reductase inhibitor might contribute to a decreased conversion of VLDL particles to 
LDL. So far, turnover studies with LDL in patients with familial hypercholesterolae-
mia have shown that lovastatin induced receptor-mediated clearance of LDL without 
a decrease in its production, whereas in non-familial hypercholesterolaemia the LDL 
decrease was due to a decreased production without influencing the LDL uptake (29, 
30). Combined VLDL and LDL turnover studies may further elucidate the influence 
of HMG CoA reductase inhibition on lipid metabolism. 
There were no correlations between basal levels of lipids and the percentual 
changes in this study, except for serum triglycerides, which were lowered to a larger-
extent in patients with higher basal values. The mechanism by which the triglycerides 
are decreased during treatment with cholesterol synthesis inhibitors has not yet been 
elucidated. Recently, it wras demonstrated that lovastatin, in addition to inhibition of 
HMG CoA reductase, increased the activity of a hepatic mitochondrial enzyme in rats 
which led to an increase of oxidation of fatty acids and a decrease in triglyceride 
synthesis (31). 
Lipoprotein Lp(a), which is an independent risk factor of atherosclerosis (32,33), 
was not influenced by simvastatin, as found in a previous study (34). 
Simvastatin can be taken in a single daily dose with the evening meal (9,35). There 
are no subjective adverse effects, whereas the alterations observed in the safety 
parameters are limited to occasional increases of the levels of ALAT and CK. These 
alterations have been noted in other studies as well and do not appear to be of clinical 
importance (5-11). The observed increases in CK levels warrant some explanation. In 
13 out of 2000 patients treated with lovastatin, an other cholesterol synthesis inhibitor 
from which simvastatin is derived, a myopathy-like syndrome has been observed 
which consisted of elevations of CK levels, muscle weakness and myalgia. In 4 of these 
patients a rhabdomyolysis occurred (36). These patients had undergone an organ 
transplantation and were using other drugs as well. It is not certain whether this 
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serious adverse effect should be contributed to lovastatin. However, a self-limiting 
increase in the serum CK levels without any symptoms like those we observed 
appears not to be of clinical importance. 
Ophthalmological examinations are performed in users of these drugs to reveal a 
possible cataract induction. In animal studies in dogs, lovastatin as well as simvastatin 
caused cataract when given in extremely high doses (37). In patients treated with 
lovastatin, even when given over a period of years, the observed increases in lens 
opacities were no higher than one would expect in the general population (38, 39). 
The efficacy of the cholesterol synthesis inhibitors is not limited to patients with 
familial hypercholesterolaemia. These drugs are also efficient in patients with the 
polygenetic form of hypercholesterolaemia (5). 
In conclusion, simvastatin, as well as other cholesterol synthesis inhibitors, appears 
to be a highly effective and well tolerated cholesterol lowering drug, which can be 
considered a major breakthrough in the treatment of severe hypercholesterolaemia. 
However, there are only limited data on its long-term safety. These drugs should only 
be prescribed to patients who have a high risk of developing cardiovascular disease. 
Such patients are: patients with a severe hypercholesterolaemia, as in heterozygous 
familial hypercholesterolaemia; patients with moderate hypercholesterolaemia with 
coronary artery disease, or in combination with other risk factors, like hypertension, 
obesity, smoking and positive family history concerning cardiovascular disease (38). 
For other patients in whom pharmacological treatment of their hypercholesterolae­
mia is warranted, the bile acid binding resins remain the drugs of first choice because 
of their well-established long term safety. 
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Chapter 5 
EFFECTS OF INHIBITION OF CHOLESTEROL 
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PRODUCTION OF ADRENOCORTICAL STEROID 
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SUMMARY 
Simvastatin, a derivative of lovastatin, is a potent inhibitor of cholesterol biosyn­
thesis and may interfere with steroid hormone production, for which cholesterol is 
required. In a single-blind, placebo-controlled study, 24 patients with severe primary 
hypercholesterolaemia (mean serum cholesterol ±SD = 10.74 ±1.59 mmol/l) were 
treated with simvastatin 40 mg per day for 8 weeks. Before and after treatment, the 
following parameters were evaluated: basal levels of ACTH, Cortisol, androstenedio-
ne, dehydroepiandrosterone and 17-hydroxyprogesterone; urinary excretion of free 
Cortisol; the Cortisol response after short-term infusion of ACTH; the ACTH and 
Cortisol response during insulin-induced hypoglycaemia. Total serum cholesterol de­
creased by 35.0 ± 8.1% (P<0.001) and low-density lipoprotein (LDL) cholesterol by 39.8 
±9.8% (P<0.001); high-density lipoprotein (HDL) cholesterol increased by 9.2 ±11.1% 
(P<0.001). Basal levels of ACTH were higher after simvastatin (2.9 ±1.9 pmoM vs 4.1 
± 2.9 pmol/1; P<0.05) whereas basal levels of steroid hormones were not significantly 
changed. The excretion of free Cortisol was unaltered. The peak Cortisol after ACTH 
infusion was lower after treatment (0.87 ± 0.23 μιηοΐ/ΐ vs 0.78 ± 0.10 μιηοΙΛ; P<0.05), but 
was unaltered during insulin-induced hypoglycaemia. We conclude that simvastatin 
lowers serum cholesterol without clinically relevant effects on the adrenocortical 
steroid hormone secretion and the hypothalamic-pituitary-adrenal axis. 
INTRODUCTION 
Cholesterol is necessary for the production of steroid hormones. It can be derived 
either from de-novo biosynthesis or from uptake of plasma lipoproteins, especially 
low-density lipoproteins (LDL) (Borkowski et al., 1972; Brown et al., 1979; Simpson et 
al., 1979; Ohashi et al., 1981). In normal man, LDL is taken up by a high-affinity 
receptor mechanism, the LDL receptor (Brown et al., 1981). In patients who lack the 
LDL receptor, as in homozygous familial hypercholesterolaemia, or who lack LDL, as 
in abetalipoproteinaemia, basal Cortisol levels are normal, but prolonged stimulation 
with ACTH results in a decreased Cortisol response (Illingworth et al., 1982a, b, 1983; 
Goldstein & Brown, 1983; Laue et al., 1987). Apparently, de-novo biosynthesis of 
cholesterol cannot entirely compensate for the decreased uptake of LDL in these 
patients. Patients with heterozygous familial hypercholesterolaemia, who have a 
reduction up to 50% in the number of functional LDL receptors, show a normal Cortisol 
response during prolonged ACTH stimulation (Illingworth et al., 1984). 
Recently, a new class of drugs for the treatment of hypercholesterolaemia has been 
developed, the group of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, the key enzyme of cholesterol biosynthesis. These drugs can lower 
serum cholesterol levels on the average by as much as 40% in patients with familial and 
non-familial hypercholesterolaemia (Hoeg et al., 1986, Mol et al., 1986,1988; Havel et 
al., 1987; Mabuchi et al., 1987). Such a large inhibition of endogenous cholesterol 
synthesis could influence steroid hormone production especially in combination with a 
limited capacity of uptake of LDL cholesterol by the LDL receptor. 
Adrenocortical steroid production was not found to be impaired after ACTH stimu-
67 
lation in patients with heterozygous familial and non-famihal hypercholesterolaemia 
by lovastatin, one of the cholesterol synthesis inhibitors (Ulingworth & Corbin, 1985; 
Fojo et al., 1987). Also, basal testosterone, LH and FSH levels were unaltered by 
lovastatin (Farnsworth et al., 1987). However, in these studies the reduction in serum 
cholesterol was limited to less than 30%. 
To evaluate the influence of a still larger inhibition of cholesterol synthesis on 
adrenocortical steroid hormone production we studied the influence on this production 
of simvastatin, a derivative of lovastatin which can lowTer total serum cholesterol on 
the average by 4Qr/r and LDL cholesterol by almost 4o7c at a dose of 40 mg per day (Mol 
et al., 1988). In 24 hypercholesterolaemic patients, basal ACTH and adrenocortical 
steroid hormone levels, the 24-h urine excretion of free Cortisol, the Cortisol response 
after administration of ACTH, and the ACTH and Cortisol response during insulin-
induced hypoglycaemia before and after treatment, were compared. 
MATERIALS AND METHODS 
Subjects 
The study design was approved by the ethical committee of our institute; all 
patients gave their informed consent. 
Twenty-four patients entered the study (13 men, eight postmenopausal and three 
premenopausal women, aged 42 ± 13 years (mean ± SD), Quetelet index (weight/ 
length2) 24.2 ± 2.2 kg/nr). Three patients had signs or symptoms of coronary heart 
disease. All 24 patients had greatly elevated serum cholesterol levels (mean ± SD total 
serum cholesterol 10.74 ± 1.59 mmol/1). Based on family studies and/or the presence of 
typical xanthomata, 21 of 24 had familial hypercholesterolaemia. In the remaining 
three patients, this diagnosis could not be established with certainty. The mean basal 
total cholesterol in these three patients was 9.31 mmol/1 (range 9.09-9.66 mmol/1). 
All patients were on a standard lipid-lowering diet (cholesterol less than 300 
mg/day; ratio saturated fatty acids to poly-unsaturated fatty acids 1 to 1) for at least 6 
weeks prior to the study. All lipid-lowering therapy was discontinued at least 6 weeks 
before the study. Other medication was kept stable; one patient used a beta-blocking 
agent because of angina pectoris, one patient used indomethacin because of ankylosing 
spondylitis, one patient used ranitidine and one patient ranitidine and domperidone 
because of gastric complaints. 
Experimental design 
At the beginning and end of the study the patients underwent a complete physical 
examination, an ophthalmological examination including colour vision test, visual 
acuity, slit lamp examination and fundoscopy, and an electrocardiogram was made. 
The patients received placebo for 4 weeks (week -4 to 0), followed by simvastatin 40 
mg daily in a single dose by mouth before the evening meal for 8 weeks (week 0 to 8). 
Evaluation of hormone secretion was done during the placebo period and at the end of 
the 8 weeks active treatment. The patients visited the outpatient clinic at 4-week 
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intervals; they underwent a brief physical examination and were questioned about 
possible adverse experiences. Blood was taken after an overnight fast to determine 
lipids and safety parameters, including haemoglobin, white blood cell count, thrombo­
cytes, bilirubin, alanine aminotransferase (ALAT), aspartate aminotransferase 
(ASAT), creatine Phosphokinase (CK) and creatinine. Compliance assessed by capsule 
counting was over 95%. 
Production of steroid hormones and ACTH 
Twenty-four hours urine excretion of free Cortisol 
Urine was collected in the 24 h prior to the ACTH test for the determination of 
creatinine and free Cortisol. 
Basal adrenocortical steroid hormone levels and short ACTH test 
The patient entered the clinic at 0830 h after an overnight fast. After lying down, an 
indwelling catheter was inserted in an antecubital vein. A solution of 500 U/ml heparin 
was instilled in the catheter to prevent clotting. This was repeated after every blood 
sample. After at least 30 min rest, blood was taken at 0900 h to determine basal ACTH, 
Cortisol, androstenedione, dehydroepiandrosterone and 17-hydroxyprogesterone con­
centrations. 17-Hydroxyprogesterone levels were not evaluated in premenopausal 
women because of an influence of the menstrual cycle on this parameter. Then a 
solution of 0.25 mg synthetic ACTH(l-24) (Synacthen, Organon, Oss, The Nether­
lands) in 100 ml 0.15 м NaCl was given intravenously in 10 min. Subsequently, blood 
was sampled at 0930,1000 and 1030 h to determine Cortisol levels. 
Insulin tolerance test (ITT) 
An ITT was performed in 20 patients. After preparation as with the ACTH test, 
blood was taken at 0850 and 0900 h to determine basal glucose, Cortisol and ACTH. At 
0900 h patients were given a bolus injection of insulin (Actrapid HM, Novo Industri 
BV, Amsterdam, The Netherlands), 0.1 U/kg body-weight intravenously. Blood was 
taken to determine glucose, Cortisol and ACTH at time points +20, +30, +45, +60, +90 
and +120 min. 
Analytical measurements 
Serum cholesterol and triglycerides were measured by enzymatic methods (no 
237574, Boehringer Mannheim GmbH, FRG and no 6684, Sera PAK, Miles, Italy, 
respectively). Very-low-density lipoprotein (VLDL) cholesterol was determined af­
ter sequential ultracentrifugation of the serum at a density < 1.006 g/ml (Demacker et 
al., 1977). High-density lipoprotein (HDL) cholesterol was determined after precipita­
tion of other lipoproteins from whole serum with polyethylene glycol 6000 (Demacker 
et al., 1980). LDL cholesterol was calculated by subtraction. The intra and inter-assay 
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coefficients of variation (CV) of lipid determinations were 3% or less. 
Urine free Cortisol (intra-assay CV less than 5%, interassay CV 8%) was determined 
as described (Meulenberg et al., 1987). ACTH (intra-assay СV 6%, interassay CV 11%) 
(Pieters et al., 1982) and Cortisol (intra-assay CV less than 5%, interassay CV 8%) 
(Smais et al., 1978) were measured in plasma by specific radioimmunoassays (RIAs). 
Androstenedione (Swinkels et al., 1988), dehydroepiandrosterone (DHEA) (Swinkels 
et al., 1987) and 17-hydroxypiOgesterone (Otten et al., 1983) (for all three: intra-assay 
CV less than 5%, interassay CV 8%) were measured in serum by specific RIAs after 
chromatography. 
Data analysis 
Lipid values were compared with those obtained at the end of the placebo period. 
The 24-h urinary excretion of free Cortisol was expressed per mmol of creatinine 
excreted. Results of the short ACTH test and the ITT were variously expressed as the 
maximal value of ACTH and Cortisol (peak ACTH and peak Cortisol); as the maximal 
rise in ACTH and Cortisol (AACTH
mi,4 and ACortisolmas); and as the areas under the 
individual curves (AUG) of the absolute changes of ACTH and Cortisol, obtained by 
planimetry. 
Statistical analyses were performed with the Wilcoxon's test or Student's i-test for 
paired data. A two-sides P-value of less than 0.05 was considered to be significant. 
Unless indicated otherwise, results are expressed as mean ± SD. 
RESULTS 
Lipids 
Total cholesterol, LDL cholesterol, VLDL cholesterol and triglycerides decreased 
significantly, whereas HDL cholesterol increased significantly during treatment (Ta­
ble 1). Compared to placebo, LDL cholesterol was 33.3% lower after 4 weeks and 39.8% 
lower after 8 weeks treatment; the value after 8 weeks treatment was significantly 
lower than after 4 weeks, indicating that a steady state had not been reached after 4 
weeks. HDL cholesterol increased by 9.2% after 8 weeks. 
Urinary excretion of free Cortisol 
Urine was analysed from 23 patients. The 24-h excretion of free Cortisol per mmol 
creatinine was 5.1 ± 2.3 μιηοΐ/ηηηιοί before treatment and 6.0 ± 2.6 μιηοΐ/ιτιηηοΐ after 
treatment. The difference was not significant. 
Basal levels of androstenedione, dehydroepiandrosterone and 17-hydroxypro-
gesterone 
Basal levels of androstenedione (in men and women, η = 24), dehydroepiandrostero-
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Table 1 Serum lipid values during placebo and treatment imth 40 mg simvastatin daily and the percentage changes in 24 patients with primary 
hypercholesterolaemia. 
Treatment I— Placebo —I Simvastatin 
Weeks -4 0 4 
Cholesterol (ттоІЛ) 10.40 ± 1.82 10.74 ± 159 7.59 ± 1.39* 
change (%) -29.3 ± 9.1 
LDL cholesterol (mmoM) 8.69 ± 1.88 8.96 ± 1 72 5.97 ± 1 44* 
change (%) -33.3 ± 10.3 
VLDL cholesterol (mmol/1) 0.66 ± 0.52 0.68 ± 0 44 0.42 ± 0.25* 
change (%) -31.4 ± 30.2 
Triglycerides (ттоІЛ) 1.75 ± 0.86 1.79 ± 0.92 1.39 ± 0.55t 
change (%) -16.0 ± 30.2 
HDL cholesterol (mmoW) 1.05 ± 0.31 1.11 ±0.34 1.20 ± 0.37+ 
change (%) + 8.1 ± 12.8 
Values are mean ± SD. 
* Ρ (vs end of placebo period) <0 001 
t Ρ (vs end of placebo period) <0 01 
t Ρ (\s 4 weeks treatment) <0 001. 
6.96 ± 
-35.0 ± 
5 39± 
-39.8 ± 
0.38 ± 
-35.0 ± 
1.24 ± 
-25.3 ± 
1.19 ± 
• 9.2 ± 
1.22*t 
8.1 
1 33*+ 
9.8 
0.25* 
37.3 
0.48*+ 
18.3 
0.29* 
11.1 
- J 
Table 2. Results of the basal levels of deltydroepiandrosterone (DHEA) (n =2i). androstene-
dione (n = 2^) and 17-hydroxyprogesterone (in men and postmenopausal women only (n = 21) 
in patients with primary hypercholesterolaemia during placebo and after simvastatin. 
Parameter (nmol/1) Placebo Simvastatin 
DHEA 13.0 ± 7.7 
Androbtenedione 4.4 ± 2.4 
17-hydroxyprogesterone 3.0 ±1.6 
11.5 ± 6.3 
4.2 ± 2.1 
2.7 ± 1.7* 
Values are mean ± SD. 
* Ρ (vs placebo): 0.0δ<Ρ<0.10. 
Table 3. Results of the short ACTH test in 24 patients with pniiiai^y hypercholesterolaemia 
during placebo and after 8 weeks of treatment with simvastatin. 
Parameter Placebo Simvastatin 
Basal ACTH (pmol/1) 2.9 ±1.9 
Basal coitisol (μηιοΐ/ΐ) 0.37 ± 0.12 
ACTH/Cortisol (ριηοΐ/μιηοΐ) 8.0 ±4.5 
Peak Cortisol (μΐηοΐ/ΐ) 0.87 ± 0.23 
ACortisol
ni,4 (μιηοΐ/ΐ) 0.50 ± 0.23 
AUG Cortisol (μπιο1/1.1ι) 0.45 ± 0.13 
4.1 ±2.9t 
0.32 ± 0.11* 
12.4 ±5.5+ 
0.78 ± O.lOt 
0.46 ± 0.12 
0.46 ± 0.13 
Peak Cortisol indicates the maximal value of Cortisol during the test. 
ACortisol
m
^ denotes the maximal change in Cortisol. 
AUG Cortisol denotes the area under the curve of the change in Cortisol. Values are mean ± SD. 
* Ρ (vs placebo): 0.05<P<0.10. 
t Ρ (vs placebo) <0.05. 
Φ Ρ (vs placebo) <0.001. 
К 0-8 
+i 
-δ 0-6 
E 
4. 
ЪО'4 
¡л 
't 
о 
о 0-2 
-L 
30 
Time (min) 
60 90 
Figure 1. Results of the short ACTH test in 24 patients with primary hypercholestemlaemia. 
During placebo and after 8 weeks simvastatin the Cortisol response to infusion of 0.25 mg 
synthetic ACTH(l-24) was evaluated. Valuesaremean+SEM.o, Placebo;; simvastatin, *P(vs 
placebo) <0.05; **P (vs placebo) <0.01. 
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ne (in men and women, η = 24) and 17-hydroxyprogesterone (in men and post­
menopausal women, и = 21) were unaltered by treatment (Table 2). 
Basal levels of ACTH and Cortisol levels during the shore ACTH test 
The results of the basal levels of ACTH and Cortisol and of the short ACTH test are 
summarized in Table 3 and Fig. 1. Mean basal ACTH levels were significantly higher 
after treatment whereas mean basal Cortisol levels tended to be lower after treatment 
(0.05 < Ρ < 0.10); the ratio basal ACTH to Cortisol was significantly higher after 
treatment. Significant differences in Cortisol levels at 30 and 90 min after ACTH 
infusion and in the peak Cortisol before and after treatment were found. There was no 
significant difference in the ACortisol
max
 or the AUG before and after treatment. 
ACTH and Cortisol levels during the insulin tolerance test 
This test was performed in 20 of the 24 patients. The test was not performed in two 
patients because of coronary artery disease, in one patient because of difficulties with 
inserting an intravenous cánula and in one patient, who used dompendone, because of 
a possible influence of domperidone on the ACTH and Cortisol response during 
hypoglycaemia. In two of 20 remaining patients, hypoglycaemia, defined as a glucose 
level of less than 2.0 mmol/1, was not obtained at both tests, and they were also 
excluded. Thus, 18 patients could be evaluated. The results are summarized in Table 4 
and Fig. 2. Basal ACTH and Cortisol levels were not significantly altered. The ratio 
basal ACTH to basal Cortisol tended to be higher after treatment (0.05 < P< 0.10). No 
differences occured in the peak ACTH and peak Cortisol, nor in the AACTHmj4 and the 
ACortisolma4, nor in the AUG of ACTH and Cortisol before and after treatment. 
Table k- Results of the ACTH and Cortisol levels during the insulin tolerance test (ITT) in IS 
patients with рптаі-у hyper eh ole sterolaemia during placebo and after 8 weeks treatment with 
simvastatin. 
Parameter 
Basal ACTH (ртоІЛ) 
Basal Cortisol (μιηοΙΛ) 
ACTH/cortisol (ρπιοΐ/μπιοί) 
Peak ACTH (ртоІЛ) 
ДАСТН
т л ч
 (ртоІЛ) 
AUG ACTH (pmoVLh) 
Peak Cortisol (μιηοΐ/ΐ) 
ACortisol,,
a4 (μπωΐ/ΐ) 
AUG Cortisol (μηιο1/1.Η) 
Placebo 
2.0 ± 1.3 
0.33 ± 0.08 
6.1 ± 3.6 
21.1 ± 12.2 
19.1 ± 12.3 
12.2 ± 8.4 
0.67 ± 0.13 
0.33 ± 0.14 
0.32+ 0.18 
Simvastatin 
2.3 ± 1.1 
0.30 ± 0.10 
8.7 ± 4.3* 
18.3 ±10.9 
15.8 ±10.4 
11.3 ± 8.0 
0.62 ± 0.15 
0.31 ± 0.16 
0.30 ± 0.20 
Peak ACTH and peak Cortisol indicate the maximal values; A ACTH
ma4 and ACortisolmil4 indicate 
the maximal changes; and AUC indicates the area under the curve of the changes in ACTH and 
Cortisol during the test. Values are mean ± SD. 
* 0.05<P (vs placebo) <0.10. 
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Adverse effects 
Simvastatin was tolerated well. Subjective complaints were limited to fatigue, 
constipation, and dry skin, each occurring in one patient. 
During the study period the mean levels of CK, ALAT and ASAT did not change 
(CK, -1% ± 10%; ALAT; +2% ± 10%; ASAT; -1% ± 12% after 8 weeks treatment). One 
patient had an increase of ALAT during treatment which exceeded the upper level of 
normal at one occasion. All other safety parameters were unaltered. There was no 
change in body-weight. 
The ophthalmological examination revealed an increase in lens opacities in two 
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Figure 2. Results of the insulin tolerance test in 18 patients with primary hypercholesterolae-
mia during placebo and after H weeks simvastatin. The response of glucose (upper panel), 
ACTH (middle panel) and Cortisol (lower panel) after intravenous administration of 0.1 U 
insulin per kg body weiglit are depicted. Values are mean ±SEM. o, Placebo; · , simvastatin. 
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patients, and a decrease in one. In one of the two patients who had an increase in 
opacities after 8 weeks treatment, these opacities were no longer observed 3 months 
later; in the second patient, the opacities persisted, without interfering with visual 
acuity. 
DISCUSSION 
The decrease of serum cholesterol, LDL cholesterol, VLDL cholesterol and trigly-
cerides and the increase of HDL cholesterol found in the current study confirm the 
results of earlier studies on the effects of simvastatin (Mol et al., 1986,1988). A steady 
state in cholesterol, triglyceride and LDL cholesterol levels was not reached before 4 
weeks of treatment. There were no major subjective or objective side-effects during 
treatment. 
Treatment with simvastatin induced no alterations in the basal levels of DHE A and 
androstenedione nor in the basal levels of Cortisol or the urinary excretion of free 
Cortisol, indicating that the basal adrenocortical androgen and Cortisol secretions were 
not influenced. 
After treatment, the ratio of basal ACTH to basal Cortisol before the short ACTH 
test was significantly higher, whereas basal Cortisol levels w ere slightly lower. Appa-
rently, a higher level of ACTH is needed to maintain the basal Cortisol level. In 
addition, the response of Cortisol during the short ACTH test after treatment showed 
a lower peak Cortisol and a significantly lower Cortisol level after 30 and 90 min. On the 
day of the ITT, which was evaluated in 18 of 24 patients, changes in the basal levels of 
ACTH and Cortisol after treatment compared to placebo were on the average less 
pronounced than on the day of the short ACTH test, but occurred in the same 
direction, and the ratio of basal ACTH to Cortisol tended to be higher. The Cortisol 
responses during insulin-induced hypoglycaemia showed no differences between va-
lues before and after treatment at any moment. Altogether, the observed alterations 
may indicate some impairment of the adrenocortical reserve for Cortisol by sim-
vastatin, which is revealed only after a supraphysiological stimulation during the 
short ACTH test and not by a less powerful stimulation during insulin-induced 
hypoglycaemia. 
The alterations in the Cortisol response during the short ACTH test of the current 
study contrast with the results of comparable studies with lovastatin, in which no 
alterations were observed (Illingworth et al., 1985; Fojo et al., 1987) However, in these 
studies cholesterol levels were decreased to a lesser extent than in the current study. 
Whether or not lovastatin influences basal ACTH levels or the Cortisol response 
during insulin-induced hypoglycaemia is not known. 
Compared to the effects of other drugs interfering with adrenocortical function, like 
ketoconazole (Pont et al., 1984), the changes effected by simvastatin are rather small 
and do not appear to be of clinical significance. Supplementation of Cortisol during 
acute stresses, such as surgery or myocardial infarction, in patients using simvastatin 
seems therefore not neccessary. 
The mechanism by which the adrenocortical cell obtains its cholesterol might be 
altered by cholesterol synthesis inhibition. Brown et al. (1979) postulated that the 
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initial, short-term increase in adrenal steroid hormone synthesis in response to ACTH 
stimulation depends on the hydrolysis of cholesteryl ester stores and on de-novo 
synthesis of cholesterol in the adrenal cells, and not on an increased uptake of LDL 
particles from plasma by the LDL receptors, because the number of LDL receptors 
cannot increase over such a short period. Prolonged stimulation with ACTH results in 
an increased number of LDL receptors and an increased influx of cholesterol with 
serum lipoproteins (Brown et al., 1979). Treatment of patients with heterozygous 
familial hypercholesterolaemia with lovastatin leads to an increase of the receptor-
mediated uptake of LDL particles as a result of induction of LDL receptors (Bilheimer 
et al., 1986). It is likely that the LDL receptor induction also takes place in the 
adrenocortical cells, and that cholesterol needs during adrenocortical stimulation can 
be partly met by an increased uptake of LDL instead of de-novo synthesis. This would 
explain why simvastatin does not significantly reduce the Cortisol response to adreno­
cortical stimulation. 
The results of our study indicate that simvastatin does not cause a clinically relevant 
impairment of the pituitary-adrenocortical axis However, other questions remain to 
be answered, including the long-term influence of simvastatin on the investigated 
parameters, and the influence on the response to long-term ACTH stimulation and on 
the hypothalamic-pituitary-gonadal axis. These and the current data may contribute 
to the establishment of the safety of this new class of drugs in the treatment of 
hypercholesterolaemia. 
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SUMMARY 
A 14-year-old Turkish girl presented with serum cholesterol levels of 15-20 т т о И , 
skin and tendon xanthomata, and anginal attacks. A coronary angiography demon­
strated severe coronary atherosclerosis including a 707c stenosis at the origin of the 
left coronary artery. The clinical diagnosis homozygous familial hypercholesterolae-
mia was confirmed by 1. investigation of the family revealing hypercholesterolaemia in 
both her parents and siblings; 2. fibroblast association studies, in which the specific 
association of low density lipoprotein (LDL) was 35% of normal; and 3. LDL turnover 
study, in w7hich the fractional catabolic rate of LDL was decreased to 0.213 pools/day. 
Treatment with cholestyramine or simvastatin had little effect on senjm cholesterol 
levels. After coronary artery bypass grafting, the patient was treated with selective 
LDL apheresis using columns containing dextran-sulfate bound to cellulose. These 
columns bind apolipoprotein В containing lipoproteins but not high density lipo­
proteins. After 2 years of therapy, the level of serum cholesterol has declined by 56%. 
Skin xanthomata have disappeared and there is no recurrence of angina pectoris. On 
repeated coronary angiography, two of the three bypasses are patent and there is no 
progression of atherosclerotic lesions. We conclude that LDL apheresis is an efficient 
procedure to lower serum cholesterol in patients who do not respond to pharmacologi­
cal treatment of hypercholesterolaemia. 
INTRODUCTION 
Familial hypercholesterolaemia is a genetic disease which is characterised by an 
autosomal dominant inheritance pattern with a gene dosage effect (1). In the heterozy­
gous patient, carrying a single mutant gene encoding for the low density lipoprotein 
(LDL) receptor, the number of functional receptors is diminished by up to 50% of 
normal, and serum cholesterol levels and LDL cholesterol levels are elevated; these 
patients are at increased risk to develop premature atherosclerosis. The heterozygous 
state occurs in the general population at a frequency of one in 500 persons in European 
and American countries, but may be more frequent in genetic isolates (1). Of male 
survivors of a myocardial infarction under 60 years of age, 5% appear to have 
heterozygous familial hypercholesterolaemia (1). Homozygous patients, carrying two 
mutant genes for the LDL receptor, are extremely rare with a frequency of one in one 
million persons. These patients have mostly inherited two different defective genes 
and are therefor 'compound heterozygotes' rather than true homozygotes (1). At least 
17 different mutations in the LDL receptor gene have been described at the molecular 
level so far (2). In homozygous patients, serum cholesterol levels are extremely high, 
up to values of 30 mmol/1, and they usually develop tendocutaneous xanthomata and 
coronary atherosclerosis in the first or second decades of life (1). 
Whereas heterozygotes can be treated effectively by a combination of diet and 
cholesterol lowering drugs, homozygous patients are mostly refractory to treatment 
by this means, due to the inability to induce functional LDL receptors. Although 
homozygous patients with some remaining receptor activity can show a small degree 
of cholesterol lowering, this is never sufficient (1,3). Alternative treatments for these 
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patients include portocaval shunting, liver transplantation and plasmapheresis (4-7). 
The latter has been shown to reduce mortality (7). However, plasmapheresis has some 
disadvantages, including the use of foreign proteins and the possible transmission of 
infectious diseases. Recently, new techniques have been developed as alternative for 
plasmapheresis which selectively remove LDL particles; these techniques include 
immuno-absorbing columns, chemical affinity columns, precipitation with heparin at 
low pH and double filtration techniques (8-12). 
We here describe a young female with severe hypercholesterolaemia and coronary 
atherosclerosis, in whom the diagnosis homozygous familial hypercholesterolaemia 
was established. She was successfully treated with selective LDL apheresis, using 
dextran-sulfate cellulose columns. 
MATERIALS AND METHODS 
Lipids, lipoproteins, apolipoproteins 
Serum lipids were obtained after an overnight fast by venipuncture. Very low 
density lipoproteins (VLDL; density (d) <1.006 g/ml) and LDL (1.006<d<1.063 g/ml) 
were isolated by sequential ultracentrifugation as described (13). Cholesterol and 
triglycerides were measured by enzymatic methods (cat no 237574, Boehringer Mann­
heim GmbH, FRG and no 6684, Sera PAK, Miles, Italy, respectively). Protein was 
determined according to Lowry et al. (14). High density lipoprotein cholesterol was 
measured after precipitation of the other lipoproteins with polyethylene glycol 6000 
(15). Apolipoproteins (apo) В and Al were determined in serum by radial immunodiffu­
sion (16). 
Low density lipoprotein turnover study 
All isolation and labeling procedures were performed under sterile conditions. 72 
hours before the start of the study, 30 ml blood was taken from the patient after an 
overnight fast. LDL was isolated from serum at 1.025<d<1.055 g/ml and iodinated with 
"^I as described (17,18). On agarose gel electrophoresis of the LDL fraction, a single 
band was found on the ß-location only. Sodium dodecyl sulfate gel electrophoresis (19) 
revealed apo B100 to be the single apohpoprotein, with only traces of apo E. On 
Ouchterlony Immunoelectrophoresis isolated LDL appeared to contain some apo E. 
In order to prevent uptake of radioactive iodine by the thyroid, the patient 
received iodine and potassium iodide by mouth from 2 days before the start of the 
turnover study throughout the entire study period. On the day of the start of the 
turnover study, 20 μϋί 1 2 >I labeled LDL was injected through an antecubital vein 
after sterilisation. Subsequently, blood was taken at the indicated time points for a 
total of 14 days. All urine was collected throughout the study in 24-houi· portions. 
109c trichloroacetic acid (TCA) precipitable plasma radioactivity and total radioac­
tivity in urine was determined in a Philips PW 4800 automatic gammacounter. The 
fractional catabolic rate (FCR) was calculated by bi-exponential analysis of the 
plasma decay curve as described (17,18). The plasma volume was calculated from 
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body weight and peripheral haematocrit (20). The absolute catabolic rate (ACR) 
was calculated from the FCR and the pool size of apoproteins in LDL; the latter 
was obtained from the plasma volume and the apoLDL concentration by multi­
plication. In steady state conditions, the ACR equals the production rate. The 
fractional catabolic rate was also obtained by determining the daily urinary radio­
activity (counts per minute (cpm)/day) divided by the log mean of the radioactivity 
present in plasma at the beginning and end of the urine collection period (cpm/ml 
plasma · plasma volume) (21,22). This U/P ratio appeared to be a stable value from 
the third day of the turnover study; the FCR was calculated as the mean value of 
days 4-14 (22). 
LDL receptor activity in fibroblasts 
Fibroblasts were cultured from skin biopsies of the forearm of the proband, her 
youngest sister, her brother and one normal control. Cell association studies were 
performed as described (23, 24). Briefly, fibroblasts were incubated with 0-200 μg 
protein/ml of '""I labeled LDL (1.019<d<1.063 g/ml). After washing and solubilisa-
tion, the cell-associated radioactivity (i.e. radioactivity bound and internalised) 
was quantitated. Aspecifically associated '"''I-LDL was determined at a labeled 
LDL-protein concentration of 20 μg/ml in the presence of an excess of unlabeled 
LDL. The specific association, i.e. the difference between total and aspecific 
association, was expressed as a percentage of the value obtained in the normal 
control. 
Procedure of LDL apheresis 
Venous access was established in antecubital veins of both arms. In the first 
months of treatment, blood was mixed with citrate and separated by cell cen-
trifugation (Fenwal Cell Centrifuge II, Travenol, Deerfield, 111., USA), and the 
plasma applied to a single column containing dextran-sulfate covalently bound to 
cellulose beads (Liposorber LA-01 (400 ml), Kaneka, Kanegafuchi, Osaka, Japan). 
These columns bind apo В containing lipoproteins (VLDL and LDL) only. During 
each treatment, 2000 to 3000 ml plasma were passed through the column. Later, 
cell separation and filtration was performed with an integrated, computer assisted 
apparatus (MA-01, Kaneka, Japan), which incorporates blood and plasma pumps, a 
heparin pump, a plasma separator consisting of polysulfone hollow fibers (Sulflux, 
Kaneka, Japan) and two small dextran-sulfate cellulose columns (Liposorber 
LA-15 (150 ml), Kaneka, Japan). After every 600 ml of plasma led over one column, 
the plasma flow is switched to the other column. While plasma is led over the 
second column, the first column is regenerated with a hypertonic solution of NaCl, 
and washed with an isotonic solution of NaCl, after which it can be used again (11). 
Theoretically, the apo В containing lipoprotein level can be decreased to zero. 
During each treatment, 3000 to 4000 ml of plasma were passed through the 
columns. The treatment procedure was performed weekly for 10 weeks, thereafter 
biweekly. Because of difficulties with establishing intravenous access, the con-
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struction of an arteriovenous fístula and use of a temporary central venous line was 
necessary. The treatment was combined with simvastatin at a dose of 40 mg per 
day. 
RESULTS 
Patient 
The 14-year-old girl of Turkish descent was found to have serum cholesterol 
levels ranging from 15 to 20 mmol/1. She was treated with a cholesterol lowering 
diet (less than 300 mg cholesterol per day, ratio polysaturated to unsaturated fatty 
acids of one) and cholestyramine. Some months later she developed angina pectoris 
during excercise. An electrocardiogram was unremarkable; an excercise test sho-
wed signs of myocardial ischaemia. A coronary angiography revealed a 50-70% 
stenosis at the origin of the left coronary artery, a 50% stenosis of the circumflex 
artery, a 70-90% stenosis proximal in the left descending artery and a 70-90% 
stenosis proximal in the first diagonal branch. The patient was then referred to our 
clinic. On physical examination, a 15-year-old girl was seen (length 1.50 m., weight 
53.7 kg) with planar and tubero-eruptive skin xanthomata on the elbows and 
marked thickening of the Achilles tendons. There were inferior lipoid arcs in her 
eyes. There were strongly elevated levels of serum cholesterol (16.93 mmol/1) and 
LDL cholesterol (14.39 mmol/1), elevated levels of VLDL cholesterol (2.00 mmol/1) 
and serum triglycerides (3.86 mmol/1), and a decreased level of HDL cholesterol 
(0.54 mmol/1) (Table 1). The decision was made to employ more agressive choleste-
rol lowering therapy after coronary artery bypass grafting. A venous bypass was 
made to the circumflex artery and a sequential bypass with the left internal 
mammarian artery to the left descending artery and the first diagonal branch. 
Table 1. Serum lipid levels of the proband and the kivdred. 
Sex Age 
(Years) 
Total 
cholesterol 
9.56 
7.22 
9.54 
7.45 
7.38 
16.93 
7.43 
16.40 
Trigly-
cerides 
6.00 
1.30 
1.86 
0.94 
1.44 
3.86 
1.50 
1.12 
HDL 
( mmol/1 )-
0.44 
0.90 
1.02 
1.19 
1.28 
0.54 
1.13 
0.89 
VLDL 
2.30 
0.32 
0.67 
0.21 
0.42 
2.00 
0.55 
0.27 
LDL** 
6.82 
5.98 
7.85 
6.05 
5.68 
14.39 
5.75 
15.24 
1-1 
1-2 
II-l 
11-2 
11-3 
II-4* 
11-5 
II-6 
m 
f 
m 
f 
f 
f 
f 
f 
Normal adult 
49 
43 
24 
21 
16 
15 
12 
6 
* : proband. 
**: d = 1.006-1.063 g/ml. 
m = male; f = female. 
<6.5 <2.0 1.0-1.4 <1.2 < 4.5 
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Family investigation 
The patient's ancestors lived in the middle-west part of Turkey. Only first 
degree relatives could be investigated. There was no known consanguity in the 
family. Serum lipid values of the family are summarised in Table 1. In both parents' 
families myocardial infarction at relatively young age was observed frequently. 
The father suffered from angina pectoris, obesity and diabetes mellitus. He had 
Achilles tendon xanthomata. He suddenly died at the age of 50, one year after the 
patient had been referred to our clinic. The mother suffered from a myocardial 
infarction at the age of 43. She had no xanthomata. The serum lipid levels of both 
parents and 5 siblings showed all elevated levels of LDL cholesterol, in the 
youngest sibling even at levels comparable to those found in the proband (Table 1); 
this is in accordance with the diagnosis homozygous familial hypercholesterolae-
mia in this subject as well as in the proband, and heterozygous familial hyper-
cholesterolaemia in all other subjects. 
LDL turnover study 
The serum cholesterol levels obtained every morning during the turnover were 
constant with an average value of 16.11 ±0.60 mmol/1 (range 15.13 -16.93 mmol/1). The 
results of the plasma radioactivity disappearance curve are shown in Figure 1; the 
calculated FCR was 0.213 pools/day, in the expected range of homozygous familial 
hypercholesterolaemia (Table 2) (1, 24). The results of the U/P ratio are shown in 
Figure 1. From the third day, this ratio was constant, indicating homogeneity of the 
LDL tracer. The calculated FCR based on the results from day 4-14 was 0.213 
pools/day. The apoLDL production was strongly elevated compared to controls 
(Table 2). 
Table 2 Resirfts of the LDL timiover study m the proband with liomozygoim familial 
hi/percholehterolaeyma (FH) 
Fractional 
catabolic rate 
(pools/day) 
apoLDL 
(mg/dl) 
apoLDL 
secretion rate 
(mg/kg. day) 
Normals (n = 6)1 
Heterozygous FH (n = 6)1 
Homozygous FH (n = 7)1 
Proband 
(plasma decay curve) 
(U/P ratio) 
0 450 ± 0.072 
0.287 ± 0.040 ' 
0.176 ± 0.040 
0.213 
0.213 
48 ± 6 
' 126 ± 21 
362 ± 126 
310 
310 
8.0 ± 0.7 
13.8 ± 3.6 
26.4 ± 10.0 
26.3 
26.3 
': from ref. no. 25. 
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U/P ratio 
100 
0.6 
0.4 
0 2 
5 θ 7 8 9 
time (days) 
10 11 12 13 14 
Figure 1. Plasma radioactirity decay (solid line) and the ratio of the radioactivity excreted 
daily in the и nneand the log mean of the radioactivity in the plasma on that day (VIP ratio; 
broken line) after injection of '•''ƒ labeled autologous LDL in a patient with homozygous 
familial hypercholesterolaemia. 
LDL receptor activity in fibroblasts 
The results of the fibroblast association studies revealed a decreased percentage 
specific association of LDL in the brother of the proband compared to the control, 
consistent with heterozygous familial hypercholesterolaemia, whereas both the 
proband and her sister had a severely decreased value, consistent with homozy-
gous familial hypercholesterolaemia (Table 3). 
LDL apheresis 
Over a period of 2 years a total of 49 treatments were performed, 13 treatments 
with the single column system, 28 treatments with the twin column system, one 
plasma-exchange with donor plasma and 7 plasma-exchanges with albumin. The 
procedures were interrupted once for 6 weeks because of holidays. After 12 months 
of treatment, a reliable intravenous access could not be established by simple 
venipuncture. The patient was treated during that time by plasmapheresis with 
albumin, if possible, for practical reasons. These problems necessitated the opera-
tive construction of an arteriovenous fistula and interruption of the therapy for 10 
weeks. 
86 
Table 3 Results of the LDL receptor activity in fibroblasts of the proband, her brother and 
her youngest sister with familial hypercholesterolaemia (FH) 
Subject 
control 
brother 
proband 
sister 
(II-l) 
(II-4) 
(I1-6) 
9c Associated 
100.0 
70.7 
34.7 
38.2 
Diagnosis 
normal 
heterozygous FH 
homozygous F H 
homozygous FH 
An example of the cholesterol alterations during one LDL apheresis is shown in 
Figure 2. There is a monoexponential decrease in the level of cholesterol of apo В 
containing lipoproteins (non-HDL cholesterol), whereas HDL cholesterol remains 
constant. The results of the serum lipid and apolipoprotein determinations before 
and during treatment are shown in Figure 3 and Tables 4 and 5. Before institution 
of LDL apheresis, the patient was treated wTith bile acid binding resins (cholestyra­
mine 16 g per day) and simvastatin (40 mg per day), both of which had only a limited 
effect on the serum cholesterol levels (decrease on cholestyramine 14%, on sim­
vastatin 11%; Table 4). Treatment with LDL apheresis resulted in a large decrease 
of serum lipid levels. Immediately after treatment, cholesterol levels were less 
than 4.0 mmol/1, rising during the 1-2 weeks till the next treatment, to levels that 
were still much lower than those prior to the institution of the LDL apheresis. The 
average serum cholesterol and apo В levels directly before the apheresis procedu­
re were 37% and 35% lower, respectively, than the average value without therapy, 
whereas during 2 years of apheresis the average level of all determinations of total 
serum cholesterol was 56% lower and that of apo В 53% lower than the average 
value without therapy (Table 4). The mean HDL cholesterol and apo Al levels 
obtained directly before apheresis were 40% and 7% higher, respectively, than the 
values obtained before institution of apheresis therapy (Table 4). 
Treatment in the second year with the automated twin- column system was more 
convenient for both the patient and the operators while comparable lipid-lowering 
results were obtained (Figure 3, Table 5). The direct lipid-lowering effect of both 
the column systems compared to plasma-exchange with albumin was slightly 
larger with regard to serum cholesterol, triglycerides and apo В levels. The 
concentrations of HDL cholesterol were markedly decreased after plasma-ex­
change with albumin, but remained constant with both methods of selective LDL 
apheresis (Table 5). 
One apheresis procedure took 5 hours in the beginning, but could be reduced to 3 
hours once an arteriovenous fistula had been made. The treatment was tolerated 
well. Side effects were limited to occasionally occurring nausea. There were no 
hypotensive periods. Laboratory investigations directly after the treatment pro­
cedure showed a decrease in serum proteins of approximately 10%; at the next visit 
after two weeks, the levels had normalised. There were no alterations in serum 
calcium or the prothrombin time. Gradually the patient developed an iron deficien­
cy anaemia, which was treated with oral iron preparations. 
The patient is doing well after 2 years. Her skin xanthomata disappeared after 
only a few months, an excercise test was unremarkable and there are no signs of 
87 
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12 
io 
8 
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treated volume (ml) 
Figure 2. Plasma cholesterol levels ofapo В containing lipoproteins (von-HDL choleste­
rol) and of HDL cholesterol during an LDL apheresis procedure. 
serum cholesterol (mmol/l) 
20 40 60 80 
time (weeks) 
100 120 140 
Figure ,i. Results of the treatment of a patient with homozygous faimlial hypercholesterol-
aemia with cholestyramine (resins), .simvastatin (sum·) and LDL apheresis (apher) combi­
ned with simvastatin. The patient wastreated with plasmapheresis using plasma at weekJS 
and albumin at weeks .19,.~>2, 50, 6.J, 6'J, 67 and 119; all other treatments were performed with 
dextran-sulfate cellulose columns as described m the text. 
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re-occurence of angina pectoris. On repeated coronary angiography, two of the 
three bypasses are patent and functioning well; there is no apparent progression of 
the atherosclerotic lesions. 
DISCUSSION 
The clinical diagnosis of familial hypercholesterolaemia in a homozygous patient 
is based on the presence of cutaneous xanthomata, juvenile atherosclerosis, toge­
ther with a plasma cholesterol level above 17.0 mmol/1 (1). In our patient, all these 
features were present. In addition, the results of the family investigation were in 
accordance with an autosomal codominant inheritance pattern. The LDL turnover 
study based on both the plasma disappearance and the U/P ratio, yielded a low 
FCR for LDL as found in homozygous familial hypercholesterolaemia (25,26). The 
results of the fibroblast binding studies were again also in accordance with a 
diagnosis of homozygous familial hypercholesterolaemia, present in both the pro­
band and her younger sister. In familial hypercholesterolaemia, the genetic defect 
leads to impairment of either the biosynthesis of the LDL receptor protein, the 
processing of the receptor in the Golgi complex, the transport of the receptor to the 
Table i. Serum cholesterol, serum triglycerides, HDIJ cholesterol (in mmolll), apolipo-
protein В and apohpoprotem Al (in mg/dl) before and during treatment with cholestyrami­
ne (10 g per day), simrastntm 0.0 mg per day), immediately before each apheresis treat­
ment, and the mean of all levels obtained during apheresis during 2 years in the proband 
with homozygous familial hypercholesterolaemia. Basal levels are the mean of-ï determi-
nations. The mean percentual change versus basal levels are given in parentheses. 
Basal Cholestvramine Simvastatin Before each 
apheresis 
mean during 
apheresis 
Serum cholesterol 17.49 
Serum triglycerides 2.62 
HDL cholesterol 0.54 
Apoprotein В 494 
Apoprotein Al 128 
15.06 (-1470 
4.06 (+5.W) 
0.57 (+ 59r) 
443 (-11%) 
113 (-11%) 
15.61 (-119, ) 10.98 (-37% ) 7.63 (-56% ) 
2.78 (+ 6%) 
0.62 (+15%) 
495 (+ 2%) 
113 (-12%) 
2.34 (-11%-) 
0.75 (+40%) 
321 (-35%) 
137 (+ 7%) 
1.75 (-33%) 
0.71 (+33%) 
230 (-53%) 
126 (- 2%) 
Table 5. Effects of treatment with plasma exchange with albumin, LDL apheresis with the 
single column system, and LDL apheresis with the twin column system in the proband. 
Results are expressed as the mean percentual change (± SD) in lipid levels before and after 
the apheresis procedure. 
Plasma 
exchange 
Single 
column 
Twin 
column 
Treatments 
Volume treated (ml) 
Change (%) 
cholesterol 
triglycerides 
HDL cholesterol 
7 
1800 ± 500 
-57± 12 
-52 ± 15 
-46 ± 19 
13 
2400 + 700 
-62 ± 8 
-34 ± 14 
-13 ± 6 
28 
3300 + 850 
-64 ± 10 
-55 ± 8 
+ 3 ± 6 
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cell surface, the binding of the LDL· particle or its internalisation into the cell (27). 
Depending on the type of defect, the resulting receptor activity is decreased or 
absent (27). The fact that a certain amount of LDL association was found in the 
fibroblast studies in our patients indicates that there is still some receptor activity, 
which means that at least one of two defective alleles leads to the production of a 
receptor with a diminished, but not absent activity. This also explains the small 
alterations in serum cholesterol levels by bile acid binding resins and simvastatin 
(2). On the other hand, the strongly decreased potency to induce LDL receptors 
apparently blunts the therapeutic effects of both drugs in this patient. 
The importance of a deficiency in LDL receptors in the development of elevated 
serum cholesterol levels was demonstrated in a 6-year-old girl with homozygous 
familial hypercholesterolaemia who was successfully treated by transplantation of 
a normal liver; the donor liver contained sufficient LDL receptors to lower the 
concentration of LDL cholesterol in the recipient to a near-normal value (δ). 
The LDL receptor defect in homozygous familial hypercholesterolaemia leads to 
both a decreased uptake and an increased synthesis of LDL particles, as was found 
in our patient. In addition, the homozygous patient differs from a normal subject in 
that the LDL particles appear to be derived not only from the conversion of VLÜL, 
but from direct synthesis as well (28). In the Watanabe heritable hyperlipidaemic 
(WHHL) rabbit, an animal model for homozygous familial hypercholesterolaemia, 
direct LDL synthesis has been demonstrated also; in addition, the direct LDL 
synthesis could be decreased by cholesterol lowering therapies in this animal (29). 
Whether or not it is possible to decrease direct LDL synthesis in patients with 
homozygous familial hypercholesterolaemia as well remains to be established. 
Treatment with the LDL apheresis technique appeared to be an appropiate way 
of lowering serum cholesterol levels in this patient. The possibility of repeated use 
during the treatment period with the twin columns system, in combination with an 
automatically controlled unit, as used in the second year made the procedure more 
convenient. The actual decrease in serum cholesterol levels is probably about 50%, 
taking into account that the increase after the treatment is more rapidly in the first 
than in the second week of treatment (6). Serum HDL cholesterol levels increased 
during treatment by 30-40%, as observed by other investigators, which may 
augment the therapeutic effect of LDL cholesterol lowering (30). We have combi-
ned treatment with LDL apheresis and cholesterol synthesis inhibition with sim-
vastatin, because an additional effect of the latter on LDL cholesterol lowering and 
increases of HDL cholesterol was anticipated (31, 32). 
We conclude that LDL apheresis is a safe and effective way of lowering choleste-
rol levels in a patient with homozygous familial hypercholesterolaemia. This me-
thod may be of use in patients with elevated cholesterol levels which can not be 
treated by diet and drugs alone. 
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SUMMARY 
The effect of partial ileal bypass surgery (PIB) on lipoprotein concentrations and 
compositions and on the catabolism of low-density lipoproteins (LDL) was studied in 
Watanabe heritable hyperlipidemic (WHHL) rabbits. After PIB, total serum chole­
sterol was 657r lower (6.22 ±1.58 vs. 17.24 ±3.22 mmol/1) and LDL cholesterol 81% 
lower (2.02 ±0.95 vs. 10.90 ±3.60 ттоІЛ) than in control WHHL rabbits; cholesteryl 
esters, expressed as percentage of mass, were 55% lower in the very-low and interme­
diate-density lipoprotein (VLDL + IDL) fractions, and 45% lower in LDL, whereas 
triacylglycerols were 89% higher in VLDL + IDL and 1217r higher in LDL. The 
fractional catabolic rate (FCR) of LDL protein (apoLDL) from operated animals was 
10% higher than that from controls in all animals (0.55 ±0.10 vs. 0.50 ±0.10 pools/day; 
Ρ <0.01). The FCR of autologous apoLDL in PIB rabbits was 50% higher than that of 
autologous apoLDL in control rabbits (0.63 ±0.05 vs. 0.42 ±0.06 pools/day); this was 
not caused by induction of receptor-mediated clearance of LDL. The production rate 
of apoLDL after PIB in PIB rabbits was 50% lower compared to control apoLDL in 
controls (26.0 ±6.7 vs. 51.7 ±16.4 mg/kg per day). We conclude that PIB lowers LDL 
cholesterol in WHHL rabbits by a decreased production of LDL, by an increased 
non-specific clearance of LDL and by compositional changes, which lead to LDL 
particles containing less cholesterol. 
INTRODUCTION 
In normal man, approx. 65% of the low-density lipoproteins (LDL) are cleared from 
the plasma by the LDL (Β, E) receptor pathway, whereas the non-receptor-mediated 
uptake accounts for 35% (1). In heterozygous familial hypercholesterolemia, however, 
the LDL receptor activity is deer-eased up to 50% due to an inherited disorder, and 
plasma LDL cholesterol is elevated (2). In that situation, the non-receptor-mediated 
uptake can be as high as 60%. In homozygous familial hypercholesterolemia, very little 
or no LDL receptor activity is found, and as much as 100% of the LDL may be taken up 
by non-receptor-mediated pathways (1, 2). Studies on the mechanisms of cholesterol 
lowering which act independently from the receptor pathway are thus of interest. 
Homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits lack the LDL 
receptor due to a monogenic inherited disorder (3). Due to a deletion in the binding 
domain of the receptor, a decreased intracellular glycosylation of the immature 
receptor and a decreased transport of the receptor to the cell surface, the LDL 
receptor activity in in-vitro binding studies is less than 5% of normal (4, 5). LDL 
cholesterol is cleared from the plasma at a decreased rate and the conversion of 
very-low-density lipoproteins (VLDL) to LDL is increased (6,7). The grossly elevated 
serum cholesterol levels lead to premature atherosclerosis and xanthomathosis (8, 9). 
This animals serves therefore as a unique model for homozygous familial hyper­
cholesterolemia in man (10). 
In WHHL rabbits, cholesterol lowering can only be achieved by mechanisms which 
act independently from receptor induction (10). Various treatments, such as bile acid 
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Sequestration by cholestyramine and partial ileal bypass (PIB), inhibition of 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and administration of pro-
bucol can reduce cholesterol levels in the WHHL rabbit (11-15). In previous studies 
concerning the effects of PIB in the WHHL rabbit, it was found that total cholesterol 
could be lowered by more than 50#, and that this cholesterol lowering was accompanied 
by an inhibition of the progi'ession of atherosclerosis (12). This cholesterol lowering is 
most likely due to bile acid sequestration, since both PIB and cholestyramine can 
decrease serum cholesterol in the WHHL rabbit (11). 
We have previously studied LDL kinetics with native and methylated LDL in 
WHHL rabbits after PIB; there was a 44% reduction of the serum cholesterol con­
centration that was accompanied by a 50% reduction in the production rate of apolipo-
proteins in LDL (apoLDL) without a change in the fractional catabolic rate (FCR); the 
receptor-mediated clearance was essentially zero both in animals with and without PIB 
(16). Studies with cultured hepatocytes from a WHHL rabbit incubated in lipoprotein-
deficient serum also did not reveal any receptor activity (5). These metabolic findings 
are in accordance with the inability of the WHHL rabbit to induce any receptor activity. 
To investigate further the mechanism that leads to a cholesterol decrease in the 
WHHL rabbit after PIB, we have evaluated the changes in concentration and composi­
tion of lipoproteins induced by PIB and the influence of these changes on LDL metabo­
lism after a much longer period after PIB, when the effects were even more pronounced 
than in our earlier study (1(5). Moreover, we have studied the metabolism of autologous 
LDL, i.e., treated LDL in treated rabbits and control LDL in control rabbits, and 
compared this to non-autologous LDL. 
MATERIALS AND METHODS 
Animals 
Homozygous WHHL rabbits were raised by crossing and back-crossing with New 
Zealand white (NZW) rabbits. They were housed individually in metal cages with a 
mesh floor and maintained on a regular chow diet (LK04, Hope Farms, Woerden, The 
Netherlands). Partial ileal bypass was performed in five WHHL rabbits under general 
anesthesia 17 weeks behore the current study at an average age of 23 weeks, essentially 
as described by Buchwald (11,17); the distal one third of the ileum was bypassed by a 
functional end to side anastomosis with the colon ascendens. After the operation, the 
animals received antibiotics (ampicillin, 750 mg intramuscular) for 3 days. They were 
given hydroxocobalamine, 50 μg intramuscularly, bimonthly to avoid vitamin B12 
deficiency. Five WHHL rabbits served as controls. 
Lipoprotein isolation, radiolabeling and reductive methylation 
After an overnight fast, blood was taken from ear arteries and mixed with EDTA for 
lipoprotein analysis. Lipoproteins were isolated by density gradient ultracentiifugation 
in a swinging bucket rotor in an IEC-B60 ultracentrifuge (Damon/IEC, Needham 
Heights, MA, U.S.A.) as described previously (18). Lipoproteins separated in this way 
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can be identified as bands in the following density ranges: VLDL and intermediate-
density lipoproteins (IDL): d < 1.025 g/ml; LDL: 1.025 < d < 1.063 g/ml; high-density 
lipoproteins (HDL): 1.063 < d < 1.185 g/ml. 
5 days before the turnover experiment, 10 ml blood was taken from each animal after 
sedation for LDL isolation. Semm was pooled per group: PIB serum from five WHHL 
rabbits after PIB and control serum from five control WHHL rabbits. LDL was isolated 
by sequential ultracentrifugation in a fixed angle rotor at 168000 g for 22 h between 
densities 1.019 and 1.050 g/ml in the presence of 0.1 mg/ml EDTA (sodium salt) and 5 
μg/ml gentamycin. Before the first ran, sodium azide 0.4 mg/ml was added. LDL was 
recentrifuged once at d = 1.050 g/ml and dialyzed overnight at 40C in 5 liters of dialysis 
buffer (0.15 M NaCl, 0.5 g/1 EDTA and 5 mg/1 gentamycin at pH = 7.5). The protein of 
LDL was iodinated with 1!1I (control LDL) or u"4 (PIB LDL) by a modification (19) of the 
method of McFarlane (20). Unreacted iodine was removed by column chromatography 
on Sephadex G-25M (columns PD-10, Pharmacia Fine Chemicals, Uppsala, Sweden). 
The LDL was dialyzed against 5 liters of dialysis buffers at 4CC. 
In a second experiment, performed to determine the receptor-mediated clearance of 
LDL in vivo, LDL was isolated in the same way as described above from one WHHL 
rabbit after PIB. A portion of the LDL was labeled with И 1І, another portion with 12,L 
The 12T-labeled LDL was chemically modified by reductive methylation with a 60 min 
reaction sequence (21). Methylation of lysine residues has been shown to abolish the 
binding of LDL to the LDL receptor without effects on non-receptor-mediated proces­
ses (3, 19). After methylation, unreacted iodine was removed by chromatography on 
Sephadex G-25M and the LDL was dialyzed overnight at 40C against 5 liters of dialysis 
buffer. As estimated by a colorimetrie method, based on the reaction of 2,4,6-trini-
trobenzene-l-sulfonic acid with primary amines (22), 70% of the lysine residues had been 
methylated. 
The efficiency of labeling was 35-60%; more than 98% of the radioactivity was 
precipitated by 10% trichloric acetic acid; 89-91% of the radioactivity was precipitated by 
50% isopropanol. There were no differences between the two LDL tracers. On sodium 
dodecyl sulphate (SDS) gel electrophoresis, both control LDL and PIB LDL were found 
to contain apoB, with only trace amounts of apoE. 
LDL turnover studies 
The first experiment was performed 17 weeks after operation. Blood was taken after 
an overnight fast from the unsedated animals and mixed with EDTA to determine lipids 
and lipoproteins. y4-labeled PIB LDL and '"I-labeled control LDL were mixed, diluted 
with 0.15 M NaCl and sterilized trough a 0.44 μΜ filter (Millipore SA, Molsheim, 
France). 2 ml portions of this mixture were injected through a marginal ear vein into the 
five WHHL controls, and the five WHHL rabbits after PIB. In addition, the mixture 
was injected into one NZW rabbit. On average, 6 μΰί >¿>l and 9 μΟΙ ' "I were injected into 
each animal. Rabbits were kept in restraining cages during the first 6 h of the experi­
ment. Afterwards, they were transferred to their cages with free access to food and 
water and only taken out for blood drawing. Blood samples (1 ml in 2 mg EDTA) were 
drawn at regular intervals for 72 h. The sample taken at 3 min was used to calculate the 
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plasma volume by isotope dilution. Total plasma radioactivity of 12>I and ''"I was 
estimated in a Philips PW 4800 automatic gammacounter. 
A second experiment was performed 18 weeks after the first in two control WHHL 
rabbits, two WHHL rabbits after PIB and one NZW. 1!,I-labeled LDL and '''I-labeled 
methyl-LDL from one WHHL rabbit after PIB were injected into each animal and 
blood samples were drawn in exactly the same way as in the first experiment. Each 
animal received 10 μϋί Ш І and 7 μΟΙ n , I . 
The fractional catabolic rate was obtained from biexponential analysis of the plasma 
radioactivity decay curves, assuming a simple two-compartment model where plasma 
LDL equilibrates with an extravascular compartment and where all irreversible loss of 
apoLDL occurs from the plasma compartment (23, 24). The absolute catabolic rate 
(ACR) was calculated from the FCR and the apoLDL pool size; the apoLDL pool size 
w
T
as obtained from the plasma volume and the apoLDL concentration by multiplication, 
and corrected for body weight. Under steady-state conditions, the ACR equals the 
production rate. 
Analytical methods 
Cholesterol was measured by the enzymatic CHOD-PAP method (No. 237574, Boeh-
ringer Mannheim, F. R. G.) (26). Phospholipid and free cholesterol were measured with 
enzymatic kits (Nos. 691844 and 310328, respectively, Boehringer Mannheim). Protein 
was determined according to the method described by Lowry et al. (27). 
Statistical analyses were performed with Wilcoxon's test for paired and unpaired 
data. A two-sided Ρ value of less than 0.05 was considered to the significant. Unless 
indicated otherwise, results are expressed as means ±S.D. 
Table I. Age, weight, se.r distribution, total cholesterol and triaq/lglycerol concentration and 
lipoprotein cholesterol and triacylglycerol concentration in WHHL control rabbits, WHHL 
rabbits 17 weeks after partial ileal bypass (PIB) and in one New Zealand White (NZW) rabbit 
Lipoprotein fractions were isolated by gradient ultracentrifugation. Results are not corrected for 
procedural losses. Value are means ±S.D. M = male, F = female. 
WHHL controls WHHL PIB NZW 
Number 
Age (vveeks) 
Weight (grams) 
Sex (M/F) 
Cholesterol (mmol/1) 
VLDL + IDL 
LDL 
HDL 
Triacvlglvcerols (mmofl) 
V L D L ' + IDL 
LDL 
HDL 
δ 
46 ± 2 
2370 ± 270 
2/8 
17.64 ± 3.22 
4.58 ± 1.59 
10.90 ± 3.60 
0.16 ± 0.04 
4.88 ± 1.13 
1.85 ± 0.92 
2.07 ± 0.42 
0.00 ± 0.01 
5 
40 ±4" 
2020 ± 290 
2/3 
6.22 ± 1.58-
3.04 ± 1.59 
2.02 ± 0.95" 
0.17 ± 0.05 
7.56 ± 5.53 
4.84 ± 4.25 
1.35 ± 0.25 
0.06 ± 0.05 
1 
13 
2700 
1/0 
1.98 
0.19 
0.51 
0.78 
0.96 
0.23 
0.07 
0.09 
a
 Ρ (vs. WHHL controls) < 0.01. 
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RESULTS 
Age, body weight, plasma lipids and lipoproteins 
Table I shows some characteristics of the studied groups. The five WHHL rabbits 
after PIB were slightly younger and lighter than the five control WHHL rabbits. 
Average total and LDL cholesterol in plasma were significantly lower than in controls 
(-65% and -817Í>, respectively). VLDL + IDL cholesterol was lower and triacylglycerols 
higher; these differences were not significant. High-density lipoprotein (HDL) choleste-
rol concentrations were similar in both groups. The chemical composition of VLDL + 
IDL and LDL in both groups is shown in Table II. After PIB, there was a relative 
increase in the percentage of mass of triacylglycerols at the expense of free cholesterol 
and cholesteryl esters in both VLDL + IDL and LDL fractions. The mass ratio 
cholesteryl esters to triacylglycerols was lower in the operated group compared to 
controls in both VLDL + IDL (0.35 ±0.14 vs. 1.46 ±0.28; Ρ < 0.01) and LDL (0.78 ±0.61 vs. 
2.94 ±1.13; Ρ < 0.05). 
Effects of PIB on LDL metabolism 
In the first turnover experiment, the effects of PIB on the apoLDL metabolism were 
studied 17 weeks after operation by simultaneous injection of 1!1I-labeled control LDL 
and 12T-labeled PIB LDL. The results are summarized in Table III and Figs. 1 and 2. In 
one WHHL rabbit after PIB, the curve obtained by biexponential analysis was not 
different from that obtained by monoexponential analysis. In WHHL rabbits after PIB, 
the apoLDL pool was 66% lower than in WHHL controls. PIB apoLDL was cleared 
faster than control apoLDL in all WHHL rabbits; the average FCR was 0.55 ±0.10 
pools/day for PIB apoLDL vs. 0.50 ±0.10 pools/day for control apoLDL (P < 0.01). In 
addition, both PIB apoLDL and control apoLDL were cleared faster in the treated 
Table II. Chemical composition offmctmm VLDL + IDL and LDL of WHHL control rabbits (n 
= 0), and WHHL rabbits 17 weeks after partial ileal bypass (PIB) (n = 5) 
Lipoprotein fractions were isolated by gradient ultracentrifugation; chemical composition was 
calculated after determination of cholesterol, free cholesterol, triacylglycerols, phospholipids and 
protein. Values are means ±S.D. 
Component 
Cholesteryl esters 
Triacylglycerols 
Free cholesterol 
Phospholipids 
Proteins 
J
 Ρ (vs. WHHL controls) < 
Composition (% 
VLDL + IDL 
controls 
36.9 ± 2.2 
25.9 ± 3.6 
7.4 ± 0.5 
17.6 ± 0.3 
12.2 ± 1.1 
0.05. 
of mavss) 
PIB 
16.7 ± 4.8b 
48.9 ± 5.6" 
6.1 ± 0.4'' 
17.7 ± 0.8 
10.6 ± 0.9a 
LDL 
controls 
34.7 ± 3.3 
12.8 ± 3.5 
7.7 ± 0.9 
19.3 ± 0.5 
25.6 ± 0.3 
PIB 
18.9 ± 7.3b 
28.3 ± 7.1b 
6.2 ± 0.Γ)1' 
21.1 ±1.1" 
25.7 ± 0.7 
b
 Ρ (vs. WHHL controls) < 0.01. 
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Table HI. Ktnetic data of turnover study intli '"¡-labeled LDLfrom control WHHL rabbits and 
'-''I-labeled LDL from WHHL rabbits 17 weeks after partial ileal bypass (PIB) in control WHHL 
mbbits, WHHL rabbits 17 weeks after PIB and one New Zealand White (XZW) rabbit 
After injection of a mixture of H1I-labeled control LDL and 12>I-labeled PIB LDL, plasma 
radioactivity was followed for 72 h. The fractional catabolic rate (FCR) was determined by 
biexponential analysis of the plasma decay curve. The absolute catabolic rate (ACK) was calcula-
ted from FCR and the apoLDL pool. Values are means ±S.D. 
Plasma volume (ml) 
ApoLDL pool (mg/kg) 
Control LDL 
FCR (pools/day) 
ACR (mg/kg per day) 
PIB LDL 
FCR (pools/day) 
ACR (mg/kg per day) 
WHHL controls 
(n = 5) 
77.3 ± 6.9 
125 ± 46 
0.42 ± 0.05 
51.7 ±16.4 
0.47 ± 0.06 
WHHL PIB 
(n = 5) 
75.3 ±14.2 
42 ± 11·' 
0.58 ± 0.05" 
0.63 ± Ο.Οδ-
26.0 ± 6.7'' 
NZW 
(n = l) 
100.7 
6.5 
1.40 
1.47 
" Ρ (vs. WHHL controls) < 0.01. 
ь
 Ρ (vs. control LDL in WHHL controls) < 0.01. 
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Figure 1. Disappearance of plasma radioactivity after simnltaneous injection of'" I-labeled 
LDLfrom WHHL control rabbits (control-LDL) and ofu~'I-labeled LDLfrom WHHL rabbits 17 
weeks after partial ileal bypass (PIB-LDL) in WHHL control rabbits (A) and WHHL rabbits 
after PIB (B). Values are means ±S.D. 
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rabbits than in the controls, although still much slower than in the NZW rabbit (Fig. 2). 
The ACR in rabbits after PIB was lower than in controls. Altogether, the FCR of PIB 
apoLDL in WHHL rabbits after PIB was 50% higher and the ACR of PIB apoLDL was 
50% lower when compared with control apoLDL in WHHL controls. 
To find further evidence for an absence of induction of receptor-mediated uptake of 
apoLDL after PIB, a second experiment was performed, when the LDL turnover study 
was repeated in some animals using 1!1I-labeled LDL and ^T-labeled methyl-LDL from 
one PIB WHHL rabbit. The results of this and the first experiment are summarized in 
Table IV. The cholesterol levels in the rabbits after PIB were comparable vñth those in 
the first experiment, the cholesterol levels of the control animals were lower. In one 
animal, there was an unexplained rapid disappearance of the methylated apoLDL, and 
plasma radioactivity (°lo of injected dose) 
100 τ 
5 0 
2 0 
10 -
о control-LDL m WHHL-controls ln-5) 
• PIB-LDL m WHHL-PIB (n=5) 
+ control-LDL m NZW Іп;1) 
24 4 8 72 
hours a f t e r in ject ion 
Figure ¿. Disappearance of plasma radioactivity of'I-labeled LDL from control WHHL rabbits 
in control WHHL rabbits and m one New Zealand White (NZW) rabbit, and ofu'I-labeled LDL 
from WHHL rabbits 17 weeks after partial ileal bypass (PIB-LDL) in WHHL rabbits after PIB. 
Values are means ± S.D. 
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Table ¡V. Fractional catabolic raten (FCR) of apoLDL turnover study in WHHL control rabbits and WHHL rabbits after partial ileal bypass (PIB) 
with '"I-labeled native LDL from a WHHL rabbit after PIB and tnethylated '''¡-labeled PIB LDL 
The study (Expt. 2) was done 35 weeks after PIB. The individual results of the first experiment (Expt. 1), in which LDL from control WHHL rabbits 
and PIB LDL were compared, are also given for PIB LDL only. After injection of a mixture of '"I-labeled PIB LDL and ''''I-labeled methylated PIB 
LDL, plasma radioactivity was followed for 72 h. The fractional catabolic rate (FCR) was determined by biexponential analysis of the plasma decay 
curve. The receptor-dependent FCR is the difference between the FCR of native PIB apoLDL and methylated PIB apoLDL. The results of one New 
Zealand white (NZW) rabbit are given for comparison. 
Expt.: 
WHHL controls 
1 
2a 
WHHL PIB 
1 
2 
NZW 
1" 
FCR of native LDL 
(pools/day) 
1 
0.42 
— 
0.65 
0.62 
-
2 
0.47 
0.55 
0.67 
0.69 
2.74 
FCR of methyl-LDL 
(pools/day) 
2 
0.38 
0.42 
_ 
0.59 
0.88 
Receptor-dependent FCR 
(pools/day) 
2 
+ 0.09 
+0.13 
-
+0.10 
+ 1.86 
Cholesterol 
(mmol/1) 
1 
22.83 
-
4.17 
6.84 
-
2 
13.12 
10.51 
4.65 
6.72 
0.85 
" Did not participate in Expt. 1. 
kinetic analysis was not possible. The FCR results in this experiment agreed well with 
the first experiment, indicating a good reproducibility of the measurement of the FCR. 
The clearance of methyl PIB apoLDL wTas slower than of native PIB apoLDL in all 
animals. The difference between FCR of native and methyl apoLDL, which equals the 
receptor-mediated part of the clearance, was of the same magnitude in controls and 
after PIB. In the NZW rabbit, the receptor-mediated uptake amounted to 68% of the 
total uptake. 
DISCUSSION 
In this study, WHHL rabbits after PIB showed a marked decrease in total and LDL 
cholesterol levels, together with a large decrease in the ratio of cholesteryl esters to 
triacylglycerols in fractions VLDL + IDL and LDL. The cholesterol decrease is most 
likely due to bile acid sequestration, since cholestyramine also lowers serum cholesterol 
(11). Also, the increases in triacylglycerols, though not significant in this study, are 
probably secondary to bile acid sequestration, as found in humans (28). 
The decrease in cholesterol (62%) and LDL cholesterol (817c) in the current study was 
more pronounced than in our previous study (cholesterol and LDL cholesterol reduction 
44% and 58%, respectively) (16). Also, the differences in the composition of the lipo-
proteins were more pronounced in the current study. The altered compositions could be 
explained by an increased synthesis of bile acids from cholesterol leading to a cholesterol 
depletion in the liver and to the production of a VLDL particle in which the cholesteryl 
esters are replaced by triacylglycerols. Rapid transfer of triacylglycerols and choleste-
ryl esters between lighter fractions and LDL would then lead to the observed composi-
tional changes in LDL. Especially in WHHL rabbits there is a veiy high lipid transfer 
activity (29), which would be in favor of this explanation. On the other hand, the 
compositional changes might be the consequence of an alteration in the catabolism of 
LDL: a shorter stay of LDL in the circulation results in a decrease of the ratio of 
cholesteryl esters to triacylglycerols of LDL (30). In the current study, we found that a 
high FCR of apoLDL was accompanied by a low ratio of cholesteryl esters to triacylgly-
cerols, wich supports the latter. 
The lower LDL production observed after PIB, on average -50%, confirms the results 
of our previous study (16). In theory, a decreased production of LDL can be the results of 
a decreased direct synthesis of LDL, a decreased production of the precursor of LDL, 
VLDL, or a decreased conversion of VLDL to LDL. In liver perfusion studies (31) and in 
recent kinetic studies (32), a direct synthesis of LDL could not be demonstrated in the 
WHHL rabbit, and is therefore unlikely. A decreased production of VLDL particles is 
also not likely. In the current study, no significant changes in protein content in VLDL + 
IDL was observed (723 ±218 mg/1 in control WHHL vs. 828 ±535 mg/1 in WHHL rabbits 
after PIB). After bile acid sequestration therapy in man, also no changes in VLDL apoB 
production were observed (33). 
A third possibility is that a smaller portion of the VLDL particles is converted to 
LDL. In the WHHL rabbit, the clearance of chylomicrons is normal, and it is assumed 
that there is a normally functioning apoE or chylomicron receptor (34). In man, it has 
been found that larger, triacylglycerol-rich VLDL particles are removed more rapidly 
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from the circulation (35). Possibly, the triacylglycerol-rich VLDL particles found after 
PIB in the WHHL rabbit are taken up to a larger extent by the apoE receptor. Studies 
on the fate of ароВ-100-containing VLDL particles in both normal and WHHL rabbits 
have shown that those which contain both apoB-100 and apoE are taken up faster and 
are converted less to lipoproteins of higher density than those VLDL particles, which 
only contain apoB-100 (32,36). The defective LDL receptor in the WHHL rabbit does 
not bind LDL, but might be able to bind to some extent large VLDL remnants that 
contain several molecules of apoE (32). The cholesterol depletion in the li\ er after PIB 
may lead to an increased production of the defective LDL receptor. This is supported by 
a study on the effects of cholesterol synthesis inhibition by lovastatin in WHHL rabbits; 
after 10 days on a diet containing 0.03% lovastatin, a decrease in total cholesterol of 43% 
was found, which was accompanied by a 3-fold increase in the messenger RNA level of 
the LDL receptor (14). The increased uptake of larger VLDL remnants by either the 
apoE receptor or the defective LDL receptor would lead to a decreased conversion to 
LDL. Indeed, we found a decreased production rate of LDL of 50% after PIB. 
The increase of the FCR of apoLDL after PIB is in contrast with observations in 
patients with homozygous familial hypercholesterolemia: portocaval shunting opera­
tion and plasmapheresis reduced LDL cholesterol levels in these patients without an 
increase in the FCR of apoLDL (37, 38). It is also in contrast with our previous study 
(16). The possibility that a huge cholesterol depletion leads to a large intrahepatic 
cholesterol deficit by which the receptor defect is partially overcome for the uptake of 
LDL is not likely, as was shown by the results of previous LDL turnover studies with 
native and methylated LDL (16) and from the results of binding studies with hepatocy-
tes (5). In agreement with these results, the turnover study with methylated and native 
apoLDL in two control WHHL rabbits and one WHHL rabbit after PIB revealed no 
receptor induction in the latter. Apparently, a mechanism different from induction of 
receptor-mediated uptake causes the increased FCR of apoLDL after PIB. 
Part of the difference between the current results and those from our previous study 
may be caused by the use of autologous LDL instead of heterologous LDL. The LDL 
particles after PIB are depleted of cholesteiyl esters and enriched in triacylglycerols 
compared to control LDL. The FCR of control LDL in PIB WHHL was found to be 8% 
lower than the FCR of PIB LDL in PIB WHHL. Because control LDL was used in our 
previous study, this might have led to a falsely low estimation of the FCR in WHHL 
rabbits after PIB. In fact, the difference between the FCR of control LDL and that of 
PIB LDL might even be higher; introduction of a non-autologous LDL particle of 
different composition can lead to a rapid transfer of lipids (29). As a consequence, the 
composition of the labeled LDL particle will become more like that of the LDL pool with 
time. 
The possibility that changes in the LDL composition can lead to an altered catabolism 
of LDL is supported by the results of several studies. Naruscewicz et al. found a 
decrease of cholesterol in WHHL rabbits after probucol, wich was accompanied by an 
increased FCR of LDL both in WHHL and NZW rabbits and suggested that changes in 
the LDL particle caused by the drag resulted in an increased uptake not mediated by 
the LDL receptor (15). Witztum et al. observed a decreased clearance of LDL when 
LDL from guinea pigs after treatment with cholestyramine was compared to normal 
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LDL (39); Young et al. obtained the same results in the human situation with human 
LDL after treatment (40). Although most of these studies concerned biological systems 
in which LDL receptor induction could occur, these results and our findings in the 
present study indicate the possibility of an influence of LDL composition on its catabo-
lism. 
In a study on the effects of cholesterol feeding on the clearance of apoLDL in NZW 
rabbits, Slater et al. found that both the receptor-mediated and the non-receptor-
mediated clearance decreased (41). It was suggested that the latter indicated the 
possibility of a saturable component in the receptor-independent LDL catabolism. On 
the other hand, cholesterol feeding induces changes in the LDL composition as well (42). 
We conclude that the huge decrease in LDL cholesterol concentrations in the WHHL 
rabbit after bile acid sequestration by PIB is caused by (1) a decreased production of 
LDL, probably due to changes in VLDL metabolism, (2) an increased clearance of LDL, 
which is not mediated by the LDL receptor and (3) the production of LDL particles that 
contain less cholesterol. 
ACKNOWLEDGMENTS 
The authors wash to thank the staff of the Central Animal Laboratory of the Medical 
Faculty (Head: Professor Dr. W.J.I. van der Gulden) for their efforts in breeding the 
WHHL rabbit. Mr. G. Giaitters and Mr. H. Eikholt are thanked for expert technical 
assistance. A.F.H.S. is Clinical Investigator of the Netherlands Heart Foundation. 
REFERENCES 
1. Goldstein, J.L. and Brown, M.S. (1977) Metabolism 2G, 1257-1275. 
2. Goldstern, J.L. and Brown, M.S. (1983) in Metabolic Base of Inherited Disease (Stanbury, J.R. Wijngaar-
den, J.B., Frednckson, D.S., Goldstein, J.L. and Brown, M.S., oris.), pp. 672-712, Mc-Graw Hill, New York. 
3. Kita, T., Brown, M.S. and Goldstein, J.L. (1981) Proc. Natl. Acad. Sci. USA 78.2268-2272. 
4. Yamamoto, T., Bishop, R.W., Brown, M.S., Goldstein, J.L. and Rüssel, D.W. (1986) Science 232,1230-1237. 
5. Attic, A.D., Pittman, R.C., Watanabe, Y. and Steinberg, D. (1981) J. Biol. Chem. 56, 9789-9792. 
6. Bilheimer, D.W., Watanabe, Y. and Kita, T. (1982) Proc. Natl. Acad. Sci. USA 79, 3305-3309. 
7. Kita, T., Brown, M.S., Bilheimer, D.W. and Goldstein, J.L. (1982) Proc. Natl. Acad. Sci. USA 79,5693-5697. 
8. Watanabe, Y. (1980) Atherosclerosis 38,27-31. 
9. Havel, R J., Kita, T., Kotite, L., Williams, P.T., Kane, J.P., Hamilton, R.L., Goldstein, J.L. and Brown, M.S. 
(1982) Arteriosclerosis 2, 467-474. 
10. Goldstein, J.L., Kita, T. and Brown, M.S. (1983) N. Engl. J. Med. 309, 288-296. 
11. Van Niekerk, J.L.M., Hendriks, Th. and Do Boer, H.H.M. (1984) Eur. Surg. Res.. 16, 282-287. 
12. Van Niekerk, J.L.M., Demacker, P.N.M., Hendnks, Th. and Do Boer, H.H.M. (1983) Atherosclerosis 48, 
243-252. 
13. Watanabe, Y., Ito T., Saeki, M., Kuroda, M., Tanzawa, К., Mochizuki, M., Tsujita, Y. and Arai, M. (1981) 
Atherosclerosis 38, 27-31. 
14. Ma, P.T., Gil. G., Sudhof, T.C., Bilheimer, D.W., Goldstein, J.L. and Brown, M.S. (1986) Proc. Natl. Acad. 
Sci. USA Sil, 8370-8374. 
15. Naniszewicz, M., Carew, Т.Е., Pittman, R.C., Witztum, J.L. and Steinberg, D. (1984) J. Lipid Res. 25, 
1206-1213. 
16. Stalenhoef, A.F.H., Van Niekerk, J.L.M., Demacker, P.N.M, and Van 't Laar, Α. (1984) J. Lipid Res. 25, 
13Ó0-1357. 
17. Buchwald, H.A. (1963) Circulation 28,649-650. 
18. Demacker, P.N.M., Van Sommeren-Zondag, D.F., Stalenhoef, A.F.H, and Van 't Laar, A. (1983) Clin. 
Chem. 29, 656-663. 
105 
19. Sigunlsson. G., Noel, S.-P. and Havel, R J . (1979) J. Lipid Res. 20,316-324. 
20. McFarlane, A.S. (1958) Nature 182,53-54. 
21. Weisgraber, K.H., Inneraríty, T.L. and Mahley, R.W. (1978) J. Biol. Ghem. 258,9053-9062. 
22. Habceb, A.F.S.A. (1966) Anal. Biochem. 14,328-336. 
23. Matthews, C.M.E. (1957) Phys. Med. Biol. 2,36-53. 
2-1. Stoudemire, J.B., Renaud, G., Shames, D.M. and Havel, R J . (1984) J. Lipid Res. 25,33-39. 
25. Demacker, P.N.M., Bocrma, G J.M.. Baadenhuijsen, H., Van Strik, R. and Jansen, A.P. (198;?) Clin. Chem. 
29,1916-1922. 
26. Demacker, P.N.M., Van Oppenraay, J.B., Baadenhuijsen, H. and Jansen, A.P. (1975) Clin. Chim. Acta 64, 
45-50. 
27. Lowiy, O.H., Rosenbrough, N J., Fair, A.L. and Randall, R J . (1951) J. Biol. Chem. 193,265-275. 
28. Beil, L'., Course, J.R., Einarsson, K. and Grundy, S.M. (1982) Metabolism 31,438-444. 
29. Son, Y.-S.C. and Zilversmit, D.B. (1986) Arteriosclerosis 6, »45-351. 
30. Lacombe, С and Nibbelink, M. (198:?) Artery 11, 273-282. 
31. Ilornick, CA., Kita, T., Hamilton, R.L., Kane, J.P. and Havel, R J . (1983) Proc. Natl. Acad, Sci. USA 80, 
6096-0100. 
32. Yamada, N.. Shames, D.M. and Havel, R J . (1987) J. Clin. Invest. 80,507-515. 
33. Soutar, A.K., Myant, N.B. and Thompson, G.R. (1982) Atherosclerosis 43,217-231. 
34. Kita, T.L., Goldstein. J.L., Brown, M.S., Watanabe, Y., Homick. C.A. and Havel. R J . (1982) Proc. Natl. 
Acad. Sci. USA 79,3623-3627. 
35. Stalenhoef, A.F.H., Malloy, MJ., Kane, J.P. and Havel, R J . (1984) Proc. Natl. Acad. Sci. USA 81, 
1839-1843. 
36. Yamada, N., Shames, D.M., Stoudemire, J.B. and Havel, R J . (1986) Proc. Natl. Acad. Sci. USA 83, 
3479-3483. 
37. Bilheimer, D.W.. Goldstein, J.I,., Grundy, S.M. and Brown, M.S. (1975) J. Clin. Invest. 56,1420-1430. 
38. Thompson, G.R., Spinks. T., Ranicar, A. and Myant, N.B. (1977) Clin. Sc. Mol. Med. 52,361-369. 
39. Witztum, J.I,., Young, S.G., Elam, R.L., Carew, Т.Е. and Fisher, M. (1985) J. Lipid Res. 26,92-103. 
40. Young, S.G. and Witztum, J.L. (1985) Clin. Res. 33,448a. 
41. Slater, H.R., Shepherd, J. and Packard, C J . (1982) Biochim. Riophys. Acta 713,435^45. 
42. Lacombe, C, Corraze, G. and Nibbelink, В. (198;?) Lipids 18, 306-312. 
106 
Chapter 8 
ALTERATIONS IN THE METABOLISM OF VERY LOW 
AND LOW DENSITY LIPOPROTEINS AFTER 
PARTIAL ILEAL BYPASS SURGERY IN THE 
WATANABE HERITABLE HYPERLIPIDEMIC RABBIT 
Marc J. T. M. Mol, Anton F. H. Stalenhoef, Pierre N. M. Demacker and 
Albert van 't Laar 
Department of Medicine, Division of General Internal Medicine, University Hospital 
Xijmegen, Nijmegen, The Netherlands 
Submitted for publication 
107 
108 
SUMMARY 
The influence of interruption of bile acid enterohepatic circulation by partial ileal 
bypass (PIB) surgery on serum lipids, lipoproteins and the turnover of very low 
(VLDL) and low density lipoproteins (LDL) was investigated in Watanabe heritable 
hyperlipidemic (WHHL) rabbits. Compared to controls, total serum cholesterol was 
48% lower after PIB (16.88 ±1.57 vs. 8.79 ±1.66 mmol/1; P<0.01), due to lower levels of 
cholesterol in VLDL (-23%), intermediate density lipoprotein (IDL; -39%) and LDL 
(-72%); serum triglycerides were 32% higher (3.86 ±1.35 vs. 5.11 ±0.82 mmol/l). The 
ratio of the percentages of mass of cholesteryl esters to triglycerides was 71% lower in 
VLDL and LDL and 67% lower in IDL (P<0.01). Compared to controls, the secretion 
rate of LDL was 33% lower (31.1 ±7.2 vs. 20.7 ±6.9 mg/kg.day; P<0.05) and the 
fractional catabolic rate (FCR) of LDL was 33% higher (0.46 ±0.06 vs. 0.61 ±0.12 
pools/day; P<0.02). The VLDL turnover showed that after PIB there was a higher 
secretion rate of VLDL apoprotein В (63.9 vs. 167.4 mg/kg.day), a higher FCR (3.84 vs. 
8.61 pools/day), a higher direct uptake (38.8 vs. 146.4 mg/kg.day) and a higher conver­
sion of VLDL to LDL (4.8 vs. 9.0 mg/kg.day). In controls, 85% of LDL originated from 
direct synthesis in controls and after PIB 59%. In both controls and treated rabbits 
there was a direct LDL synthesis which was 52% lower after PIB (26.3 vs. 12.6 
mg/kg.day). 
INTRODUCTION 
The Watanabe heritable hyperlipidemic (WHHL) rabbit is characterized by grossly 
elevated levels of serum cholesterol (1). The removal of LDL from the serum is 
impaired, and the conversion from VLDL to LDL is increased, due to a monogenic 
inherited defect of the low density lipoprotein (LDL) receptor (2-6). The elevated 
cholesterol levels lead to premature atherosclerosis and xanthomatosis (7). A similar 
disturbance in the LDL metabolism is found in patients with homozygous familial 
hypercholesterolemia in man; therefore, this animal serves as a unique model for this 
disease (8, 9). 
The treatment of hypercholesterolemia in patients with heterozygous familial 
hypercholesterolemia by bile acid binding resins or cholesterol synthesis inhibitors is 
aimed at increasing the uptake of LDL from the blood by an increase in the number of 
functioning LDL receptors on the cell surface (10). In the WHHL rabbit, functioning 
LDL receptors are not present on the cell surface nor can induction of these receptors 
take place. Yet, it is possible to Іол ег serum cholesterol levels in this animal by various 
means, including administration of cholestyramine, partial ileal bypass surgery (PIB), 
or treatment with probucol and cholesterol synthesis inhibitors (11-18). This choleste­
rol lowering was accompanied by a decrease of the progression of atherosclerosis 
(12,14). 
We have previously performed turnover studies with radiolabeled LDL and me-
thylated-LDL in WHHL rabbits after PIB and found that a 50% reduction of the 
serum cholesterol level after PIB was caused by a decreased production of LDL 
particles and not by an increased uptake of LDL by receptor- mediated processes (17, 
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18). The mechanism of the decreased production of LDL is not known; possible 
mechanisms are a decreased production of very low density lipoprotein (VLDL), a 
decreased conversion of VLDL to LDL, or a decreased direct LDL production (17,18). 
In the present study we have further evaluated the influence of interruption of the 
enterohepatic circulation of bile acids by PIB on the production of LDL in the WHHL 
rabbit by performing a simultaneous turnover study with LDL and VLDL. These 
studies enhance the insight in the mechanism by which LDL is decreased as well as in 
the formation of LDL in the situation that the LDL receptor-mediated processes are 
absent. 
MATERIALS AND METHODS 
Animals 
Homozygous WHHL rabbits were raised by crossing and back-crossing with New 
Zealand white (NZW) rabbits. They were maintained on a regular chow diet (LK04, 
Hope Farms, Woerden, the Netherlands). PIB was performed in 6 WHHL rabbits 
under general anesthesia 9 weeks before the current study at an average age of 31 
weeks essentially as described (11,19); the distal one third of the ileum was bypassed 
by a functional end to side anastomosis with the colon ascendens. After the operation, 
the animals received antibiotics (ampicillin 750 mg intramuscular) for 3 days. Six 
WHHL rabbits served as controls. 
Lipoprotein isolation and radiolabeling 
After an overnight fast, blood was taken from ear arteries and mixed with EDTA 
for lipoprotein analysis. Lipoproteins were isolated by sequential ultracentrifugation 
in a fixed angle rotor in an IEC-B60 ultracentrifuge (Damon/IEC, Needham Heights, 
MA, USA) at the following densities (d): d<1.006 g/ml, VLDL; 1.006<d<1.019 g/ml, 
intermediate density lipoproteins (IDL); and 1.019<d<1.063 g/ml, LDL (20). 
Six days before the turnover experiment 10 ml of blood was taken after sedation 
from each animal for VLDL and LDL isolation. Serum was pooled per group: PIB 
serum from the 6 WHHL rabbits after PIB and control serum from 6 control WHHL 
rabbits. VLDL and LDL from both groups were isolated by sequential ultracen­
trifugation at 168,000 g in a fixed angle rotor in the presence of 0.1 mg/ml EDTA and 5 
μg/ml gentamycin. Before the first run sodium azide 0.4 mg/ml was added. VLDL was 
isolated for 14 hours at a density of less than 1.006 g/ml and LDL for 22 hours at a 
density between 1.019 and 1.050 g/ml. VLDL and LDL wTere recentrifuged once at 
d=1.006 and d=1.050 g/ml, respectively, and dialyzed overnight at 40C against 5 liters of 
dialysis buffer (0.15 M NaCl, 0.5 gil EDTA and 5 mg/1 gentamycin at pH = 7.5). The 
protein of VLDL and LDL from each group was iodinated with 12T (VLDL) and '"I 
(LDL) by a modification (21) of the method of McFarlane (22). Unreacted iodine was 
removed by column chromatography on Sephadex G-25M (columns PD-10, Pharmacia 
Fine Chemicals, Uppsala, Sweden), followed by dialysis against 5 liters of dialysis 
buffer at 4°C overnight. 
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VLDL and LDL turnover studies 
The turnover experiment was performed Í) weeks after surgery. Two days before 
the turnover study, all animals were sedated and a silicone catheter was inserted into 
an ear vein; the length of the catheter was adjusted so that the tip of the catheter was 
situated in the right atrium. A solution of 10% dextrane in 0.15 M NaCl was instilled 
into the catheter to prevent clotting. On the day of the turnover experiment, blood was 
taken after an overnight fast for determination of lipids and lipoproteins. Subsequent-
ly, the silicone catheter was prolonged so that blood could be drawn from outside the 
cage with as minimal stress as possible to the animal. After the first 8 hours, the 
animals were taken out of their cages for blood drawing. 
Autologous '"'T-labeled VLDL and "'I-labeled LDL were mixed and then diluted 
with autologous plasma. Two ml portions of this mixture were injected through a 
marginal ear vein into the 6 WHHL controls, and the 6 WHHL rabbits after PIB. 18 to 
2δ μα i r , l and 16 to 21 μΟί И1І were injected. Blood samples (2 ml in 2 mg EDTA) were 
drawn at regular intervals for 48 hours for VLDL data and for 72 hours for LDL data. 
In one animal after PIB, the catheter became obstructed and blood drawing was done 
by venipuncture; the results of this animal were not included in the VLDL data. 
During the entire study, the animals had free access to water. They were given their 
regular chow diet after blood drawing at 12, 24 and 48 hours. 
Total plasma radioactivity of niI-labeled LDL of each animal was determined in a 
Philips PW 4800 automatic gammacounter. To estimate the radioactivity of apo В 
bound 1 2 ,I in fractions VLDL, IDL and LDL, plasma samples of 6 control WHHL 
rabbits and 5 WHHL rabbits after PIB were pooled per group and the fractions 
VLDL, IDL and LDL were separated by sequential ultracentrifugation at densities 
d=1.006 g/ml, 1.019 g/ml and 1.063 g/ml, respectively, as described above. The 50% 
(v/v) isopropanol precipitable 1 2 Ί radioactivity of each fraction was determined as 
follows: after determination of the radioactivity of a sample, apo В was precipitated 
with 50% isopropanol and the radioactivity of 50% of the total volume was measured 
in the supernatant; the isopropanol precipitable radioactivity was calculated. For 
LDL, the isopropanol precipitable fraction was determined after dialysis against 
0.15 M NaCl. 
Determination of the VLDL, IDL and LDL pool sizes 
The plasma volume was calculated from the body weight and the hematocrit using 
the formula: plasmavolume (in ml)= (1- hematocrit) · 57 · weight (in kg), where 57 is 
the blood volume in ml per kg of body weight (4). The protein concentration of each 
fraction was determined after a single ultracentrifugation spin. Based on the results of 
isopropanol precipitable radioactivity of the labeled fractions and analysis of the 
radioactivity distribution on sodium dodecyl sulphate (SDS) gel electrophoresis the 
apo В content was calculated as a percentage of total protein in the respective fraction. 
This percentage was estimated to be 70% for VLDL and 90% for LDL of the total 
protein content in each fraction in this group of rabbits; based on the results of other 
investigators, for IDL a percentage of 80% was assumed (23). The pool size was 
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calculated by multiplication of plasma volume and apo В protein concentration, and 
expressed per kg body weight. 
Kinetic analysis 
The fractional catabolic rate of apoLDL was obtained from bi-exponential analysis 
of the plasma radioactivity decay curves, assuming a simple two-compartment model 
where plasma LDL equilibrates with an extravascular compartment and where all 
irreversible loss of apoLDL occurs from the plasma compartment (24,25). 
The VLDL turnover data were analysed with the SAAM 29 program (26). The 
model (Figure 1) consisted of two parallel processing pathways, one slowly and one 
rapidly turning over. In this model, there was no direct input of IDL. The LDL 
fraction wras considered to be metabolically homogenous. LDL could be derived from 
both IDL and directly from VLDL. The FCR of LDL used was that calculated from 
the LDL turnover. This model provided an acceptable fit for both studied groups 
although there was a higher calculated than observed mass of the IDL pool. 
The absolute catabolic rate was calculated from the FCR and the apo В pool size. In 
steady state conditions, the absolute catabolic rate equals the secretion rate (SR). 
IDL 
LDL 
Figure 1. Model used in the avalysis of the kinetic data of the very low density lipoprotein 
(VLDL) turnover in control WHHL rabbits and WIII1L rabbits !) weeks after partial ileal 
bypass (PIE). IDL indicates intermediate density lipoproteins, LDL indicates low density 
lipoproteins. 
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Analytical methods 
Cholesterol and triglycerides were measured by the enzymatic CHOD-PAP me­
thod (no 237574, Boehringer Mannheim GmbH, FRG and no 6684, Sera PAK, Miles, 
Italy, respectively) (27). Phospholipid and free cholesterol were measured with en­
zymatic kits (nos 691844 and 310328, respectively, Boehringer Mannheim GmbH, 
FRG). Protein was determined according to the method of Lowry et al. (28). SDS gel 
electrophoresis of each label was performed in 3%/4% discontinuous gels as described 
(29). After staining and destaining the protein bands were cut out and counted for 
radioactivity (29). Heparin-Sepharose chromatography of the VLDL tracer was 
performed as described (30,31). Gradient gel electrophoresis of purified lipoproteins 
was performed as described (32): 5 μg of lipoprotein-protein was brought into the slits 
of a commercially available 3-16% Polyacrylamide gel (Pharmacia, Uppsala, Sweden). 
Isoelectric focusing of apoproteins was performed as described (33). Electron micro­
scope pictures of the VLDL fractions were made after negative staining (34). Diame­
ters of 200 particles were measured to determine the average size. 
Statistical analyses were performed with Wilcoxon's test for paired and unpaired 
data. A 2-sided P-value of less than 0.05 was considered to be significant. Unless 
indicated otherwise results are expressed as mean ±SD. 
RESULTS 
Serum lipids, lipoproteins and lipoprotein composition 
There were no significant differences in weight, age and sex distribution between 
control WHHL and WHHL rabbits after PIB (Table 1). After PIB, serum cholesterol 
Table 1. Age, iveight, ,se.r distribution, total serum cholesterol and triglycerides concentrations 
and lipoprotein cholesterol and triglycerides concentrations in WHHL control rabbits and 
WHHL rabbits 9 weeks after partial ileal bypass (PIB). 
WHHL controls WHHL PIB 
Number 
Age (weeks) 
Weight (grams) 
Sex (M/F) 
Cholesterol (mmol/l) 
VLDL 
IDL 
LDL 
Triglycerides (ттоІЛ) 
VLDL 
IDL 
LDL 
6 
39 ± 1 
2770 ± 150 
2/4 
16.88 ± 1.57 
6.07 ± 1.24 
2.87 ± 0.40 
9.83 ± 2.81 
3.86 ± 1.35 
1.76 ± 0.89 
0.55 ± 0.17 
1.66 ± 0.41 
6 
40 ± 1 
2530 ± 210 
2/4 
8.79 ± 1.66-
4.67 ± 0.95 
1.75 ± 0Λ0Δ 
2.75 ± 1.02a 
5.11 ±0.82 
3.12 ± 0.64'1 
0.86 ± 0.07b 
1.31 ± 0.33 
": Ρ (vs. WHHL controls) < 0.01. 
b
: Ρ (vs. WHHL controls) < 0.05. 
Values are mean ± SD. M = male, F = female. 
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Table 2. Chemical composition of fractions very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL) and loiv density 
lipoproteins (LDL) of WHHL rabbits (η=β) and WHHL rabbits 9 weeks after partial ileal bypass (PIB) (n=6). 
Component (% of mass) 
Cholesteryl esters (CE) 
Triglycerides (TG) 
Free cholesterol 
Phospholipids 
Proteins 
CE/TG 
controls 
44.2 ± 11.3 
22.4 ± 7.0 
9.3 ± 1.9 
15.6 ± 2.7 
8.4 ± 1.3 
2.4 ± 1.9 
VLDL 
PIB 
26.0 ± 4.9b 
38.2 ± 4.3h 
9.7 ± 1.8 
17.0 ± 0.9 
9.2 ± 1.3 
0.7 ± 0.2'' 
controls 
43.1 ± 5.0 
15.5 ± 3.7 
10.3 ± 0.5 
19.8 ± 1.3 
11.4 ±0.9 
3.0 ± 0.9 
IDL 
PIB 
28.2 ± 2.8b 
29.5 ± 3.3" 
9.0 ± 0.5" 
20.4 ± 0.4 
12.9 ± 0.7b 
1.0 ± 0.2h 
controls 
42.6 ± 4.8 
13.2 ± 3.7 
7.9 ± 0.3 
19.3 ± 0.2 
17.1 ± 1.8 
3.5 ± 1.2 
LDL 
PIB 
26.3 ± 4.1h 
25.5 ± 2.1'' 
7.0 ± 0.4'' 
20.0 ± 0.5" 
21.3 ± 3.1" 
1.0 ± 0.21' 
a
: Ρ (vs. WHHL controls) <0.05. 
b
: Ρ (vs. WHHL controls) <0.01. 
Values are mean ± SD. 
concentration was 48% lower, due to lower levels of cholesterol in all fractions: VLDL 
(-23%), IDL (-39%) and LDL (-72%). Triglycerides concentrations were 32% higher 
after PIB, mainly due to changes in VLDL (+77%) and IDL (+56%); in LDL, triglyceri­
des were 21% lower. 
Composition analysis of the fractions VLDL, IDL and LDL showed a relative 
higher percentage of TG at the expense of cholesteryl esters in WHHL rabbits after 
PIB (Table 2). The ratio cholesteryl esters to triglycerides was lower in all fractions 
(VLDL -71%, IDL -67%, LDL -71%). 
Characteristics of radiolabeled VLDL and LDL 
The characteristics of the labeled VLDL and LDL are summarized in Table 3. For 
both labels, there were no differences in TCA precipitable radioactivity, isopropanol 
precipitable radioactivity, and in lipid extractable radioactivity. There were no diffe­
rences in the ratio of radioactivity bound to apo В and apo E, the particle diameter and 
the percentage bound to heparin-Sepharose in VLDL between the two tracers. 
Gradient gel electrophoresis of fractions VLDL, IDL and LDL showed no differences 
in migration distances between the lipoprotein fractions of control rabbits and those of 
rabbits after PIB. Isoelectric focusing of the VLDL fraction showed no differences in 
the apoprotein С and E pattern between the two groups. The validity of the VLDL 
tracer used was also evaluated by recentrifugation of the tracer after mixing with pool 
plasma of each group. 87% and 92% of the label was recovered in the VLDL fraction for 
controls and PIB VLDL, respectively. Only traces (1-2%) were found in the LDL 
fraction. Also, both VLDL tracers were comparable in this respect. 
Table 3. Characteristics of injected fractions VLDL and LDL. 
After sequential isolation of VLDL (d < 1.006 g/ml) and LDL (1.019 < d < 1.050 glml) from 
control WHHL rabbits and WHHL rabbits 7 weeks after partial ileal bypass (PIB), fractions 
were la beled with iodine. The tests were all peiformed on the radiolabeled fraction, except for the 
electron microscopic evaluation of the diameter of VLDL. 
VLDL LDL 
10% TCA precipitable RA (%) 
50% isopropanol 
precipitable RA (%) 
Lipid-bound RA (%) 
Specific activity (cpm/ng) 
SDS-gels 
apoE/apoBlOO RA 
apoB48/apoB100 RA 
Hoparin-Sepharose 
bound/unbound RA 
Particle diameter (nm) 
controls 
98 
77 
7 
81 
0.14 
0.05 
0.11 
34 ± 8 
PIB 
99 
81 
7 
211 
0.14 
0.05 
0.15 
33 ± 8 
controls 
98 
88 
nd 
426 
0.06 
0.20 
nd 
nd 
PIB 
99 
89 
nd 
183 
0.05 
0.16 
nd 
nd 
RA = (bound) radioactivity 
nd = not determined 
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Figure á. Plasma radioactivity disappearance cunes of '"I-labeled low density lipoprotein 
(LDL) in control WHHL rabbits (v=6) and WHHL rabbits 9 weeks after partial ileal bypass 
(PIB; n=6). 
Tabled. Kinetic data of the turnover study with "Ί-labeled LDL from control WHHLrabbits in 
control WHHL rabbits, and "'I-labeled LDL from WHHL rabbits 9 weeks after partial ileal 
bypass (PIB) in WHHL rabbits aftei· PIB. After injection of '"I-labeled autologous LDL 
plasma radioactivity was followed for 72 hours. The fractional catabolic rate (FCR) was 
determined by biexponentml analysis of the plasma decay curve. The secretion rate (SR) was 
calculated from tfie FCR and the apoLDL pool. 
Plasmavolume (ml) 
Apo В LDL pool (mg/kg) 
LDL 
FCR (pools/day) 
SR (mg/kg.day) 
WHHL controls 
(n=6) 
110 ± 9 
68.0 ± 10.8 
0.46 ± 0.06 
31.1 ± 7.2 
WHHL PIB 
(n=6) 
100 ± 9 
33.7 ± 6.6a 
0.61 ± олг" 
20.7 ± 6.91' 
Ρ (vs. WHHL controls) < 0.01. 
Ρ (vs. WHHL controls) < 0.02. 
Ρ (vs. WHHL controls) < 0.05. 
Values are mean ± SD. 
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Lipid levels during the turnover experiment 
There were only small alterations in plasma lipid levels during the experiment. 
After 48 hours, plasma cholesterol was on the average 19 ±2% lower in controls and 17 
±9% in PIB animals, when compared to basal values. Plasma triglycerides decreased 
during the first 12 hours on the average by 11 ±10% in controls and by 10 ±15% in 
treated rabbits compared to basal values. Animals were fed after blood sampling at 12, 
24 and 48 hours, after which triglycerides increased, on the average 10 ±17% in controls 
and 28 ±29% in PIB animals. Changes in triglycerides levels were not significantly 
different between groups at any time during the experiment. 
LDL turnover data 
The results of the LDL turnover are shown in Figure 2 and Table 4. There was a 
more rapid plasma decay curve of apoLDL in WHHL rabbits after PIB than in 
WHHL controls. After PIB, the apoLDL pool was 50% lower, the calculated FCR of 
apoLDL was 33% higher and the secretion rate was 33% lower. 
VLDL turnover data 
In one PIB WHHL rabbit, blood sampling could not be performed by using an 
intravenous cánula and was done by venipuncture. The results of this animal are not 
included in the VLDL turnover data and in the kinetic analysis. 
The results of plasma radioactivity bound to apo В in each fraction is shown in 
Figure 3. After PIB, the VLDL decay was more rapid than in controls. The amount of 
radioactivity found in the IDL fraction was less than in controls at all time points. In 
LDL, the curves were virtually identical for both groups. 
The results of the SAAM analysis of the kinetic data are shown in Table 5. 
VLDL: The VLDL pool was slightly higher after PIB. Compared to controls, the FCR 
of VLDL was 125% higher, the direct uptake was 275% higher and the secretion rate 
was 160% higher after PIB. In controls, 61% of VLDL was taken up directly, whereas 
in WHHL rabbits after PIB this percentage was 87%. The absolute amount of apo В 
converted to IDL or LDL was slightly lower after PIB (Table 5). 
IDL: The pool size and secretion rate of IDL were slightly lower after PIB. In control 
WHHL rabbits, 83% of IDL was directly taken up, whereas in PIB WHHL rabbits, 
this was 65%. 
LDL: From the LDL turnover data, results indicated a lower apo В pool, a higher 
FCR and a lower secretion rate after PIB. The absolute amount of radioactivity 
transferred from VLDL to LDL was 88% higher after PIB, but accounted only for a 
small portion of the calculated LDL production in both controls and PIB rabbits. In 
controls, 7.5% of VLDL apo В secreted was converted to LDL, and in treated animals 
this amounted to 5.4%. Only 18% of LDL production could be explained from conver­
sion from VLDL and IDL in controls, whereas in PIB WHHL this amounted to 41%. 
Synthesis from other sources than from this conversion was assumed, and this direct 
synthesis was 52% lower after PIB. Total apo В synthesis was two times higher in 
animals after PIB. 
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Table J. Kinetic data of the turnover nUidy with 'r'I-IabeIed VLDL from control WHHL rabbits 
h> control WHHL rabbits, and '~~'I-labeled VLDL from WHHL rabbits 9 weeks after partial ileal 
bypass (ΓΙΒ) in WHHL rabbits after PIR. 
After injection of'-'I-labeled autologous VLDL blood was sampled for £8 hoiirs and pooled per 
group; fractions VLDL, IDL and LDL were isolated by sequential itltracentrifugation, and the 
radioactivity bound to apo В was estimated. The fractional catabolic rate (FÜR) was detenni-
ned by RAAM ¿9 analysis of the plasma decay curves. The secretion rate (SR) was calculated 
from the FCR and the apo В VLDL pool. 
WHHL controls 
(n=6) 
WHHL PIB 
(n=5) 
VLDL 
SR (mg/kg.day) 
Apo В pool (mg/kg) 
FCR (pools/day) 
direct uptake 
conversion to IDL 
conversion to LDL 
Direct uptake (mg/kg.day) 
Conversion to IDL (mg/kg.day) 
Conversion to LDL (mg/kg.day) 
IDL 
SR (mg/kg.day) 
Apo В pool (mg/kg) 
FCR (pools/day) 
direct uptake 
conversion to LDL 
Direct uptake (mg/kg.day) 
Conversion to LDL (mg/kg.day) 
LDL 
SR (mg/kg.day) 
synthesis 
from VLDL+IDL (mg/kg.day) 
direct synthesis (mg/kg.day) 
Apo В pool (mg/kg) 
FCR (pools/day) 
Total apo В synthesis (mg/kg.day) 
63.9 
16.6 
3.84 
2.33 
1.47 
0.04 
38.8 
24.4 
0.7 
24.4 
18.6 
1.32 
1.09 
0.22 
20.4 
4.1 
31.1 
4.8 
26.3 
68.0 
0.46 
167.4 
19.4 
8.61 
7.54 
0.95 
0.13 
146.4 
18.5 
2.6 
18.5 
14.5 
1.27 
0.83 
0.45 
12.0 
6.5 
21.8 
9.0 
12.6 
34.5 
0.63 
90.2 180.0 
DISCUSSION 
In the present study the influence of interruption of the enterohepatic circulation of 
bile acids by PIB on the metabolism of VLDL and LDL in the WHHL rabbit was 
evaluated. Cholesterol levels, especially in the LDL fraction, can be lowered by this 
procedure; this cholesterol-lowering effect is accompanied by a relative decrease in 
the amount of cholesterol and a relative increase in the amount of triglycerides in the 
fractions VLDL, IDL and LDL. Studies in man on the effects of the bile-acid binding 
resin colestipol on composition of lipoproteins showed comparable changes with 
regard to cholesterol and triglycerides (35). The altered compositions are likely to be 
secondary to the interruption of the enterohepatic circulation of bile acids, causing an 
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increased synthesis of bile acids from cholesterol which results in a cholesterol 
depletion in the liver. Secondary to this cholesterol depletion VLDL particles are 
secreted which are poor in cholesteryl esters relative to triglycerides. In the circula­
tion, transfer and exchange of triglycerides and cholesteryl esters between lighter 
fractions and LDL may explain the observed compositional changes in LDL. This is 
supported by the fact that WHHL rabbits have a high lipid transfer activity (36). On 
the other hand, the compositional changes might be the consequence of an alteration in 
the catabolism of the lipoproteins itself. In the current study, we found a higher FCR 
of VLDL and LDL in the rabbits after PIB. A shorter circulation time may result in a 
decrease of the ratio cholesteryl esters to triglycerides (37). 
The 33% lower total LDL production observed after PIB is in agreement with the 
results of our previous studies (17, 18). Theoretically, this decreased production of 
LDL can be the result of a decreased direct synthesis of LDL, a decreased production 
of the precursor VLDL, or a decrease of the fraction of VLDL which is converted to 
LDL. In the current study it was found that after PIB total synthesis of VLDL 
particles was not lower but 160% higher. Furthermore, the absolute amount of VLDL 
which was converted to LDL was 100% higher, and the relative amount was about 
equal. Consequently, total LDL production could not be explained by conversion from 
VLDL alone, although the fraction of total LDL production due to this conversion was 
higher after PIB (18% vs. 44%). The decreased synthesis of LDL was entirely due to a 
decreased production of the direct LDL synthesis by 55%. This finding contrasts with 
% of injected dose 
: o VLDL controls · VLDLPB 
I л IDL controls A IDLPB 
о LDL controls • LDL PB 
0 . 1 I — ι 1 1 1 1 
0 10 20 30 40 50 
time (hours) 
Figure S Apoprotein В bound radioactivity curves for very low demity lipoprotein (VLDL), 
intermediate density lipoproteins (IDL) and low density lipoproteins (LDL) in 6 control 
WHHL rabbits and 5 WHHL rabbits 9 weeks after partial ileal bypass (PIB) 
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the results of liver perfusion studies in the WHHL rabbit, in which no direct synthesis 
of LDL was reported, and with the results of previous kinetic studies with VLDL in 
the WHHL rabbit (23, 38). In these liver perfusion studies, VLDL particles were 
isolated which were different from those isolated in the plasma, in that they were on 
the average much larger and more triglyceride-rich (23). Indeed, in a recent study on 
the fate of large, triglyceride rich particles within the VLDL fraction of the WHHL 
rabbit, it was found that less than 5% of the VLDL particles in the circulation 
accounted for more than 40% of the apo В transport (39). These results indicate that 
the tracer used is important in the measurement of apo В transport, and that 
measurement of total apo В transport is seriously hampered by the fact that VLDL 
particles in the circulation may not be representative for VLDL metabolism, since 
they have been subjected to selection. Also, studies on the fate of apo B100 containing 
VLDL particles in both normal and WHHL rabbits have shown that those which 
contain both apo В100 and apo E are taken up faster and are converted less to 
lipoproteins of higher density than those VLDL particles which only contain apo B100 
(23, 40). Yamada et al suggested that in the WHHL rabbit the VLDL uptake was 
mediated by some receptor mechanism as well (40). In the WHHL rabbit the clearance 
of chylomicrons appears to be normal, and it is assumed that there is a normally 
functioning apo E or chylomicron-remnant receptor (41). In man, it has been found 
that larger, triglyceride rich VLDL particles are removed more rapidly from the 
circulation without conversion to denser lipoproteins (29,42). Altogether, these fin­
dings indicate that size, composition and apo E content all contribute to the fate of the 
VLDL particle. In this respect, no differences were found in the current study 
between control WHHL rabbits and WHHL rabbits after PIB in apo E content or 
particle size in the VLDL fraction (Table 3), but there were large differences in the 
particle composition (Table 2). However, it is not clear by which mechanism the 
triglyceride-rich VLDL particles which are found after PIB may be preferentially 
taken up. Possibly, they are taken up to a larger extent by the apo E receptor. The 
defective LDL receptor in the WHHL rabbit does not bind LDL, but might be able to 
bind to some extend large VLDL remnants (23,40). The cholesterol depletion in the 
liver after PIB may lead to an increased production of the defective LDL receptor. 
This is supported by a study on the effects of cholesterol synthesis inhibition by 
lovastatin in WHHL rabbits; after ten days on a diet containing 0.03% lovastatin, a 
decrease in total cholesterol of 43% was found which was accompanied by a 3-fold 
increase in the messengerRNA level of the LDL receptor (15). This suggests the 
possibility of an increased uptake of VLDL particles by this defective receptor after 
interruption of the enterohepatic circulation of bile acids. Altogether, there are some 
arguments to explain the increased uptake of larger VLDL remnants by either the 
apo E receptor or the defective LDL receptor which would lead to a decreased 
fractional conversion to LDL. However, since total VLDL production was found to be 
higher after PIB, actually more LDL was formed from VLDL than in controls. 
In other animal species than the WHHL rabbit, direct production of LDL was found 
in kinetic studies, in in vitro studies with hepatocytes and in liver perfusion studies 
(43- 48). In miniature pigs, this direct LDL synthesis could be lowered by cholesterol 
synthesis inhibition and bile acid sequestration (48). The mechanism by which the 
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direct LDL synthesis can be decreased as we found in our current study is uncertain, 
but may be due to an alteration in the amount of cholesterol and triglycerides which 
are available in the liver for production of lipoproteins. If lipoproteins are secreted in 
which cholesterol is replaced by triglycerides, this can lead to the production of 
particles which are less dense. In a study on the effects of free fatty acids on the 
production of lipoproteins in the human hepatoma cell line Hep-G2, a decrease in apo В 
in LDL and an increase in VLDL was found (49). This mechanism could explain both 
the decreased LDL secretion and at least in part the increase of VLDL secretion we 
observed in the current study. 
One might speculate that in the WHHL rabbit a huge cholesterol depletion leads to a 
large intrahepatic cholesterol deficit by which the receptor defect is partially over­
come for the uptake of LDL. This possibility was rejected by the results of previous 
LDL turnover studies with native and methylated LDL in WHHL rabbits after PIB 
(17,18) and from the results of binding studies with hepatocytes (5). Apparently, a 
mechanism different from induction of receptor-mediated uptake causes the increased 
FCR of apoLDL after PIB (18). When they studied the effects of cholesterol feeding on 
the clearance of apoLDL in NZ W rabbits, Slater et al found that both the receptor-
mediated and the non-receptor-mediated clearance decreased (50). The latter indica­
tes the possibility of a saturable component in the receptor-independent LDL catabo-
lism but also the possibility of an influence of particle composition on the clearance of 
LDL, since cholesterol feeding induces changes in the LDL composition as well (51). 
The possibility that changes in the composition of LDL may alter its metabolism w7as 
also addressed in studies on the effects of bile acid sequestration on LDL metabolism 
in both men and the guinea pig (52,53). 
We conclude that interruption of the enterohepatic circulation of bile acids after PIB 
in the WHHL rabbit lowers cholesterol levels by an increased uptake of LDL, a 
decreased total production of LDL which is due to a decreased direct synthesis of LDL 
which exceeds an increased conversion of VLDL to LDL, and cholesterol depletion of 
the particles. 
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SUMMARY 
The effects of cholesterol synthesis inhibition on serum lipids, lipoproteins and the 
turnover of very low density lipoproteins (VLDL) and low density lipoproteins (LDL) 
were investigated in Watanabe heritable hyperlipidemic (WHHL) rabbits. In 2 diffe­
rent experiments, total serum cholesterol was 35% and 36% lower in WHHL rabbits 
after 4 weeks treatment with simvastatin than in controls (19.50 ±3.37 (n=7) vs. 12.49 
±3.61 mmol/1 (n=7) and 19.42 ±3.37 (n=7) vs. 12.59 ±1.51 mmol/1 (n=7), respectively) due 
to lower levels of cholesterol in VLDL+intermediate density lipoproteins (IDL) (-45% 
and -55%, respectively) and LDL (-30% and -23%, respectively). The ratio of the 
percentages of mass of cholesteryl esters to triglycerides was 63% and 24% lower, 
respectively in VLDL+IDL and 38% and 6% lower in LDL for both experiments. 
Compared to controls, the secretion rate of LDL was 15% lower (68.8 ±19.0 vs. 58.8 ±8.9 
mg/kg.day; Ρ >0.05) and the fractional catabolic rate (FCR) of LDL apoproteins was 
22% higher (0.41 ±0.10 vs. 0.50 ±0.06 pools/day; Ρ >0.05). The VLDL turnover analysis 
showed that there was a slightly higher secretion rate of VLDL apoprotein В after 
simvastatin (72.7 vs. 89.3 mg/kg.day), a higher FCR (17.48 vs. 20.29 pools/day) and a 
higher direct uptake (23.3 vs. 60.8 mg/kg.day) compared to controls. The conversion of 
VLDL to LDL was higher after simvastatin (11.8 vs. 24.8 mg/kg.day). LDL originated 
for 84% from direct synthesis in controls and for 45% after simvastatin. The direct 
LDL synthesis was 51% lower after simvastatin (62.0 vs. 30.5 mg/kg.day). Comparing 
autologous and non-autologous VLDL as a tracer revealed no differences. These 
results indicate that simvastatin in the WHHL rabbit lowers cholesterol by a de­
creased direct synthesis of LDL and by cholesterol depletion of the particles VLDL, 
IDL and LDL. 
INTRODUCTION 
The Watanabe heritable hyperlipidemic (WHHL) rabbit is characterized by grossly 
elevated levels of serum cholesterol (1). Due to a monogenic inherited defect of the low 
density lipoprotein (LDL) receptor, the uptake of LDL from the serum is impaired, 
and the conversion from VLDL to LDL is increased (2-6). The elevated cholesterol 
levels lead to premature atherosclerosis and xanthomatosis (7). A similar defect in the 
LDL metabolism is found in patients with homozygous familial hypercholesterolemia 
in man; therefore this animal serves as a unique model for this disease (8,9). 
Treatment of hypercholesterolemia in patients with heterozygous familial hyper­
cholesterolemia by bile acid binding resins or cholesterol synthesis inhibitors is 
achieved by an increased uptake of LDL from the blood by an increase in the number 
of functional LDL receptors on the cell surface (10). In the WHHL rabbit, no functional 
LDL receptors are found on the cell surface nor can induction of these receptors take 
place. Yet, it was found to be possible to lower serum cholesterol levels in this animal 
by various means, including cholestyramine, partial ileal bypass surgery, probucol and 
cholesterol synthesis inhibitors (11-17). This cholesterol lowering was accompanied by 
a decrease of the progression of atherosclerosis (12,14). 
We have previously performed turnover studies with radiolabeled LDL and me-
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thylated LDL in WHHL rabbits after PIB and found that a 50% cholesterol reduction 
after PIB was caused by a decreased production of LDL particles and was not due to 
an increased uptake of LDL by receptor-mediated processes (17). 
We have further evaluated the influence of cholesterol lowering therapies on the 
production of LDL in the WHHL rabbit by performing simultaneous turnover studies 
with autologous LDL and VLDL in animals with and without treatment with sim­
vastatin, an inhibitor of the cholesterol synthesis (18,19). Also, we have compared the 
metabolism of VLDL from control WHHL rabbits and from rabbits after treatment 
with simvastatin in both treated and control WHHL rabbits. 
MATERIALS AND METHODS 
Animals 
Homozygous WHHL rabbits were raised by crossing and back-crossing with New 
Zealand white (NZW) rabbits. They were maintained on a regular chow diet (LK04, 
Hope Farms, Woerden, the Netherlands). In two different experiments, 14 rabbits 
were divided into two groups of seven animals each, matched for sex, weight and lipid 
levels. Simvastatin (Merck Sharp & Dohme, Rahway, NY, USA) was mixed with the 
ingredients of the food at a weight percentage of 0.03, and the food was pelletized as 
usual. The first group was kept on the regular chow diet and served as controls. The 
second group was fed simvastatin containing chow diet. The dose of simvastatin was 12 
mg/kg.day. Some characteristics of the animals used in both experiments are given in 
Table 1. ' 
Lipoprotein isolation, radiolabeling and reductive methylation 
After an overnight fast, blood was taken from ear arteries and mixed with EDTA 
for lipoprotein analysis. In the first experiment, lipoproteins were isolated by gradient 
ultracentrifugation in a swing out rotor in an IEC-B60 ultracentrifuge (Damon/IEC, 
Needham Heights, MA, USA) (20); lipoproteins separated by this method can be 
identified as separate bands at the following density ranges: VLDL+IDL d<1.025 
g/ml; LDL: 1.025<d<1.063 g/ml. In a second experiment, lipoprotein fractions were 
isolated by sequential isolation in the same ultracentrifuge, at the following density 
ranges: VLDL d<1.006 g/ml; IDL 1.006<d<1.019 g/ml; and LDL 1.019<d<1.063 g/ml 
under conditions described below. 
In the first experiment, which was performed to study the catabolism of autologous 
VLDL and LDL, 10 ml blood was taken from each animal after sedation six days before 
the turnover experiment for VLDL and LDL isolation. Serum was pooled per group: 
serum from WHHL rabbits after simvastatin treatment and control serum from 
control WHHL rabbits. VLDL and LDL from both groups were isolated by sequential 
ultracentrifugation in the presence of 0.1 mg/ml EDTA and δ μg/ml gentamycin. 
Before the first run sodium azide 0.4 mg/ml was added. VLDL was isolated for 14 
hours at 168,000 g in a fixed angle rotor at a density (d) of <1.006 g/ml. After removing 
the fi-action IDL at 1.006<d<1.019 g/ml by another run of 14 h at 168,000 g, LDL was 
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isolated after 22 hours at 168,000 g at 1.019<d<1.050 g/ml. VLDL and LDL were 
recentrifuged once at d=1.006 and d=1.050 g/ml, respectively, and were dialyzed 
overnight at 40C in 5 liters of dialysis buffer (0.15 M NaCl, 0.5 g/1 EDTA and 5 mg/1 
gentamycin at pH = 7.5). The protein of VLDL and LDL from each group was 
iodinated with 1 2 Ί (VLDL) and Π ΙΙ (LDL) by a modification (21) of the method of 
McFarlane (22). Unreacted iodine was removed by column chromatography on Se-
phadex G-25M (columns PD-10, Pharmacia, Uppsala, Sweden). The labeled lipo­
proteins were dialyzed against 5 liters of dialysis buffer at 40C. In the second experi­
ment, which was performed to compare the turnover of autologous versus non-
autologous VLDL, VLDL was isolated as described above. VLDL from controls was 
labeled with H 1I, and VLDL from treated animals with 12,L 
VLDL and LDL turnover studies 
Two days before the turnover experiment, the animals were sedated and a silicon 
catheter was inserted into an ear vein; the length of the catheter was chosen so that 
the tip of the catheter was situated in the right atrium. A solution of 10% dextrane in 
0.15 M NaCl was instilled into the catheter to prevent it from clotting. On the day of the 
turnover study, blood was taken after an overnight fast and mixed with EDTA for 
measurement of lipids and lipoproteins. The silicon catheter was prolonged so that 
blood could be drawn from outside the cage with as minimal stress as possible for the 
animal during the first 8 hours. Afterwards, the animals were taken out of their cages 
for blood drawing. 
In the first experiment, autologous '^I-labeled VLDL and '"I-labeled LDL were 
mixed and then diluted with autologous plasma. In the second experiment, this was 
done with labeled autologous and non-autologous VLDL. In each experiment, two ml 
portions of the mixture were injected through a marginal ear vein. The first experi­
ment concerned 7 treated animals and 5 controls, and the second experiment 5 treated 
animals and 4 controls. The amount of radioactivity injected ranged from 18 to 24 μΟΐ 
12r>I and 8 to 10 μΟί H1I in the first experiment and from 11 to 14 μ€ί '^І and 27 to 34 μϋί 
1111 in the second experiment. Blood samples (2 ml in 2 mg EDTA) were drawn at 
regular intervals to obtain VLDL decay curves (for 24 hours in the first experiment 
and for 48 hours in the second experiment) and LDL decay curves (for 72 hours in the 
first experiment). In both experiments, one animal died during the study. In 4 animals 
blood could only be drawn by venipuncture or after manipulaton of the catheter; the 
results of these animals were excluded in the analysis of VLDL kinetics, because 
stress may cause hypertriglycendernia and thus may influence VLDL kinetics. Du­
ring the entire study, the animals had free access to water. They were given their 
regular chow diet after blood drawing at 10, 24 and 48 hours. 
In the first experiment, total plasma radioactivity of l f lI labeled LDL of each animal 
was estimated in a Philips PW 4800 automatic gammacounter. To determine the 
radioactivity of apolipoprotein (apo) В bound radioactivity in fractions VLDL, IDL 
and LDL, equal volumes of the plasma samples of 3 control WHHL rabbits and 4 
WHHL rabbits after simvastatin were pooled per group and the fractions VLDL, IDL 
and LDL were separated by sequential ultracentrifugation at densities d<1.006 g/ml, 
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1.006<d<1.019 g/ml and 1.019<d<1.063 g/ml, respectively, as described above. The 
isopropanol precipitable 12oI radioactivity of each fraction was determined as follows: 
after determination of the radioactivity of a sample, apo В was precipitated with 50% 
(v/v) isopropanol and the radioactivity of 50% of the total volume was measured in the 
supernatant; the isopropanol precipitable radioactivity was calculated. For LDL, the 
isopropanol precipitable fraction was determined after dialysis overnight against 0.15 
M NaCl. 
In the second experiment, the apo В bound radioactivity in fractions VLDL, IDL 
and LDL, were determined after pooling of plasma samples of 2 control WHHL 
rabbits and 3 WHHL rabbits after treatment, as described above. 
Determination of the VLDL and LDL pool sizes 
The plasma volume was calculated from the body weight and the hematocrit using 
the formula: plasmavolume (in ml)= (1- hematocrit) · 57 · weight (in kg), where 57 is 
the blood volume in ml per kg of body weight (4). The protein concentration of each 
fraction was determined after a single ultracentrifugation spin. Based on the results of 
isopropanol precipitable radioactivity of the labeled fractions and analysis of the 
radioactivity distribution on sodium dodecyl sulphate (SDS) gel electrophoresis, the 
apo В content was calculated as a percentage of total protein in the respective fraction. 
This percentage was estimated to be 70% for VLDL and 90% for LDL of the total 
protein content in each fraction in this group of rabbits; based on the results of other 
investigators, for IDL a percentage of 80% was assumed (23). The pool size was 
calculated by multiplication of plasma volume and apo В protein concentration, and 
was expressed per kg of body weight. 
Kinetic analysis 
The fractional catabolic rate (FCR) of apoLDL was obtained from bi-exponential 
analysis of the plasma radioactivity decay curves, assuming a simple two-compart­
ment model where plasma LDL equilibrates with an extravascular compartment and 
where all irreversible loss of apoLDL occurs from the plasma compartment (24,25). 
The VLDL turnover data were analyzed with the SAAM 29 program (26). The model 
used is shown in Figure 1. The model consisted of two parallel processing pathways, one 
slowly and one rapidly turning over, in which VLDL only entered the system. In this 
model, there was no direct input of IDL. The LDL fraction was considered to be 
metabolically homogeneous. LDL could be derived both from IDL and directly from 
VLDL. This model provided an acceptable fit for both groups studied. 
The absolute catabolic rate was calculated from the FCR and the apo В pool size. In 
steady state conditions, the absolute catabolic rate equals the secretion rate (SR). 
Analytical methods 
Cholesterol and triglycerides were measured by the enzymatic CHOD-PAP me­
thod (cat. no 237574, Boehringer Mannheim GmbH, FRG and no 6684, Sera PAK, 
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IDL 
LDL 
Figure 1. Model used in the analysis of the kinetic data of the very low density lipoprotein 
(VLDL) turnover in control WHHL rabbits and WHHL rabbits i weeks after treatment with 
simoastatm. IDL indicates intermediate density lipoproteins, LDL low density lipoproteins. 
Miles, Italy, respectively) (27). Phospholipid and free cholesterol were measured with 
enzymatic kits (cat. nos 691844 and 310328, respectively, Boehringer Mannheim 
GmbH, FRG). Protein was determined according to the method described by Lowry 
et al. (28). Sodium dodecyl sulphate (SDS) gel electrophoresis of each label was 
performed in 3%/4% discontinuous gels as described (29). VLDL was used as a carrier 
and for tracing the apoprotein B100, E and С bands after shortly staining with 
Coomassie Brilliant Blue. After electrophoresis, the protein bands were excised and 
the radioactivity was estimated. Non-denaturating gradient gel electrophoresis of 
VLDL and LDL was performed as described (30): 5 μg of lipoprotein-protein was 
loaded onto the slits of a commercially available 3-16% Polyacrylamide gel (Pharmacia, 
Uppsala, Sweden). 
Statistical analyses were performed using Wilcoxon's test for paired and unpaired 
data. A 2-sided P-value of less than 0.05 was considered to be significant. Unless 
indicated otherwise results are expressed as mean +SD. 
RESULTS 
Serum lipids, lipoproteins and lipoprotein composition 
There were no differences in weight, age, sex distribution and basal lipids between 
control WHHL rabbits and simvastatin treated WHHL rabbits in both experiments 
(Table 1). In both experiments, the serum cholesterol concentrations were lower in 
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Table 1. Age, weight, sex distribution, total serum cholesterol and tnglycerides concentration and percentual changes in 2 experiments with each 7 
WHHL control rabbits and 7 WHHL rabbits before and during treatment with control chow diet and chow diet containing 0.03% simvastatin, 
respectively. 
EXPERIMENT 1 
WHHL controls WHHL simvastatin 
EXPERIMENT 2 
WHHL controls WHHL simvastatin 
Age (weeks) 
Weight (grams) 
Sex (M/F) 
Cholesterol (mmol/l) 
week 0 
week 1 
week 2 
week 4 
Triglycerides (mmol/l) 
week 0 
week 1 
week 2 
week 4 
19 ± 0 
1870 ± 270 
2/5 
19 ± 0 
1890 ± 80 
2/5 
27 ± 2 
2530 ± 150 
3/4 
26 ± 4 
2550 ± 100 
3/4 
18.67 ± 1.75* 
18.93 ± 3.55 (+ 1%) 
18.92 ± 2.(58 (4 1%) 
19.50 ± 3.37 (+ 4%) 
1.92 ± 0.56* 
1.38 ± 0.47 (-28%) 
2.64 ± 0.86 (+39%) 
1.79 ± 0.68 (- 790 
18.71 ± 3.44* 
15.26 ± 3.98 (- 19%)a 
13.16 ± 3.84 (- 31<%)b 
12.49 ± 3.61 (- 34%)b 
2.10 ± 1.34* 
2.55 ± 1.10 (+ 32%)b 
3.86 ± 1.37 (+109%) 
2.71 ± 1.19 (+ 42%)a 
22.48 ±2.41* 
21.06 ± 1.64 (- 6%) 
20.23 ± 1.68 (-10%) 
19.42 ± 3.37 (-13%) 
2.54 ± 0.85* 
2.14 ± 0.72 (-13%) 
2.39 ± 0.79 (- 1%) 
4.07 ± 1.15 (+70%) 
22.19 ± 1.68* 
16.56 ± 1.64 (-25%)'' 
14.33 ± 1.26 (-36%)'' 
12.59 ± 1.51 H13%)" 
2.28 ± 0.51* 
1.72 ± 0.52 (-26%) 
1.84 ± 0.56 (-17%) 
2.86 ± 0.84 (+28%) 
a
: Ρ (vs. WHHL controls) <0.05. 
b
: Ρ (vs. WHHL controls) <0.01. 
": values are the mean of two determinations. 
Values are mean ± SD. M = male. F = female. 
Table 2 Concentrations of plasma lipids infractions ven/ low density and intermediate density lipoproteins (VLDL + IDL) and low density 
lipoproteins (LDL) of WHHL control rabbits (n=7) and WHHL rabbits i weeks after a diet containing 0 03% simvastatin (n=7)from experiment 1, 
and in fractions VLDL + IDL, very low density (VLDL), intermediate density lipoproteins (IDL) and LDL of WHHL control rabbits (n=7) and 
WHHL rabbits i weeks after a diet containing OMc/r simvastatin (n=7)from experiment 2. In experiment 1 the fractions were isolated by gradient 
ultracentnfugation, in expenment 2 by sequential ultracentnfugation 
EXPERIMENT 1 EXPERIMENT 2 
WHHL controls WHHL simvabtatin WHHL controLs WHHL simvastatin 
VLDL + IDL 
Cholesterol (mmol/1) 
Triglycerides (mmol/1) 
VLDL 
Cholesterol (mmol/l) 
Triglycerides (mmol/1) 
IDL 
Cholesterol (mmol/1) 
Triglycerides (mmol/1) 
LDL 
Cholesterol (mmol/l) 
Triglycerides (mmol/1) 
3.50 ± 0.91 
0.55 ± 0.18 
14.24 ± 2.45 
1.21 ± 0.45 
1.92 ± 0.76b 
0.94 ± 0.82 
9.99 ± 3.66b 
1.81 ± 0.50 
7.22 ± 2.22 
2.38 ± 1.08 
4.18 ± 1.91 
1.76 ± 0.91 
3.04 ± 0.60 
0.62 ± 0.23 
11.28 ± 2.66 
2.11 ± 0.33 
3.27 ± 1.18b 
1.37 ± 0.68 
1.71 ± 0.95" 
0.94 ± 0.53 
1.56 ± 0.35b 
0.43 ± 0.19 
8.74 ± 2.01 
1.80 ± 0.26 
a
: Ρ (vs. WHHL controls) <0.05. 
b
: Ρ (vs. WHHL controls) <0.01. 
Values are mean ± SD. M = male, F female. 
WHHL rabbits after 4 weeks of treatment than in controls (-36% and -35%, respecti­
vely), due to lower levels of cholesterol in all fractions; the changes were larger in the 
lighter fractions VLDL+IDL than in LDL (Table 2). The levels of serum triglycerides 
increased in the simvastatin treated group in the first experiment, but did not change 
significantly in the second. 
Analysis of the composition of fractions VLDL+IDL and LDL in the first experi­
ment showed a relatively higher amount of triglycerides at the expense of cholesteryl 
esters in WHHL rabbits after simvastatin. The ratio cholesteryl esters to triglyceri­
des was lower both in the VLDL+IDL (-63%) and in the LDL fraction (-56%) (Table 3). 
In the second experiment, compositional changes were qualitatively the same as in the 
first experiment, although less pronounced (Table 4). In this experiment the amount of 
triglycerides was relatively high in all animals compared to the first experiment. The 
ratio cholesteryl esters to triglycerides was lower in all the fractions in the treated 
group, but only significant in the VLDL+IDL and VLDL fraction (change -24% and 
-31%, respectively). 
Characteristics of radiolabeled VLDL and LDL 
Of the radioactivity in the tracers used in both experiments, 2-4% was precipitated 
in 10% trichloroacetic acid (TCA). The radioactivity precipitable in 50% isopropanol 
ranged from 71-80% in VLDL and from 82-85% in LDL. 10-14% of radioactivity in the 
VLDL labels could be extracted in organic solvents. On SDS gels, the radioactivity 
bound to apoE amounted to 16-18% ofthat bound to apoBlOO for VLDL and to 5-7% for 
LDL. There were no differences between the tracers used in any of these characteris­
tics. Gradient gel electrophoresis of fractions VLDL, IDL and LDL and SDS gel 
electrophoresis of VLDL and LDL showed no qualitative differences between the 
lipoprotein fractions of control rabbits and those of rabbits after simvastatin. The 
validity of the VLDL tracer used was also evaluated by recentrifugation of the tracer 
Table 3. Chemical composition of fractions very low density and intermediate density lipo­
proteins (VLDL + IDL) and low density lipoproteins (LDL) of WHHL control rabbits (n=7) 
and WHHL rabbite ί weeks after a diet containing 0.03% simvastatin (n= 7) from experiment 1. 
The fractions were isolated by gradient ultracentrifngatwn. 
Component (% of mass) 
Cholesteryl esters 
Free cholesterol 
Triglycerides 
Phospholipids 
Proteins 
CE/TG 
CHOL/Protoins 
VLDL 
controls 
48.0 ± 4.3 
9.3 ± 0.6 
13.8 ± 3.9 
16.2 ± 0.5 
12.8 ± 1.2 
3.8 ± 1.5 
4.5 ± 0.8 
+ IDL 
simvastatin 
32.8 ± 7.2b 
8.5 ± 1.7 
26.7 ± 7.8b 
17.2 ± 1.5 
14.8 ± 1.5a 
1.4 ± 0.9b 
2.8 ± 0.8a 
LDL 
controls 
41.6 ± 3.4 
8.2 ± 0.5 
6.4 ± 2.5 
17.3 ± 0.8 
26.Ó ± 2.8 
7.5 ± 2.9 
1.9 ± 0.3 
simvastatin 
35.2 ± 4.8l, 
7.6 ± 0.7* 
12.6 ± 4.5" 
18.2 ± 0.6 
26.5 ± l . lb 
3.3 ± 1.7b 
1.6 ± 0.3 
": Ρ (vs. WHHL controls) < 0.05. 
b
: Ρ (vs. WHHL controls) <0.01. 
Values are mean ±SD. CE = cholesteryl esters; TG = triglycerides; 
CHOL = free cholesterol and cholesteryl esters. 
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Table ί. Chemical composition of fractions very low density and intermediate density lipoproteins (VLDL + IDL), very low density (VLDL), 
intermediate density (IDL) lipoproteins and low density lipoproteins (LDL) of WHHL control rabbits (n=7) and WHHL rabbits U weeks after a diet 
containing Ο.Ο,ΊΨο simvastatin (n=7)from experiment 2. The fractions were isolated by sequential ultracentrifugation. 
Component (% of mass) 
Cholesteryl esters 
Free cholesterol 
Triglycerides 
Phospholipids 
Proteins 
CE/TG 
CHOL/Proteins 
VLDL 
controls 
37.0 ± 2.2 
8.2 ± 0.5 
21.8 ± 3.2 
17.4 ± 1.3 
15.6 ± 1.7 
1.7 ± 0.3 
2.9 ± 0.3 
+ IDL 
simvastatin 
30.1 ± 2.7b 
8.2 ± 1.1 
24.1 ± 3.6 
16.8 ± 1.8 
20.6 ± 3.8b 
1.3 ± 0.3" 
1.9 ± 0.3b 
VLDL 
controls 
36.4 ± 2.3 
7.7 ± 0.5 
27.6 ± 2.8 
15.7 ± 1.7 
12.6 ± 1.9 
1.3 ± 0.2 
3.6 ± 0.6 
simvastatin 
28.1 ± 4.1b 
8.2 ± 1.1 
32.1 ± 3.3a 
14.2 ± 4.4 
17.6 ± 6.0 
0.9 ± O ^ 
2.3 ± 0.8a 
IDL 
controls 
37.5 ± 3.1 
8.8 ± 0.5 
13.9 ± 2.6 
19.7 ± 0.8 
20.1 ± 1.5 
2.8 ± 0.8 
2.3 ± 0.3 
simvastatin 
31.6 ± З.Э" 
8.4 ± 0.4 
16.4 ± 4.0 
19.1 ± 0.7 
24.5 ± 1.6b 
2.1 ± 0.8 
1.6 ± 0.2b 
LDL 
controls 
36.8 ± 2.5 
7.1 ± 0.5 
12.7 ± 2.5 
18.0 ± 0.6 
25.4 ± 0.9 
3.0 ± 0.8 
1.7 ±0.1 
simvastatin 
35.6 ± 3.7 
6.8 ± 0.4 
13.6 ± 3.1 
17.3 ± 0.3 
26.6 ± 1.5 
2.8 ± 1.0 
1.6 ± 0.2 
-: Ρ (vs. WHHL controls) <().05. 
b
: Ρ (vs. WHHL controls) <0.01. 
Values are mean ± SD. CE = cholesteryl esters; TG : triglycerides; CHOL = free cholesterol and cholesteryl esters. 
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Figure ¿. Plasma radioactivity disappearance cwres of '" / labeled low density lipoprotein 
(LDL) IH control WHHL rabbits (n=5) and WHHL rabbits i weeks after treatment with 
simvastatin (n=6) 
Table 5. Kinetic data of the turnover study with '"¡labeled loiv density lipoprotein (LDL) from 
control WHHL rabbits in control WHHL rabbits, and " Ί labeled LDL from WHHL rabbits 
after b weeks diet containing 0.0,1 % simvastatin m treated WHHL rabbits After injection of "'I 
labeled autologous LDL plasma radioactivity ivas followed for 72 hours. The fractional 
catabohc rate (FCR) was determined by biexponential analysis of the plasma decay curve. The 
secretion rate (SR) was calculated from the FCR and the apo В LDL pool. 
Plasmavolume (ml) 
Apo В LDL pool (mg/kg) 
LDL 
FCR (pools/day) 
SR (mg/kg.day) 
WHHL controls 
(n=5) 
80 ± 6 
170 ± 24 
0.41 ± 0.10 
68.8 ± 19.0 
WHHL simvastatin 
(n=6) 
82 ± 5 
120 ± ЗО" 
0.50 ± 0.06 
58.8 ± 8.9 
a
: Ρ < 0.05. 
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after mixing with pool plasma of each group. 95% of the label was recovered in the 
VLDL fraction, and only traces were found in the IDL (1 to 4%) and LDL fraction (1 to 
24c) in both experiments. 
LDL turnover data 
The results of the LDL turnover are shown in Figure 2 and Table 5. There was a 
more rapid plasma decay curve of apoLDL in WHHL rabbits after simvastatin than in 
WHHL controls. After simv astatin, the apo В LDL pool was 29% lower, the calculated 
FCK of apoLDL was 22% higher and the secretion rate was 15% low er. The differen­
ces were significant for the apo В LDL pool only. 
VLDL turnover data 
VLDL turnover data were obtained after pooling of the blood of only those animals 
in w'hich blood sampling could be perfomned without stress. This yielded 4 treated 
animals and 3 control animals in the first expenment, and 3 treated animals and 2 
control animals in the second expenment. The lipid changes in these ammals were 
% of injected dose 
0 5 10 15 20 25 
time (hours) 
Figure S Apol ipoprotei η В bound radioactivity curres of autologous veiy low density lipo­
protein (VLDL) for VLDL, intennediate density lipoproteins (IDL) and low density hpo-
pi oteins (LDL) in 3 с ontrol WHHL rabbits and i WHHL labbits Í weeks after treatment with 
simvastatin in expenment 1 The results of control rabbits are shown in solid lines and open 
symbols The ìesidls of simvastatin tieated animals are shown in broken lines and closed 
symbols Circles denote VLDL, triangels IDL, squares LDL 
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comparable to those of the entire group. Serum cholesterol levels in treated animals 
were 44% and 47% lower than in controls for the two experiments, respectively, 
versus 36% and 35% in the respective entire groups; VLDL+IDL cholesterol were 
50% and 70% lower, respectively, versus 45% and 55% in the respective entire groups. 
In the first experiment, the decay of the radioactivity bound to apo В in VLDL was 
more rapid than in controls, especially in the first hours (Figure 3). The amount of apo 
В bound radioactivity in the IDL fraction was comparable for both groups in the first 
hours, whereas after 24 hours this amount was lower in the treated group. The amount 
of radioactivity in apo В in the LDL fraction was increased after treatment. 
The results of the SAAM analysis of the kinetic data of the first experiment are 
shown in Table 6. 
VLDL: The VLDL secretion rate was 23% higher and the VLDL pool was slightly 
higher after treatment. Compared to controls, the FCR of VLDL was 16% higher and 
the direct uptake was 160% higher after simvastatin. In controls, 32% of VLDL was 
directly removed from the plasma, whereas in WHHL rabbits after simvastatin this 
was 68%. The absolute amount of apo В converted to IDL or LDL was 42% lower after 
treatment (49.4 vs. 28.6 mg/kg.day). 
IDL: The IDL secretion rate was 45% lower and the pool size was unaltered after 
simvastatin. In control WHHL rabbits, more than 90% of IDL was directly removed 
from the plasma, whereas in treated rabbits, this was only 17%. The amount of VLDL 
which was taken up without conversion to LDL, either directly or through the IDL 
compartment, was equal in both groups (60.9 vs. 64.5 mg/kg.day for controls and 
treated animals, respectively). The FCR of IDL was 45% lower after simvastatin. 
LDL: Results from the LDL turnover data indicated a 33% lower apo В pool, a 10% 
higher FCR and a 25% lower secretion rate after simvastatin. The absolute amount of 
apo В transferred from VLDL to LDL was 100% higher after simvastatin, but 
accounted for a minority of the calculated LDL production in both controls and treated 
rabbits. In controls, 16% of VLDL apo В secreted was converted to LDL, and in 
treated animals this amounted to 28%. For controls, only 16% of LDL production could 
be explained from conversion from VLDL and IDL, whereas in treated rabbits, this 
amounted to 45% of the total production. A direct synthesis of LDL was therefore 
assumed, which was 51% lower in the group treated with simvastatin. Total apo В 
synthesis appeared to be slightly decreased after simvastatin. 
In the second experiment, the radioactivity curves after injection of autologous 
VLDL showed that the decay of apo В in VLDL was more rapid and the decay of apo В 
in IDL was faster after 24 hours in the treated group than in controls. The radioacti­
vity recovered in the LDL fraction was increased after treatment (Figure 4). In these 
respects, the results were comparable to those of the first experiment. Comparing the 
results of the non-autologous and the autologous VLDL tracer in both groups showed 
that there were only small differences in the decay curves and the respective FCR's of 
VLDL and LDL in both groups (Figure 5, Table 7). 
DISCUSSION 
The results of the present study indicate that serum cholesterol levels in the WHHL 
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Table 6. Kinetic data of the turnover experiment 1 with U''I labeled VLDL from control WHHL 
rabbits in control WHHL rabbits, and U~'I labeled VLDL from WHHL rabbits after 4. weeks on a 
diet containing 0M9c simvastatin in treated WHHL rabbits. After injection of u'l labeled 
autologous VLDL blood was sampled for ¿4 hours and pooled per group; fractions VLDL, IDL 
and LDL were isolated by sequential ultracentnfugation, and the radioactivity bound to apo В 
was estmated. 
WHHL controls WHHL simvastatin 
(n=3) (n=4) 
VLDL 
SR (mg/kg.day) 
Apo В pool (mg/kg) 
FCR (pools/day) 
direct uptake 
conversion to IDL 
conversion to LDL 
Direct uptake (mg/kg.day) 
Conversion to IDL (mg/kg.day) 
Conversion to LDL (mg/kg.day) 
IDL 
SR (mg/kg.day) 
Apo В pool (mg/kg) 
FCR (pools/day) 
direct uptake 
conversion to LDL 
Direct uptake (mg/kg.day) 
Conversion to LDL (mg/kg.day) 
LDL 
SR (mg/kg.day) 
synthesis from 
VLDL + IDL (mg/kg.day) 
direct synthesis (mg/kg.day) 
Apo В pool (mg/kg) 
FCR (pools/day) 
Total apo В synthesis (mg/kg.day) 
FCR = fractional catabolic rate 
SR = secretion rate 
rabbit are lowered by cholesterol synthesis inhibition by simvastatin and that this 
cholesterol lowering effect is accompanied by a decrease in the relative amount of 
cholesterol and an increase in the relative amount of triglycerides in fractions VLDL, 
IDL and LDL. The cholesterol lowering effects are more pronounced in the fractions 
VLDL and IDL than in LDL. 
There were large differences in the basal lipid concentrations and lipid alterations 
between the two experiments. We and also others have observed these differences 
between different groups earlier in WHHL rabbits (4), which stresses the necessity to 
perform every time simultaneous experiments in both control and treated animals. 
In the first kinetic experiment no differences were found in the apo В pool sizes of 
72.7 
4.2 
17.48 
5.60 
9.50 
2.38 
23.3 
39.5 
9.9 
39.5 
11.6 
3.41 
3.25 
0.16 
37.6 
1.9 
73.8 
11.8 
62.0 
155.2 
0.48 
134.7 
89.3 
4.4 
20.29 
13.81 
4.98 
1.53 
60.8 
21.9 
6.7 
21.9 
11.7 
1.87 
0.32 
1.54 
3.7 
18.1 
55.3 
24.8 
30.5 
104.8 
0.53 
119.8 
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Figure U Apolipoprotein В bound radioactivity πιι- еч of autologous vei~y low denbity lipo­
protein (VLDL) jor VLDL, intermediate density lipoproteins (IDL) and Unt density lipo­
proteins (LDL) in 2 control WHHL rabbits and .i WHHL rabbits i weeks after treatment with 
simvastatin in experiment ¿ The results of control rabbits are shown in solid lines and open 
symbols The results of simvastatin treated animals are shown m broken lines and closed 
symbols Circles denote VLDL, triangles IDL, squares LDL 
VLDL and IDL. This indicates that the observed differences in the cholesterol 
concentration in these fractions between treated and control rabbits were due to 
changes in composition. Indeed the relative amount of cholesterol to proteins in the 
fraction VLDL+IDL was 36% lower after simvastatin than in controls. This largely 
explains the 45% lower cholesterol level in VLDL+IDL. The LDL data indicated a 
29% decrease in the pool size of LDL apo B, which was due to compositional changes as 
well as to slight alterations in the FCR and secretion rate. 
The altered compositions are likely to be caused by a cholesterol depletion in the 
liver as a result of the cholesterol synthesis inhibition resulting in the production of 
VLDL particles relatively poor in cholesteryl esters and neh in triglycerides. Trans-
fer and exchange of triglycerides and cholesteryl esters between lighter fractions and 
LDL would lead to the observed compositional changes in LDL. This may especially 
be true for WHHL rabbits, because of their very high lipid transfer activity (31). 
In the first turnover study, the total LDL production was 15% lower after sim-
vastatin, although the difference was not significant. Total synthesis of VLDL apo B, 
as found in the same experiment, was slightly higher after cholesterol synthesis 
inhibition and the amount of radioactivity which was transferred to the LDL ft'action 
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Figure ί Apolipoprotein В boimd radioactivity curves for VLDL, IDL and LDL m 2 control 
WHHL rabbits (upper panel) and J WHHL labbits after 4 weeks treatment with simvastatin 
(lower panel) m experiment 2 At t=0 they were injected with " Ί labeled VLDLfrom control 
WHHL rabbits and '''I labeled VLDL β om WHHL rabbits after 4 weeks treatment with 
simvastatin The results of control VLDL are shown in solid lines and open symbols The 
results of VLDL from simvastatin treated animals are shown in broken lines and closed 
symbols Circles denote VLDL, triangles IDL, squares LDL 
Table 7 Fractional catabohc rates (FCR) of the turnover experiment 2 with '"[labeled VLDL 
from control WHHL rabbits and U'I labeled VLDLfrom WHHL rabbits after4 weeks on a diet 
containing 0 03% simvastatin in both controls and ti eated rabbits After injection of both VLDL 
tracers blood was sampled for 48 hours and pooled per gioup, fractions VLDL, IDL and LDL 
were isolated by sequential ultracentnfugation, and the radioactivity bound to apo В was 
estimated 
WHHL controls (n=2) 
control VLDL 
simvabtatin VLDL 
WHHL simvastatin (n=3) 
control VLDL 
simvabtatin VLDL 
FCR VLDL 
(poolb/day) 
6.22 
5 82 
10 76 
12 61 
FCR IDL 
(pools/day) 
0 81 
117 
1.28 
111 
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was more than 2-fold higher in treated animals than in controls. These findings 
indicate that cholesterol synthesis inhibition increases the conversion of VLDL to 
LDL; since total LDL production is diminished rather than increased, there must be a 
direct LDL synthesis, which is decreased by cholesterol synthesis inhibition. 
In other animal species than the WHHL rabbit, direct production of LDL was found 
in kinetic studies, in in vitro studies with hepatocytes and in liver perfusion studies 
(32-36). In addition, this direct LDL synthesis could be decreased by bile acid seque­
stration with cholestyramine and by cholesterol synthesis inhibition with lovastatin 
(37,38). Direct LDL synthesis has also been found in patients with homozygous 
familial hypercholesterolemia (39,40). In the WHHL rabbit no direct LDL synthesis 
has been found so far from liver perfusion studies (23,41). This may be explained by the 
fact that in these liver perfusion studies VLDL particles were isolated which were 
different from those found in the circulation, in that they were much larger and 
triglyceride-rich (41). 
It has been reported that large, triglyceride rich particles in the VLDL fraction of 
the WHHL rabbit, which account for less than 5% of total VLDL particles in the 
circulation, accounted for more than 40% of the apo В transport through the VLDL 
compartment, without conversion to LDL (42). This resembles the human situation, in 
which also larger, triglyceride-rich VLDL particles are removed rapidly from the 
circulation without conversion to denser lipoproteins (43,44). VLDL particles contain­
ing both apo В100 and apo E in both normal and WHHL rabbits have been shown to be 
taken up faster and converted less to lipoproteins of higher density than those VLDL 
particles which only contain apo BlOO (23,45). Altogether these findings indicate that 
composition, size and apo E content determine the fate of the VLDL particle. In the 
current study VLDL particles were taken up to a larger extent after simvastatin 
without conversion to IDL or LDL. However, the uptake of IDL was higher in 
controls than after simvastatin, and total uptake of VLDL + IDL apo В was 84% of 
VLDL apo В production in controls and 72% in treated rabbits. No differences were 
found between control WHHL rabbits and WHHL rabbits after simvastatin in size 
after gradient gel electrophoresis, nor in apo E content in the VLDL fraction, but 
there were evident differences in the particle composition (Tables 3 and 4). The results 
of the second kinetic experiment, although conducted in a limited number of animals 
only, showed that the increased conversion of VLDL to LDL did not appear to be due 
to changes in the VLDL particle induced by cholesterol synthesis inhibition but by 
some mechanism induced in the rabbit by simvastatin. 
Generally, the mechanisms of the conversion of VLDL to LDL are not fully 
elucidated (46). The LDL receptor may play a role in this process, together with 
lipases (39,47). A defect in either the receptor, apo E or hepatic lipase results in a 
decreased conversion of VLDL to LDL, as is found in homozygous familial hyper­
cholesterolemia, familial dysbetalipoproteinemia and hepatic lipase deficiency in hu­
mans (39,48). It might be possible that in the WHHL rabbit the defective LDL 
receptor, which does not bind LDL, plays a role in the conversion of VLDL to LDL 
also, possibly by interaction of the receptor with apo E of VLDL. The observed 
increase of this conversion after treatment with simvastatin could be caused by an 
increased production of the defective LDL receptor as a result of the cholesterol 
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depletion in the liver. After cholesterol synthesis inhibition in WHHL rabbits a 
decrease in total cholesterol of 43% accompanied by a 3-fold increase in the messen-
gerRNA level of the LDL receptor has been reported (15). 
Previous studies in the WHHL rabbit have shown that bile acid sequestration by 
partial ileal bypass surgery lowered serum cholesterol by 50%; from kinetic studies 
with LDL it was found that this decrease was caused by a 50% reduction of the 
production of LDL particles (17). VLDL turnover studies showed both a lowered 
direct LDL synthesis and an increased conversion of VLDL to LDL after partial ileal 
bypass surgery (49). The mechanism by which the direct synthesis of LDL is de­
creased either by bile acid sequestration or by simvastatin is uncertain, but it may be 
due to an alteration in the amount of cholesterol and triglycerides which are available 
in the liver for production of lipoproteins. If particles are synthesized in which 
cholesterol is replaced by triglycerides, this may lead to the production of particles 
which are less dense. It has been shown in vitro that addition of free fatty acids to the 
medium of the human hepatoma cell line Hep-G2 leads to a relative decrease of the 
LDL production and an increase of the VLDL production (50). Such a mechanism 
could explain the observed decrease in the direct LDL secretion, and the somewhat 
higher VLDL synthesis after simvastatin. 
We conclude that cholesterol synthesis inhibition by simvastatin in the WHHL 
rabbit leads to a decrease in the concentration of cholesterol, especially of the VLDL 
fraction, and a cholesterol depletion of the lipoproteins. Changes in particle composi­
tion, a lower LDL production and an increased LDL clearance play a role in the 
observed cholesterol decrease. The decreased LDL production is the result of a 
decreased direct LDL synthesis and an increased synthesis of LDL from VLDL, 
which occur at the same time. 
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Chapter 10 
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147 
148 
Een verhoogd cholesterolgehalte van het serum gaat gepaard met een verhoogde 
kans op vroegtijdige aderverkalking, met name van de kransslagaderen. 
Cholesterol wordt in de bloedbaan vervoerd samen met triglyceriden (vetten), 
fosfolipiden en speciale eiwitten, de zogenaamde apolipoproteinen, in deeltjes die 
lipoproteinen genoemd worden. Men onderscheidt 2 soorten triglyceriderijke lipo-
proteinen: de chylomicrons, die cholesterol en vet van de darm door het lichaam 
transporteren en de zogenaamde 'very-low-density lipoproteins' (VLDL) die door de 
lever worden gemaakt en triglyceriden transporteren naar de overige weefsels. Een 
deel van de VLDL-deeltjes wordt na het afstaan van triglyceriden direct weer 
opgenomen en een deel wordt omgezet tot triglyceride-armere 'intermediate density 
lipoproteins' (IDL). Deze IDL-deeltjes geven triglyceriden af aan de weefsels en 
worden vervolgens opgenomen in de lever of verder omgezet tot de zwaardere 
'low-density-lipoprotein' (LDL)-deeltjes, die nog minder triglyceriden bevatten en 
grotendeels uit cholesterol bestaan. Overigens zijn er aanwijzingen uit dierexperi-
menteel onderzoek dat LDL-deeltjes ook direct, dus niet door omzetting van VLDL, 
kunnen worden gemaakt. De LDL-deeltjes bevatten het merendeel van het choleste-
rol in het bloed. Bij een verhoogd gehalte van met name deze deeltjes bestaat er een 
verhoogde kans op een vroegtijdige aderverkalking. Tenslotte zijn er de 'high-densi-
ty-lipoprotein' (HDL)- deeltjes die zeer cholesterolrijk zijn en die onder meer een rol 
spelen bij het transport van cholesterol terug naar de lever. Een hogere spiegel van 
het HDL-cholesterol blijkt gepaard te gaan met een verminderde kans op hart- en 
vaatziekten. 
De kans op vroegtijdige aderverkalking is in het bijzonder verhoogd bij mensen met 
familiaire hypercholesterolemie, een erfelijke aandoening van de cholesterolstof-
wisseling, waarbij er een verlaging is van het aantal receptoren voor het LDL-deeltje. 
Deze receptoren zijn eiwitstructuren op het oppervlak van lichaamscellen, die het 
LDL (en ook IDL) uit de bloedbaan kunnen opnemen. Bij patiënten met een heterozy-
gote familiaire hypercholesterolemie, die van één van beide ouders de ziekte hebben 
geërfd, is door een erfelijk defect het aantal LDL-receptoren verlaagd tot 50% van 
normaal. Hierdoor is het cholesterolgehalte in het bloed sterk verhoogd tot 2 tot 3 
maal het normale gehalte. Deze aandoening komt bij 1 op de 500 mensen voor. Veel 
zeldzamer is de homozygote vorm (1 per miljoen mensen), waarbij van beide ouders de 
aandoening is geërfd. Hierdoor zijn er geen of nauwelijks LDL-receptoren, waardoor 
het serumcholesterol extreem verhoogd is tot 6 maal de normale waarde. Bij deze 
patiënten treden klachten van kransslagaderlijden soms al op voor het tiende levens-
jaar. 
Overigens is bij het grootste deel van de patiënten met een verhoogd cholesterolge-
halte in het bloed geen sprake van familiaire hypercholesterolemie, maar bestaat er 
een combinatie van erfelijke factoren die samen met andere factoren zoals een chole-
sterolrijk dieet een daling van het aantal LDL-receptoren op het celoppervlak ver-
oorzaakt, waardoor er een verhoogd cholesterolgehalte van het serum ontstaat. 
Interventiestudies waarbij het cholesterolgehalte werd verlaagd met geneesmid-
delen en dieet hebben aangetoond dat hiermee de kans op het ontstaan van aderver-
kalking van de kransslagaderen met ziekte en sterfte als gevolg, afneemt. Wanneer 
naast dieet geneesmiddelen nodig zijn, dan waren tot op heden de zogenaamde 
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galzuurbindende kunstharsen de middelen van eerste keus. Deze middelen binden 
galzuren (die uit cholesterol worden gevormd) in de darm, zodat deze niet kunnen 
worden heropgenomen, en onttrekken zo cholesterol aan het lichaam. De lever, het 
centrale orgaan voor de stofwisseling van cholesterol in het lichaam dat 75% van alle 
LDL-receptoren bevat, zal hierop meer LDL-receptoren maken waardoor meer LDL 
uit de bloedbaan wordt opgenomen. Als gevolg hiervan daalt het cholesterolgehalte. 
De behandeling met deze geneesmiddelen is echter moeizaam, enerzijds omdat de 
gebruikte medicijnen veelal onvoldoende effect hebben, anderzijds omdat de midde-
len onaangenaam zijn om in te nemen en er vaak bijwerkingen optreden, met name 
buikklachten. In de afgelopen jaren zijn er nieuwe geneesmiddelen ontwikkeld voor 
de behandeling van een hoog cholesterolgehalte. Deze zogenaamde cholesterolsyn-
theseremmers remmen in het lichaam de aanmaak van cholesterol, en stimuleren zo de 
productie van LDL-receptoren en de opname van cholesterol uit de bloedbaan in de 
cellen. 
In hoofdstuk 2 tot en met 4 worden de effecten van simvastatine, één van deze 
nieuwe geneesmiddelen, op de serumlipiden en lipidensamenstelling beschreven bij 
gebruik als enige therapie en samen met galzuurbindende kunstharsen door patiënten 
met een heterozygote familiaire hypercholesterolemie. Simvastatine bleek het chole-
sterol in 4 weken te verlagen met gemiddeld 16%, bij een dosis van 2.5 mg per dag, tot 
gemiddeld 36% bij 80 mg per dag. Het maakte geen verschil of het medicament in één 
keer 's avonds of verdeeld over twee giften werd ingenomen. Tijdens een halfjaar 
behandeling met simvastatine in een dosering van eerst 20, later 40 mg per dag, daalde 
het serumcholesterol met gemiddeld 85-40%. Ook tijdens langduriger behandeling 
van gemiddeld 2 jaar bleef het cholesterolverlagend effect behouden. In combinatie 
met galzuurbindende kunstharsen daalde het cholesterol met gemiddeld 48%. Tijdens 
gebruik van simvastatine steeg het 'high-density-lipoprotein' (HDL)- cholesterolge-
halte, dat beschermt tegen hart- en vaatziekten, met ca. 8%. De samenstelling van de 
LDL-deeltjes veranderde niet door het middel. Simvastatine werd zeer goed ver-
dragen. Bij geen van de onderzochte patiënten was er aanleiding het gebruik van het 
middel te onderbreken. Bij laboratoriumonderzoek bleek bij ca. 10% van de behandel-
de patiënten een stijging op te treden van spier- en leverenzymen in het bloed. Dit 
ging echter niet gepaard met klachten en steeds daalden deze enzymen spontaan 
terwijl het middel werd voortgezet. (Overigens werd in grotere studies in een klein 
percentage van de patiënten (minder dan 1%) een aanhoudende stijging van de 
leverenzymen gevonden, die pas overging na staken van het middel. Tijdens gebruik 
van lovastatine, een aan simvastatine verwante stof, werd bij minder dan 0.5% van de 
patiënten een stijging van de spierenzymen gevonden samen klachten van spierpijn 
en vermoeidheid in de spieren.) 
Cholesterol is in het lichaam nodig voor onder meer de aanmaak van geslachts- en 
bijnierschorshormonen. Een sterke remming van de aanmaak van cholesterol zou de 
productie van deze hormonen nadelig kunnen beïnvloeden. In hoofdstuk 5 wordt het 
effect van simvastatine beschreven op de resultaten van diverse tests van de functie van 
de bijnierschors bij patiënten met een hoog cholesterolgehalte. Simvastatine verlaagde 
in deze studie het serumcholesterol met gemiddeld 35% na 8 weken. Hierbij bleek een 
geringe invloed op de maximale productie van één van deze hormonen, het Cortisol, 
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tijdens stimulatie met ACTH. Ook bleek er onder basale omstandigheden meer ACTH 
aanwezig, het hormoon dat de bijnierschors aanzet tot produktie van hormonen. Deze 
verschillen waren echter klein en lijken klinisch niet van belang te zijn. 
Op grond van de gegevens in hoofdstuk 2-5 lijkt simvastatine een zeer effectief en 
veilig geneesmiddel voor de medicamenteuze behandeling van een hoog cholesterol-
gehalte. Bovendien blijkt de toevoeging van galzuurbindende kunstharsen een be-
langrijke extra daling te veroorzaken. Gegevens over de effecten op lange termijn 
ontbreken echter nog. Het gebruik van dit middel dient vooralsnog te worden beperkt 
tot patiënten met een sterk vergrote kans op het ontwikkelen van een ziekte door 
aderverkalking van de kransslagaderen. Het onderzoek is beperkt tot personen met 
een hoog cholesterolgehalte die -behoudens het hebben van aandoeningen van de 
kransslagaderen- overigens gezond waren, en in strikte zin kan over het gebruik van 
dit middel bij aanwezigheid van andere aandoeningen nu geen uitspraak worden 
gedaan. 
In hoofdstuk 6 worden de klinische, biochemische en metabole aspecten beschreven 
van 2 patiënten met de zeer zeldzame homozygote vorm van familiaire hypercholeste-
rolemie. Deze patiënten bezitten nauwelijks of niet de mogelijkheid LDL-receptoren 
te maken. Therapieën met galzuurbindende kunstharsen en simvastatine bleken dan 
ook nauwelijks effect te hebben. Eén van beide patiënten kreeg op 14- jarige leeftijd 
klachten ten gevolge van vernauwingen van de kransslagaderen, waarvoor een opera-
tie nodig was. Daarna werd zij behandeld met LDL-aferese, een techniek waarbij het 
LDL door filtering uit het bloed wordt verwijderd. Gedurende 2 jaar behandeling met 
intervallen van 2 weken was hiermee een verlaging van het cholesterol met ca. 50% 
mogelijk. Er trad een stijging op van het HDL-cholesterol. De tevoren aanwezige 
stapelingen van cholesterol in de huid (Xanthomen) verdwenen. Na 2 jaar behandeling 
toonde een afbeelding van de kransslagaderen geen belangrijke toename van de 
vernauwingen. 
Bij het onderzoek naar de stofwisseling van cholesterol wordt gebruik gemaakt van 
het 'Watanabe heritable hyperlipidemic' (WHHL)-konijn. Dit konijn heeft ten gevol-
ge van een erfelijke afwijking een vrijwel volledige afwezigheid van LDL-receptoren 
op de cel. Hierdoor treedt er een sterke verhoging op van het cholesterol in de 
bloedbaan leidend tot aderverkalking. Dit dier is zodoende een uitstekend model voor 
de homozygote vorm van familiaire hypercholesterolemie. Men zou verwachten dat 
door de afwezigheid van LDL-receptoren cholesterolverlagende therapieën niet 
werken, net als bij patiënten met homozygote familiaire hypercholesterolemie. Zowel 
onderbreking van de enterohepatische kringloop van galzuren (door kunstharsen of 
door een operatie waarbij het laatste deel van de dunne darm wordt uitgeschakeld 
('partial ileal bypass' of PIB) waardoor de galzuren niet meer kunnen worden herop-
genomen) als remming van de cholesterolsynthese met simvastatine bleken echter 
wel degelijk effectief. Ontdekking van de weg waarlangs deze cholesteroldaling tot 
stand komt zou meer inzicht kunnen geven in de stofwisseling van lipiden in het 
algemeen en in de vorming van LDL in het bijzonder, en zou wellicht kunnen leiden tot 
een nieuwe benadering van patiënten met een hoog cholesterolgehalte. 
In hoofdstuk 7 wordt het effect van PIB op het serumcholesterol, de samenstelling 
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van de deeltjes en het metabolisme van LDL beschreven. PIB verlaagde het LDL-
cholesterol met 80%, en veranderde de samenstelling van VLDL-, IDL- en LDL-
deeltjes sterk, waardoor er een relatieve verrijking optrad met triglyceriden ten 
koste van cholesterol. De fractie van de LDL-deeltjes die werd opgenomen uit de 
bloedbaan bleek onder invloed van PIB met 50% toegenomen; dit was niet het gevolg 
van een opname via LDL-receptoren. De productie van het LDL nam onder invloed 
van PIB met 50% af. 
In hoofdstuk 8 werd het effect van PIB op de omzetting van VLDL naar LDL 
onderzocht. De daling van het LDL-cholesterol en de veranderingen in de samenstelling 
van LDL door PIB kwamen overeen met die in hoofdstuk 7 beschreven. Na PIB was de 
aanmaak van VLDL bijna 3 maal zo groot als bij de controledieren. De VLDL-deeltjes 
werden versneld opgenomen en de hoeveelheid VLDL die werd omgezet tot LDL bleek 
bijna 2 maal zo groot onder invloed van PIB. Zowel bij de controledieren als na PIB was 
de totale LDL productie groter dan die welke het gevolg was van de omzetting van 
VLDL tot LDL. Er was dus een directe LDL-synthese. De verlaagde aanmaak van LDL 
na PIB bleek het gevolg van een afname van de directe LDL-synthese met ruim 50%. 
In hoofdstuk 9 werd het effect van cholesterolsyntheseremming met simvastatine 
op de lipoproteïnen en hun stofwisseling bestudeerd bij WHHL-konijnen. Simvastati-
ne verlaagde het cholesterolgehalte met 35%, ten gevolge van een verlaging in met 
name de VLDL- en IDL-deeltjes. De analyse van de deeltjes toonde een relatieve 
verrijking met triglyceriden en een afname van het gehalte aan cholesterol, die het 
grootst was in de VLDL- en IDL-deeltjes. De aanmaak van LDL nam door sim-
vastatine af, en de opname nam toe, maar de verschillen waren slechts klein. Er was 
een geringe toename van de aanmaak en van de directe opname van VLDL en van de 
omzetting van VLDL naar IDL of LDL. Uiteindelijk werd er ruim 2 maal zoveel LDL 
uit VLDL gevormd tijdens behandeling met simvastatine. Zowel bij behandelde als 
onbehandelde dieren bleek de omzetting van VLDL naar LDL onvoldoende om de 
volledige LDL-vorming te verklaren. Het verschil, de directe LDL-synthese, werd 
door simvastatine gehalveerd. De veranderingen in omzettingen van VLDL onder 
invloed van simvastatine bleken niet te worden bepaald door veranderingen in het 
VLDL-deeltje zelf. 
De conclusies die kunnen worden getrokken uit de in dit proefschrift beschreven 
onderzoeken zijn de volgende: 
- Simvastatine is een effectief medicament bij de behandeling van hypercholesterole-
mie. 
- Het cholesterolverlagend effect van simvastatine als monotherapie is kleiner dan 
dat van de combinatie van simvastatine met een galzuurbindend kunsthars. 
- Bijwerkingen van simvastatine zijn voorbijgaande, symptoomloze stijgingen van 
spier- en leverenzymen. 
- Onder invloed van simvastatine verandert de samenstelling van de LDL-deeltjes 
niet. 
- Simvastatine heeft geen klinisch relevante nadelige invloed op de functie van de 
bijnierschors. 
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- Simvastatine is nauwelijks werkzaam bij patiënten met een homozygote familiaire 
hypercholesterolemie. 
- LDL-aferese is een effectieve en goed verdragen methode om het LDL-cholesterol-
gehalte te verlagen bij patiënten die met dieet en geneesmiddelen onvoldoende 
kunnen worden behandeld. 
- De cholesteroldaling bij het WHHL-konijn onder invloed van 'partial ileum bypass' 
(PIB) is het gevolg van een grotere opname van het LDL, een verminderde 
productie van LDL en een vermindering van de hoeveelheid cholesterol per LDL-
deeltje. 
- Vermindering van de productie van LDL door PIB bij het WHHL-konijn is een 
gevolg van een verminderde directe synthese van LDL; de hoeveelheid LDL 
gevormd uit VLDL is door PIB toegenomen. 
- De cholesteroldaling bij het WHHL-konijn door simvastatine treedt vooral op in de 
lichtere VLDL- en IDL-fracties en is grotendeels het gevolg van een vermindering 
van het cholesterolgehalte van de deeltjes. 
- Simvastatine veroorzaakt geen grote verschillen in de productie en de opname van 
LDL-deeltjes bij het WHHL-konijn. 
- Ook tijdens behandeling met simvastatine treedt er bij het WHHL-konijn een 
sterkere omzetting op van VLDL naar LDL en een vermindering van de directe 
LDL-synthese. 
- De sterkere omzetting van VLDL naar LDL na simvastatine bij het WHHL-konijn 
lijken het gevolg van veranderingen in de stofwisseling die onafhankelijk zijn van de 
veranderingen in de VLDL-deeltjes. 
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DANKWOORD 
Mijn dank gaat uit naar iedereen die op enige wijze aan de totstandkoming van dit 
proefschrift bijgedragen heeft. 
Op de eerste plaats dank ik de vele patiënten van de lipiden-polikliniek, die bereid 
waren de soms belastende onderzoekingen te ondergaan. De verpleegkundigen van de 
polikliniek waren behulpzaam bij het verzamelen van de vele bloedmonsters. De 
medewerkers van het Laboratorium Algemeen Interne Geneeskunde (Hoofd: Dr. P. 
N. M. Demacker), in het bijzonder Heidi Hak-Lemmers, Pieternel van Heijst en 
Anneke Hijmans voerden mij snel in in de laboratoriumtechnieken en verluchtten veel 
laboratonumwerk. De medewerkers van het Instituut voor Nucleaire Geneeskunde 
(Hoofd: Prof. Dr. F. H. M. Corstens), in het bijzonder Wim van den Broek en Emile 
Koenders, waren behulpzaam bij de proeven met radioactief gemerkte lipoproteinen. 
De medewerkers van het Centraal Dierenlaboratorium (Hoofd: Prof. Dr. W. J. I. 
van der Gulden), voerden met veel zorg de experimenten uit. Hennie Reynen loste het 
probleem van een teruglopende vruchtbaarheid van de hypercholesterolaemische 
konijnenstam op. Sedertdien is de voortplanting van de konijnen weer spreekwoorde-
lijk. Gerrie Grutters wist met grote inzet en kunde de konijnen te canuleren en 
behoedde samen met Hennie Eikholt de onderzoeker voor diepe wanhoop tijdens de 
turnover-experimenten. 
Cor Wennekers verzorgde de bijnierfunctietests en voerde de gegevens in de 
computer in. De medewerkers van het Laboratorium voor Experimentele en Chemi-
sche Endocrinologie (Hoofd: Prof. Dr. T. J. Benraad) verrichtten de laboratoriumbe-
palingen van het bijnierfunctieonderzoek. In het bijzonder dank ik Dr. Jan van 
Laarhoven voor zijn hulp. De medewerkers van de afdeling Plasmaferese (Hoofd: Dr. 
R. S. G. Holdrinet, later Dr. T. de Witte), in het bijzonder Gaby Martens-Ticoalu, 
Marian Peeters-Preenen en Aart Plas, dank ik voor hun bijdrage aan het ontwikkelen 
van de selectieve LDL-aferese. 
Drs. Jos Rademaekers van de afdeling Oogheelkunde (Hoofd: Prof. Dr. A. Deut-
man) heeft vanaf het begin de vele oogheelkundige onderzoekingen verricht. 
Dr. Monique Kleinherenbrink-Stins, Instituut voor Experimentele Gerontologie 
TNO, Rijswijk, dank ik voor het verrichten van het elektronenmicroscopisch onder-
zoek. 
De medewerkers van de Medische Illustratie en Lucie van 't Laar-Langerveld 
verzorgden het grootste deel van de tekeningen. Ans Ruesen-Maandag dank ik voor 
haar secretariële ondersteuning. Minny Meeuwissen voerde gedurende lange tijd 
grote hoeveelheden patiëntengegevens in de computer in. De heer P. Vermeulen 
ontwierp de omslag van dit proefschrift en verzorgde de druk. 
I gratefully acknowledge the support of Dr. Chris Packard, Royal Infirmary, 
Glasgow, UK, for kindly inviting me to his institute and for performing the computer 
analysis of the turnover data. I hope we will continue our co-operation in the future. 
Alle medewerkers van de 'lipidengroep' wil ik hier dankzeggen voor de leerzame en 
prettige samenwerking en voor de mogelijkheden die zij mij boden op velerlei gebied. 
In deze onderzoeksperiode heb ik in meerdere opzichten meer van de wereld gezien. 
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Tenslotte dank ik Marlies, mijn lieve vrouw, door wie mijn geestelijk dieet geva-
rieerd bleef; en die een onmisbare rol speelde bij mijn overgang van 'jonge onder-
zoeker' naar 'ouder-onderzoeker'. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 7 september 1957 te Geldrop. De 
middelbare schoolopleiding gymnasium-B werd gevolgd aan het Lyceum Augustinia-
num te Eindhoven; het einddiploma werd behaald in 1975. Van 1975 tot 1976 studeerde 
hij biologie aan de Katholieke Universiteit te Nijmegen. Het propaedeutisch examen 
werd behaald in 1976. In 1976 werd de studie geneeskunde begonnen aan de Ka-
tholieke Universiteit te Nijmegen. Het doctoraalexamen werd in 1981 afgelegd en het 
artsexamen in 1984. 
Sedert 1984 is hij werkzaam als arts in opleiding tot internist in de Kliniek voor 
Inwendige Ziekten (Hoofd: Prof. Dr. A. van 't Laar) van het Academisch Ziekenhuis te 
Nijmegen. De in dit proefschrift beschreven onderzoekingen werden verricht in de 
periode 1985 tot 1989. In verband hiermee werd de opleiding gedurende 2 jaar 
onderbroken. 
Hij is getrouwd met Marlies Rasing; zij hebben een zoon, Tim. 
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STELLINGEN 
behorende bij het proefschrift 
CHOLESTEROL LOWERING 
IN FAMILIAL 
HYPERCHOLESTEROLEMIA 
Studies in man and rabbit 
Marc Mol 
Nijmegen, 21 juni 1990 
1. In tegenstelling tot de galzuurbindende kunstharsen veroorzaken de remmers 
van de cholesterolsynthese geen verandering in de samenstelling van LDL. 
(Dit proefschrift, hoofdstuk 4; Young SG, Witztum JL, Carew TE, et al. J Lipid 
Res 1989;30:225-238). 
2. Wegens de onbekendheid met mogelijke nadelige effecten op lange termijn dient 
het gebruik van remmers van de cholesterolsynthese vooralsnog beperkt te 
worden tot patiënten met een sterk verhoogd risico op het ontwikkelen van 
aandoeningen van de kransslagaderen door een verhoging van het cholesterolge-
halte in het serum. 
(Dit proefschrift; Van 't Laar A. Ned Tijdschr Geneesk 1989;133:332-334; Grundy 
SM. New EnglJ Med 1988;319:24-33). 
3. Remming van de cholesterolsynthese door simvastatine heeft geen klinisch rele-
vante nadelige invloed op de functie van de bijnierschors. 
(Dit proefschift, hoofdstuk 5). 
4. Selectieve LDL-aferese moet worden overwogen bij een patiënt met een ver-
hoogd cholesterolgehalte van het serum die op andere manieren onvoldoende kan 
worden behandeld. 
(O.m. dit proefschrift, hoofdstuk 6). 
5. Bij de mens en bij het konijn met homozygote familiaire hypercholesterolemie 
wordt LDL zowel gevormd door omzetting van VLDL naar LDL, als door directe 
aanmaak. 
(Dit proefschrift, hoofdstukken 8 en 9; James RW, Martin B, Pometta D, et al. J 
Lipid Res 1989;30:159-169). 
6. De daling van het cholesterolgehalte van het serum door behandeling met rem-
mers van de cholesterolsynthese wordt niet beïnvloed door het apoE fenotype 
van de patiënt. 
(De Knijff P, Stalenhoef AFH, Mol MJTM, et al. Atherosclerosis 1990; in press; 
O'Malley JP, Illingworth DR. Metabolism 1990;39:150-154). 
7. Dermatomyositis kan optreden als paramaligne verschijnsel bij een chondrosar-
coma. 
(Mol MJTM, Stalenhoef AFH, Boerbooms AMT. Arthritis Rheum 1986-^9:813-
814). 
8. Verlaging van het verhoogde calciumgehalte in het serum bij patiënten met een 
hyperparathyreoïdie door zowel chirurgische als medicamenteuze behandeling 
kan leiden tot aanvallen van pseudojicht. 
(Pieters GFFM, Mol MJTM, Boerbooms AMT, De Boer HHM, Smals AGH, 
Kloppenborg PWC. Neth J Med 1989;34:258-263). 
9. Aanvallen van hypoglycémie kunnen ontstaan door de aanwezigheid van auto-
antilichamen tegen insuline. 
(Mol MJTM, Pieters GFFM, Storms GEMG, eigen waarneming). 
10. Onder patiënten met oesofagusvarices die nog niet eerder hebben gebloed is er 
geen groep aan te wijzen bij wie profylactische sclerotherapie een gunstige 
invloed heeft op de overleving. 
(Editorial. Lancet 1988;i: 1369-1370). 
11. Bij de behandeling van solitaire hersenmetastasen, die toegankelijk zijn voor 
chirurgie, heeft chirurgische extirpatie in combinatie met radiotherapie een 
gunstiger effect op zowel de overleving als de kwaliteit van het leven dan 
radiotherapie alleen. 
(Patschell RA, Tibbs PA, Wals JW, et al. N Engl J Med 1990;322:494-500). 
12. Doordat de remmers van de cholesterolsynthese meestal een gunstig effect 
hebben op het lipidengehalte in het serum, dreigt deze groep medicamenten te 
worden voorgeschreven voordat een diagnose is gesteld. Dit komt uiteindelijk de 
patiënt niet ten goede. 
13. Voor de stimulering van klinisch wetenschappelijk onderzoek en het opleiden van 
goede klinische onderzoekers is een zodanige vorm van financiering nodig dat 
oudere assistent-geneeskundigen in opleiding (AGIO's) en jonge specialisten 
vrijgemaakt kunnen worden voor promotie-onderzoek. Het AIO-stelsel heeft 
hier eerder een negatieve dan een positieve invloed. 
14. Het gunstige effect van het bedrijven van duursport op de levensverwachting 
komt grofweg overeen met de totale tijdsduur dat deze duursport in het leven is 
beoefend. 
(Kannel WB, persoonlijke mededeling). 
15. Uit het oogpunt van zorg voor de volksgezondheid en het milieu zijn er meer 
argumenten voor vleesquotering dan voor visquotering. 



